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Abstract
“Traumatic brain injury” (TBI) encompasses a heterogeneous group of physio-pathological
phenomenon. Prognosis, clinical course evaluation and treatment of brain trauma remain chal-
lenging. Brain damage results from both the initial physical insult (primary injury), and also
continues to occur in the ensuing hours to days because of secondary brain aggressions. Among
secondary injuries following TBI, Cortical Spreading Depolarizations (CSD) have emerged since
the mid-90s. CSD are waves of depolarization propagating along the cortex at a speed of 1-5
mm/min that induced a massive energetic demand to repolarize the cells. CSD are partici-
pating to prognosis because their occurrence and duration are related to outcome in diﬀerent
acute brain injuries (TBI, sub-arachnoid hemorrhage and ischemic stroke). During my thesis,
our main goal was to determine whether the CSD reinforced neuronal death following brain
trauma that can explain the poor prognosis. In a ﬁrst study we delineated brain regions where
neuronal death occurs following lateral ﬂuid percussion injury (LFPI) in order to record CSDs
in this area. Then, as we wanted to assess the energetic balance of this tissue during CSD
using biosensors, we had primarily to check for the biosensor reliability to oxygen (O2) and
temperature (To). As oxygen and temperature were diﬀerent from bench (in vitro) to bedside
(in vivo) monitoring, we developed algorithms to compute oﬄine the in vivo values obtained for
glucose, lactate or glutamate brain concentrations respecting the local O2 concentrations and
To measured in the cortex. Finally, using the biosensors, we described the dynamic real time
metabolic changes occurring after CSDs in 3 conditions: A healthy cortex, an injured cortex
after LFPI, and when CSD occurred in cluster after LFPI. Although the normal brain displayed
a hyper-glycolytic state following CSD (transient low glucose concentrations + prolonged ele-
vated lactate concentrations), TBI tissue exhibited a diﬀerent pattern that could be metabolic
crisis (very low glucose concentrations + normal to low lactate concentrations). However, as
pyruvate was not monitored, these results might also parallel the “low pyruvate state” described
in humans. Finally, preliminary results showed that neither glutamate excitotoxicity, nor H2O2
overproduction are candidate to sustain the mechanisms by which CSD might participate to
secondary injury. Understanding CSDs patho-physiology gave us new insights about their im-
plications in secondary brain aggressions and rose further questions about their toxicity.
Key words: Cortical spreading depolarizations, traumatic brain injury, brain metabolism,
biosensors
Résumé
Les traumatismes crâniens (TC) représentent la première cause de décès ou de handicap avant
l’âge de 45 ans, avec une incidence en Europe de 235/100 000 habitants. Chez les patients sur-
vivant à un TC, les séquelles sont fréquentes allant de l’état végétatif chronique au syndrome
post-concussionnel compliquant principalement la réinsertion socio-professionnelle et familiale
des victimes. Cependant la nature des lésions cérébrales provoquées par un TC est encore
mal connue et les thérapies susceptibles d’empêcher la progression des lésions neurologiques
sont très limitées. Un TC provoque d’abord des lésions directement dues à l’impact (lésions
primaires). D’autres mécanismes secondaires vont avoir lieu dès les premières minutes suivant
le TC et peuvent évoluer sur plusieurs jours. Elles sont susceptibles d’être atténuées par une
thérapeutique appropriée et sont donc l’objet de la plupart des eﬀorts de recherche actuels.
Néanmoins, notre connaissance de ces phénomènes d’agression primaires et secondaires, est
incomplète et ne permet pas d’expliquer correctement l’évolution des TC.
Les dépolarisations corticales envahissantes (DCE) ou “cortical spreading depolarizations””sont
un des événements délétères contribuant aux lésions secondaires consécutives au TC. Les DCE
sont des vagues de dépolarisation massive associées à un mauvais pronostic. Elles sont car-
actérisées par une dépression de l’activité électrocorticographique et une dépolarisation des
neurones corticaux et des astrocytes qui se propagent sur le cortex. Les DCE s’accompagnent
d’une augmentation des besoins métaboliques visant à restituer au tissu son état d’homéostasie
neurochimique et de polarisation cellulaire. Les conséquences des DCE sur le métabolisme
cérébral sont encore mal connues aussi bien sur un tissu sain qu’après agression cérébrale. Il
existe des arguments pour penser que l’incidence, le nombre et la durée des DCE sont associés
à un moins bon pronostic chez l’homme après agression cérébrale. Cependant, les mécanismes
par lesquels ces DCE auraient une toxicité directe reposent encore sur des arguments le plus
souvent indirects et sont mal compris.
L’objectif principal de ce travail de thèse a été de caractériser les conséquences neurochimiques
et micro-vasculaires des DCE aﬁn de mieux comprendre leur physiopathologie dans un cortex
sain ou agressé par un TC sévère.
Dans une première étude nous avons caractérisé les dommages cellulaires engendrés par un TC
sévère expérimental chez le rat. Le modèle de percussion latérale de ﬂuide (LFP) est le plus
utilisé et reproduit une partie des conséquences d’un TC modéré ou sévère chez l’homme. Dans
cette étude nous avons déterminé la perte de neurones engendrée par un LFP sévère en utilisant
une méthode automatisée de comptage des neurones. Nous avons ainsi mis en évidence une
diminution de la densité neuronale dans le cortex temporal, le thalamus dorsal et dans l’aire
CA3 de l’hippocampe. Cette perte de neurone était associée avec une augmentation de la den-
sité totale de cellules suggérant la présence d’une gliose réactionnelle. Dans un second temps
nous avons étudié les conséquences du LFP sur les cellules gliales et observé une augmentation
de la densité de cellules microglies dans ces mêmes régions (thalamus, cortex temporal et CA3).
Ces cellules microgliales étaient pourvues d’un phénotype activé. Cette première étude nous a
permis de déﬁnir les régions où la perte neuronale était la plus importante après un LFP et de
déﬁnir le cortex temporal comme une zone de « pénombre traumatique » où nous avons avons
considéré que les conséquences neurochimiques et microvasculaires des DCE pouvaient être les
plus importantes.
Dans une deuxième étude nous avons validé la technique de mesure par diﬀérents biocap-
teurs enzymatiques (glucose, lactate, glutamate). Ceux-ci génèrent un signal qui repose sur
une réaction enzymatique d’oxydation qui est dépendante de la température et de la con-
centration d’oxygène. Comme les conditions de calibration des biocapteurs et les conditions
d’enregistrement in vivo sont diﬀérentes, nous avons fait varier in vitro les conditions de tem-
pérature et d’oxygène aﬁn de reproduire les conditions dynamiques observées au cours des DCE.
Nous avons étudié séparément l’inﬂuence des deux paramètres (O2 et To) sur le signal des bio-
capteurs et développé des algorithmes pour corriger les mesures des concentrations cérébrales
de glucose, lactate ou glutamate déterminées par les biocapteurs.
Enﬁn dans une troisième étude, nous avons étudié les eﬀets des DCE sur la micro vascularisa-
tion cérébrale, sur les concentrations cérébrales d’oxygène, de glucose et de lactate sur cerveau
non agressé, après LFP et en déclenchant les DCE par cluster. Au cours de ces travaux nous
avons montré que les DCEs isolées sur un cortex non agressé conduisaient à une hyper-glycolyse
aérobie (glucose bas, élévation du lactate, élévation de la CMRO2). Au contraire après un LFP
sévère, où les concentrations cérébrales de glucose sont déjà abaissées par rapport aux condi-
tions dans les cerveaux non agressé, les DCE entrainaient un eﬀondrement du glucose, sans
augmentation compensatrice du lactate et une diminution de l’oxygène tissulaire. La répétition
de ces DCEs sous forme de clusters après un LFP conduisait à une réponse métabolique plus
marquée encore en termes de diminution du glucose évoquant une la crise métabolique.
Sur le plan de la réponse vasculaire à la demande métabolique induite par les DCE, sur tissu
cérébral non agressé, celles-ci induisaient une augmentation du débit sanguin cérébral (CBF)
local. Par contre, en situation pathologique, il est montré qu’on assiste à un découplage vasculo-
métabolique avec une moindre réponse hyperhémique aux DCEs jusqu’à une ischémie terminale
en passant par des réactions oligémiques intermédiaires. Dans notre modèle de LFP sévère, les
DCEs conduisaient à une réaction hyperhémique, signiﬁcativement réduites par rapport aux
animaux non traumatisés. Nous n’avons pas observé d’évènements ischémiques, ce qui concorde
avec le fait que le CBF dans ce modèle est diminué mais sans atteindre les seuils ischémiques
observés dans les modèles d’ischémie cérébrale. Enﬁn, lors de la répétition de DCEs en cluster,
nous avons mis en évidence une augmentation progressive et compensatrice du CBF. Ainsi nous
pouvons raisonnablement penser que les clusters de DCE peuvent participer à la génération
d’oedèmes vasogéniques observés en pathologie humaine. Pour conclure, il apparait que les
DCE constituent un challenge énergétique majeur pour le parenchyme cérébral, avec des con-
séquences diﬀérentes en fonction de l’état du cortex sous-jacent. Cependant la toxicité directe
des DCE sur le parenchyme cérébral nécessite de plus amples expérimentations.
Mots clés: traumatismes crâniens, dépolarisations corticales envahissantes, métabolisme cére-
bral, biocapteurs
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Part I
Introduction
M.C. Escher, Dag en nacht - 1938, Woodcut in black and grey.
9
IThe term, “traumatic brain injury (TBI)” encompasses a heterogeneous group of patholog-
ical disorders, each with its own clinical presentation, pathophysiology, natural history, treat-
ment, and prognosis. Anticipation of clinical course and prognostic determination are landmark
feature that underpin the need for intervention or treatment. These questions daily challenge
physicians, and therefore are the basis of every classiﬁcation, as well as clinical or pre-clinical
trials.
The fact that brain damage not only results from the initial physical insult (primary injury),
but also continues to occur in the ensuing hours to days because of secondary brain aggressions,
is a major concept that became the basis of current TBI care. Several new techniques have
been developed over the past decades to evaluate these brain aggressions and make bounds
with clinical course and outcome.
The introduction part of my thesis will be organized around these concepts of secondary brain
aggressions in the context of TBI:
In the ﬁrst instance, I will give a description of TBI main characteristics and classiﬁcations.
The second chapter will be dedicated to the description of secondary brain aggressions with a
close focus on brain metabolism physiology.
Subsequently, diﬀerent techniques available for brain monitoring will be presented with their
advantages and drawbacks.
Finally the last chapter will discuss the relevance of “cortical spreading depolarizations” as part
of brain aggressions.
This part will broach several concepts underlying my work about the neuro-chemical analysis
of cortical spreading depolarizations after severe traumatic brain injury.
10
Chapter 1
Traumatic brain injury: repercussion
and evaluation
1.1 Epidemiology
TBI Incidence shows a substantial variation between countries with an estimates for hospital-
izations ranging from 100 to 400 new cases per 100 000 population per year, which makes it the
second neurological disorder in etiology [1, 2]. With 3.7 million patients in Europe and 3.3 mil-
lion in the US (1.1% of total population), TBI’s direct cost was estimated over $7 billions with
an additional indirect cost almost twice as high (i.e. e33 billions, in Europe year 2010) [3, 4].
However the TBI incidence has been calculated according to hospitalized patients, therefore
mild or moderate TBI might be miss-evaluated. Even though, the incidence of TBI is decreas-
ing, mainly thanks to prevention measure among the youth and road safety improvement [5].
Some countries (e.g. New Zealand, Denmark or Canada) did not display signiﬁcant decrease of
TBI during the past decade [6, 7, 8].
Locally using the Rhône (France) car accident register, Orriols et al. found that the incidence
of severe traumatized patients younger than 10 years old was dropping [9]. Worldwide TBI
epidemiology is operating a switch during the past decade. Injuries begin to result now pre-
dominantly from falls rather than traﬃc accident with larger proportion of older patients with
more co-morbidity compromising their outcome [10, 7, 8].
A large proportion of TBI victims are still children and young adults, and TBI remains the
leading cause of disability in people under 40 years of age. For that matter TBI is a major
public health issue, so that large clinical trials are ongoing and received huge European funding.
The TBIProject started in 2011 and aims to provide an objective and evidence-based solution
for management of TBI by improving diagnostics and treatment decisions for an individual
patient. As part of the TBIProject the “International Mission for Prognosis and Analysis of
Clinical Trials in TBI” (IMPACT) lead in 2010 to recommendation for improving clinical tri-
als design [11] with a large database that allow investigators to develop a prognosis score in
2008 available on-line (http://www.tbi-impact.org/?p=impact/calc) [12]. More recently,
the CENTER-TBI project started in October 2013 and aims namely at reﬁning and improving
outcome assessment and develop health utility indices for TBI, using multidimensional ap-
proaches. It will collect multiple data (genetic, MRI, electro-physiology, bio-markers. . . ) from
many centers across Europe.
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I 1.2. Classiﬁcation and scores
Score Motor response Verbal response Eye opening
1 None None None
2 Decerebrate Incomprehensible To pain
3 Decorticate Inappropriate To Speech
4 Withdrawal Confused Spontaneous
5 Localizing Oriented
6 Obeying
Table 1: Glasgow coma score as it is use nowadays, adapted from Teasdale publication [13].
The motor response to oral command or painful stimulus range from 1 to 6, the verbal response
from 1 to 5 and the eye opening from 1 to 4. Overall the GCS range from 3 to 15.
1.2 Classiﬁcation and scores
1.2.1 Early evaluation
To classify injury severity in patients undergoing accidental trauma (with or without head
injury), the “Advancement of Automotive Medicine Association” described the abbreviated
injury scale (AIS) with the ﬁrst version of in the 70s and the latest revision being the AIS c©
Update 2008. This anatomical scoring takes into account lesions sites and severity, ranking
from 1 (minor) to 6 (fatal), and is the basis for the Injury Severity Score (ISS) calculation of
patient with multiple injuries.
Among these injuries, direct or indirect head impact lead to a wide range of diﬀerent lesions.
TBI may be categorized by mechanism of injury, clinical severity, radiological appearance,
pathology or distribution (focal vs. diﬀuse). Homogeneous edema and axonal lesions are the
landmark of diﬀuse injury, for example during deceleration, blast or sport accident. Conversely
heterogeneous injury encompass bone fracture, penetrating lesions, hematoma or edema, with
or without visible external injury.
TBI severity ranges from minor (minimal complaints, no visible structural damage) to virtu-
ally fatal. Therefore, a clinical score has been described by Graham Teasdale in 1974, which
measures independently three behavioral aspects (i.e. motor responsiveness, verbal response
and eye opening) [13] (table 1). This Glasgow coma scale (GCS) is easy to asses and remains a
gold standard for daily consciousness assessment of comatose patients, and is use for TBI acute
severity classiﬁcation and help predicting patient’s outcome [12]:
• Mild: GCS ≥ 13.
• Moderate: GCS 9 → 13
• Severe: GCS ≤ 8
It should be noted that the GCS can be diﬃcult to determine in some situation when any
behavioral aspect cannot be assessed (e.g. verbal response in artiﬁcially ventilated patients or
the motor response if paresis is present).
Although TBI is considered to be self-explanatory, in practice this terminology continues to be
plagued by ambiguity, especially at the mild end of the severity spectrum. Indeed, mild TBI
deﬁnition lack information about loss of consciousness, amnesia, confusion . . . Therefore, the
American Academy of neurology reﬁned its classiﬁcation in 3 subgroups allowing for a more
detailed clinical analysis:
• Grade 1: Transient confusion lasting less than 15 minutes, without loss of consciousness.
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Category Deﬁnition
Diﬀuse injury I No visible intra-cranial pathology seen on CT scan
Diﬀuse injury II Cisterns are present with midline shift 0–5 mm and/or
lesions densities present; no high or mixed density lesion
≥ 25 cc may include bone fragments and foreign bodies.
Diﬀuse injury III Cisterns compressed or absent, with midline shift of 0–5
mm, no high or mixed density lesions of ≥ 25 mL
Diﬀuse injury IV Midline shift of > 5 mm, no high or mixed density lesion
of ≥ 25 mL
Evacuated mass lesion (V) Any lesion surgically evacuated
Nonevacuated mass lesion (VI) High or mixed density lesion of ≥ 25 mL, not surgically
evacuated
Table 2: Marshall computerized tomography classiﬁcation
• Grade 2: Transient confusion lasting greater than 15 minutes, without loss of conscious-
ness.
• Grade 3: Any loss of consciousness.
During the early period of patients care, TBI severity will be determine according to clinical
examination using GCS. If any loss of consciousness was present, brain computerized axial
tomography scan (CT) is an essential exam to map precisely any intra-cranial lesion. With
data from the “Traumatic Coma Data Bank” Marhsall et al. build a classiﬁcation for severe
TBI [14, 15] (Table 2. This scale provide an average evaluation of the prognosis 6 month after
the injury (ROC AUC = 0.74), with good inter-rater and intra-rater reliability [16].
More recently, data from the IMPACT database indicate that Marshall CT classiﬁcation was
strongly related to outcome. The worse outcomes were found in patients with CT class III or
IV, prognosis in patients with mass lesions was better for epidural hematoma and poorer for
an acute sub-dural hematoma. Moreover, multi-variable analysis indicated that individual CT
characteristics added substantial information to the prognostic value of the CT classiﬁcation
alone, meaning that physician have to read into CT more than just the Marshall classiﬁca-
tion [17].
Even though CT is unavoidable and easily accessible in every hospital, magnetic resonance
imaging (MRI) overstep its ability especially when clinical examination is very little aﬀected.
1.2.2 Post-acute and follow-up evaluation
The ultimate goal and also the more challenging is long term outcome evaluation. Glasgow
outcome scale (GOS) is commonly used for long term outcome scoring after brain injury. Rang-
ing from 1 to 5, this scale is alike the modiﬁed Rankin scale (1 → 6) used to evaluate patients
after cerebral ischemic stroke. It class patients between dead, comatose, or presenting severe
to low disability (Table 3). The extended GOS add an upper and lower scale to the 3 → 5
categories, allowing for a more precise distinction of better outcomes [18]. These categoriza-
tions are easy to asses during clinical trials, however they still rough for neurological functions
follow up during post-acute and rehabilitation period. Therefore additional evaluation scales
have been developed.
The coma recovery scale revised (CRS-R c©) explore diﬀerent neurological functions (i.e. audi-
tory, visual, motor, verbal, communication, arousal and brain-stem reﬂexes) and can be used to
follow their progress during post-acute care and rehabilitation. Further evaluation use during
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rehabilitation encompass daily life ability (e.g. functional independence measure (FIM), frontal
assessment battery at bedside (FAB) and Neurobehavioral Rating Scale(NRS)) and quality of
life features (e.g. quality of life after brain injury (QOLBI) questionnaire).
Early clinical examination together with anatomical data from brain CT fails to give a reliable
long term prognosis evaluation. Therefore more accurate imaging techniques have been used
to address the relation between anatomical lesions and neurological deﬁcits.
Since MRI spatial resolution is over 10 times that of conventional CT, it became a preferred
technique for anatomical injury mapping. Conventional morphological MRI include T1, T2,
T2∗ and FLAIR (axial ﬂuid attenuated inversion recovery) weighted images. T2 and FLAIR
sequences are better for edema, contusion, hematoma and sub-arachnoid hemorrhage visualisa-
tion. Whereas T2∗ highlight diﬀuse axonal lesions as multiple white matter micro hemorrhage.
However even T2∗ underestimates white matter injury, which are more precisely measured with
diﬀusion tensor imaging (DTI) sequence [19]. It should be noted that MRI lesions are dynamic
after TBI, and while some might disappear over time (edema or hematoma), other can come
out as a consequence of secondary brain aggressions or natural primary lesion evolution.
Even thought, brain imaging is not recommended after mild TBI without loss of consciousness
or amnesia, white matter lesions have been shown in US military personnel who had a mild
TBI [20]. Moreover it has been shown that these DTI modiﬁcations are associated with cogni-
tive dysfunction such as memory and learning [21, 22].
In the intensive care unit (ICU), acute management of severe TBI might no allow an extended
MRI with DTI sequence. Thereby MRI is usually perform in the sub-acute period (≥ 10
days), trying to predict consciousness recovery and long term disability. The team in the
“Pitié-salpêtrière hospital” lead by Pr Louis Puybasset (Paris, France) shown in 2009 that DTI
imaging was a reliable bio-marker. In fact fractional anisotropy in the inferior longitudinal
fasciculus, in cerebral peduncle, in posterior limb of the internal capsule, and in posterior cor-
pus callosum was speciﬁcally decreased in unfavorable outcome group compare to the favorable
one [23]. In 2012 they even build a DTI score that has a 64% sensitivity and a 95% speciﬁcity
for the prediction of unfavorable outcome (i.e. extended GOS of 1, 2 or 3-) [24].
In the end, what matters to many intensivists is whether patient will have favorable or un-
favorable outcome. Indeed this rough dichotomy is used in many clinical trials analysis, as
describe above with DTI evaluation. If (1) dead or comatose patient are commonly accepted as
“bad” outcome and (2) low to moderate disability as “good” outcome, the GOS 3 (i.e. moderate
disability with the need for assistance in everyday-life) is matter of struggling debate. Indeed
decreasing mortality in favor of severe handicap should be a matter of society. Therefore avail-
able techniques interpretation for prognosis or clinical course evaluation should be taken with
great precaution as it can end up with discussion about intensity of care limitation.
1.3 Traumatic brain injury sequels
1.3.1 Mortality
Severe TBI reaching the ICU have between 30% and 70% mortality rate [25, 26, 27]. Although
it should be noted that 54% of severe traﬃc accident (at least one AIS ≥ 4 lesion) with
an associated head trauma will die, 80-90% of the fatalities occurring on the scene of the
accident [9, 28]. In Pennsylvania the overall mortality rate was 7.8% with a decreasing trend
from 1998 to 2007 [29]. Between 2006 and 2010 in Canada, there was a 15% mortality increase,
likely related to increased patient’s age and comorbidity. The in-hospital mortality rate was
mainly related to TBI severity, age, and comorbidity index [8].
Moreover, TBI survivors keep a vulnerability compared to general population, decreasing their
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Score outcome description eGOS
1 Dead or no consciousness
2 Persistent vegetative state Severe damage with prolonged state of unre-
sponsiveness and a lack of higher mental func-
tions
3 Severe disability Severe injury with permanent need for help with
daily living
U/L
4 Moderate disability No need for assistance in everyday life, employ-
ment is possible but may require special equip-
ment
U/L
5 Low disability No or light damage with minor neurological and
psychological deﬁcits
U/L
Table 3: Glasgow outcome scale and extended GOS adding upper and lower categories to
GOS 3 to 5
life expectancy. In fact, a follow-up Scottish study shown a 7 fold higher mortality rate 13 years
after TBI compared to general population, even in the elderly [30]. 75% of deaths occurred
during the ﬁrst year after TBI, and this early mortality rate was twice that of traumatized
patients without head injury and close to 10 times that of general population (age, sex, social
status . . .matched) [30].
1.3.2 Post traumatic seizure
Post traumatic seizure (PTS) is often the ﬁrst episode of seizure secondary to TBI, with epilepsy
(i.e. recurrent seizure) appearing over time. According to TBI severity and latency, its inci-
dence ranges between 2 and 66% [31, 32, 33, 34]. PTS onset can be either immediate, early (i.e.
within 7 days) or late [35]. In the ICU, around 22% of moderate or severe TBI patients undergo
non-convulsive seizure, 25% of whom will develop a non-convulsive status epilepticus [36].
The main risks factor for developing PTS are an early seizure, an acute intra-cranial hematoma
or concussion, GCS ≤ 9 and scalp fracture [35, 37]. More recently, a prospective multi-center
study in China identiﬁed 3 main factors using multivariate analysis: Frontal or temporal lo-
bar contusion (OR= 2), linear fracture (OR= 2.9) and the initial GCS (9-12: OR= 2, 3-8:
OR= 4.1) [34].
Even though PTS are associated with TBI severity and intra-cranial lesions, prophylactic treat-
ment is not recommended [32]. In fact prophylactic phenitoine or valproate administration did
not prevent late PTS, even though it decreased early PTS rate [38, 39]. However, recommen-
dations for PTS management rely on very few studies [32] and new anti-epileptic drugs still
have to prove their beneﬁcial eﬀects.
1.3.3 Sensory and motor disability
Sensory and motor disability prevalence depends on TBI severity, the existence of intra-cranial
hematoma and surgical procedure. It can be absent after mild TBI and rise to 100% in severe
TBI survivors.
Theses disabilities are very heterogeneous depending on brain lesion’s localization, and include:
• motor dysfunction such as paresis, axial hypotonia, dyskinesia and extrapyramidal syn-
drome
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• sensory deﬁcit including anesthesia, hypoesthesia, allodynia, spatial neglect, visual deﬁcit,
vertigo
• cranial nerve palsy
• algodystrophy, chronic pain, that are more related to trauma severity than to TBI [40],
like peripheral neuropathy
• urinary tract and digestive dysfunction
• sleep disorders
Even if 85% of severe TBI survivors regain consciousness, 25 to 45% keeps a severe disability
and only 10 to 15% have a good recovery [41]. Therefore, rehabilitation is a crucial period that
can take several months or years before consolidation, and should be started as soon possible
to improve patient outcome [42].
1.3.4 Cognitive dysfunction
Severe TBI cause initial major consciousness disorder and depending on injury location can
lead to persistent vegetative state (no evidence of awareness without interaction with other
people) or minimally conscious state (fragment of meaningful interaction with the environment
are preserved such as eye contact, grasping to command or answer with a word). Up to 50% of
mild and moderate TBI, and 76% of severe TBI suﬀer from memory loss or mood disorder one
year after the accident [43]. After severe TBI, 10% of the survivors will develop agitation [44],
over 30% irritability [45], and up to 35% aggressive behavior [46].
Mood disorder such as anxiety seems to correlate with major depression [47] and addictive
behavior after TBI [48]. Depression usually occurs late after the injury in 25 to 50% of severe
TBI. Suicide is also 4 times more frequent after severe TBI than in general population (matched
for social, economic en geographic features) [49].
1.3.5 Chronic traumatic encephalopathy
Chronic traumatic encephalopathy (CTE) was originally reported in 1928 by Harrison Mart-
land, a New Jersey pathologist, who described the clinical aspects of a progressive neurologi-
cal deterioration (“punch drunk”) that occurred after repetitive brain trauma in boxers [50].
CTE is clinically associated with symptoms of irritability, impulsivity, aggression, depression,
short-term memory loss and heightened suicidal that usually begin 8–10 years after experienc-
ing repetitive mild traumatic brain injury. With advancing disease, more severe neurological
changes develop that include dementia, gait and speech abnormalities and Parkinsonism. In
late stages, CTE may be clinically mistaken for Alzheimer’s disease or frontotemporal demen-
tia.
CTE is a progressive tauopathy that occurs as a consequence of repetitive mild TBI [51]. The
spectrum of pathological hyperphosphorylated tau locations ranged in severity from focal to
disseminated brain regions, including the medial temporal lobe. The degree of lesion’s exten-
sion is correlated with clinical symptoms [51].
Nevertheless single moderate to severe TBI can lead to widespread and extensive tau and Aβ
pathology many years after injury. This could represent a substrate for the long-term devel-
opment of neurodegenerative disease, such as Alzheimer’s disease, known to be at increased
incidence in long-term TBI survivors [52].
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1.3.6 Social rehabilitation
Among a 1000 patient cohort who underwent mild TBI after traﬃc accident, although 75% felt
well before the accident, 70% felt accident related diﬃculties afterwards. 30% reported bad
health condition whereas almost all felt healthy prior the accident [53]. Among traumatized
people, 80% underwent work interruption whatever the trauma location. Likewise, up to 72%
young victims interrupted their study after traﬃc accident [40].
GCS, amnesia duration, hospital length of stay, cognitive dysfunction, and GOS were all
correlated to social rehabilitation (i.e. work return, hobbies, family and social relationships
. . . ) [54, 49].
Brain injury that underpin impaired neurological functions and outcome results from the initial
physical insult (primary injury), but also from secondary brain aggressions appearing within
the ﬁrst minutes after the injury and lasting days to months or even years following the TBI.
Multiple and intricate mechanisms take place during TBI clinical course. The Next chapter
will describe known processes acting on brain tissue, with a special focus on brain metabolism
physiology.
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Secondary brain aggressions
patho-physiology
The concept of secondary brain aggression after TBI date from the mid-60s based on post-
mortem histological analysis showing necrotic lesions in the corpus callosum, the hippocampus,
the white matter, the external capsula, and the brain-stem that were not direct consequences
of head injury [55]. Therefore emerges the distinction between primary injury that is a direct
consequences of head injury, and secondary brain aggressions that can induce new injuries
within the ﬁrst minutes to hours or days after the accident [56].
Physicians can-not act on primary lesions apart from preventing traﬃc, sports and everyday
life, accidents. Conversely secondary brain aggressions are a central component of TBI care
management.
The next sections will describe on one hand what is called “systemic insults to the brain”, and
then more recent discovery about local aggressions including: brain vascularization, inﬂamma-
tion, excito-toxicity, electrophysiological events and metabolic modiﬁcations.
2.1 Systemic insults to the brain
The ﬁrst studies conducted in dogs about systemic insult to the brain such as hypoxia or
hypotension showed similar histological lesions of the white matter and the centrum semio-
vale [57]. After severe TBI either hypercapnia (PaCO2 > 45mmHg) or hypotension (mean
arterial pressure (MAP)< 90mmHg) has been observed and linked to increased intra-cranial
pressure (ICP) [58]. Likewise, hypertension and hypoxia are known since the 70s to be more
frequent in TBI patients with worse outcome [59].
Nowadays “systemic insults to the brain” (Table 4) have been integrated in head injured pa-
tients prognosis score such as the one from the IMPCAT trial [12]. Apart from hypoxia and
hypotension, anemia is also one of the systemic insults that can occur after a trauma with hem-
orrhage. It will decrease the arterial content of oxygen and therefore brain energy supply. In
fact it has been shown that red blood cell transfusion can increase brain oxygen concentration
after sever brain injury [60].
Patients with severe head injury also have increased serum glucose which level is associated
with in adverse patient outcome [61]. Recently studies have investigated glycemic control in
the neurocritical care population. Research in severe brain injury documents deleterious eﬀects
of tight glucose control, and cerebral micro-dialysis (cMD) studies demonstrate lower brain glu-
cose and increased episodes of hypoglycemia with tight glucose control (80-100 mg/dL) [62, 63].
Therefore present recommendations target a blood glucose concentration between 144 and 180
mg/dL (8-10mmol/L) [64]. These “moderate” insulin protocols are common in ICUs and ap-
pear to avoid hyperglycemia and low glucose variability [64]. Finally electrolyte disorders such
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Insult category Grade 1 Grade 2 Grade 3
Raised ICP mean ≥ 20mmHg mean ≥ 30mmHg mean ≥ 40mmHg
Hypotension mean ≤ 70mmHg mean ≤ 55mmHg mean ≤ 40mmHg
or systolic ≤ 90mmHg or systolic ≤ 70mmHg or systolic ≤ 50mmHg
Hypertension mean ≥ 110mmHg mean ≥ 130mmHg mean ≥ 150mmHg
or systolic ≥ 160mmHg or systolic ≥ 190mmHg or systolic ≥ 220mmHg
Low CPP mean ≤ 60mmHg mean ≤ 50mmHg mean ≤ 50mmHg
Hypoxia SaO2 ≤ 90% SaO2 ≤ 85% SaO2 ≤ 80%
Pyrexia Temp ≥ 38oC Temp ≥ 39oC Temp ≥ 40oC
Tachycardia HRT ≥ 120bpm HRT ≥ 135bpm HRT ≥ 150bpm
Bradycardia HRT ≤ 50bpm HRT ≤ 40bpm HRT ≤ 30bpm
Table 4: Systemic insult to the brain deﬁned by the Edinburgh University secondary
insult grades (EUSIG). Deﬁnition of secondary insult grades: Each derangement must be
sustained for at least 5 minutes to be deemed a secondary insult, with the exception of pyrexia,
which must last at least 60 minutes. Adapted from signorini et al. 1999 [66].
as metabolic acidosis or dys-natraemia are also related to worse outcome [65].
2.2 Brain metabolism
2.2.1 General physiology
About 20% of the oxygen and 25% of the glucose consumed by the human body are dedicated to
cerebral functions and homoeostasis (oxygen cerebral metabolic rate (CMRO2) ≈ 5ml ·min−1 ·
100g−1 and glucose cerebral metabolic rate (CMRglucose) ≈ 31μmol ·min−1 ·100g−1). Therefore
20% of cardiac output is delivered to the brain which represents only 2% of the total body
mass. Maintenance and restoration of ion gradients dissipated by signaling processes as well as
uptake and recycling of neurotransmitters, are the main processes contributing to the high brain
energy needs under physiological conditions. However brain aggression induces inﬂammation,
oxidative stress, cell destruction or edema, thereby enhancing energy demand. Nevertheless a
little is known about how the brain is able to adapt to such a challenge.
2.2.2 Neuronal activity, metabolism and vascular coupling
2.2.2.1 Neuro-vascular coupling
The vascular cortical organization includes deep capillary beds fed by perpendicularly oriented
penetrating arterioles that branch from superﬁcial pial arteries [67] (Fig 1A). The topology and
morphology of this microvasculature are characterized by a large degree of heterogeneity that
can change over time. As a consequence, erythrocyte ﬂuxes and velocities in capillaries is also
miscellaneous [68]. Interestingly this heterogeneity appears to be reduced during brain acti-
vation with functional hyperemia [68]. Based on these observation, a model emerges whereby
capillary transit time heterogeneity (CTH) reduction during functional hyperemia (i.e. capil-
laries diameter homogenization) counteract inherent reduction in oxygen extraction fraction as
cerebral blood ﬂow (CBF) increase [68, 69]. Indeed, according to this model, oxygen availability
depends on blood ﬂow and dynamic changes in oxygen conductance: as capillary transit times
becomes short, an increasing proportion of blood is shunted through the capillary bed, and its
oxygen unavailable to brain tissue. Thereby under ﬁxed CTH any increase in the CBF would
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decrease oxygenation [70].
The vasomotricity of Arterioles and veinules depends on circumferential smooth muscle cells
(SMCs) placed around arterioles and with a more fenestrated patch-work phenotype around
veinules. Smaller vessels 3 − 10μm (branches of penetrating arterioles) are covered with NG2
expressing cells including SMCs and pericytes [71, 72]. During physiological in vivo brain acti-
vation, increases in CBF almost always accompany evoked neuronal activity. This vasodilation
occurs ﬁrst in capillary regions covered by NG2-cells [73]. Based on NG2-cells morphology, Hill
et al recently suggested that small vessels diameter (< 10μm) depend on SMCs intracellular
calcium modiﬁcation but not on pericytes which does not express smooth muscle actin [71].
Indeed, functional hyperemia occurs ﬁrst in the deeper vessels and is characterized by an early
peak and a late plateau. The early vasodilation displays a retrograde propagation to the
pial artery spreading threw endothelial cells gap-junctions (over 2mm/s) [74, 75, 76]. This
endothelial propagation leads to the shortest route to larger arteries, selecting the optimal ar-
teriolar branches to generate a localized increase in CBF. Then a more localized and sustained
parenchymal hyperemia occurs, that is dependent to the stimulus duration [74]. Hence, Chen
et al. hypothesized that this pattern may be representative of a threshold eﬀect, whereby
endothelial hyperpolarization occurs only at the onset of stimulation, whereas slower NO and
prostanoid-dependent dilation is repeatedly triggered by continuing stimulation [74]. What
drives vasodilation onset remains controversial, and may imply both astrocytes and vasoactive
neurons.
All vessels below the pial surface are surrounded by astrocytes, especially capillaries covered
by astrocyte processes [77]. Astrocytes occupy non-overlapping territories wrapping a large
proportion of dendrites [78]. Thereby, their ability to sense neuronal activity through these
“synaptic islands” together with their strong relationship with capillaries make them good
candidates for local neuro-vascular coupling. In fact increased extracellular glutamate during
neuronal activity will induce an increase in astrocytic intracellular calcium that can potentially
activate two pathways (Fig 1A):
• Cytoplasmic phospholipase A2 generating arachidonic acid, which is converted to prostaglandins
and epoxy-eicosatrienoic acid, both able to relax SMCs [74]. It has also been suggested
that arachidonic acid diﬀuses to vascular smooth-muscle cells and is metabolized to 20-
hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor that can inhibit smooth mus-
cle’s large-conductance Ca2+-sensitive potassium channels (KCa) [79, 80]. This vasocon-
striction is blocked during neuronal activation by nitric oxide (NO) release [73]. However,
both NO and 20-HETE synthesis are supposed to be limited under in vivo oxygen concen-
tration [81]. During pathological process such as cortical spreading depolarization (CSD)
20-HETE release has been shown to engage in the sustain hypo-perfusion that follow the
depolarization [82]. Therefore acting on either NO or 20-HETE can be a way to improve
CSD subsequent vascular pattern [82, 83].
• KCa opening in the plasma membrane of astrocytic end-feet. Increases in extracellular
potassium concentration can subsequently hyperpolarize SMCs through inward rectiﬁer
potassium channels, leading to a vasodilation. Conversely, at extracellular levels ≥ 20
mM, K+ depolarizes SMCs, activating voltage-dependent calcium channels and inducing
vasoconstriction [80].
Beside astrocyte’s action on vascular diameter, general brain condition such as oxygen con-
centration and cell metabolism can modulate vascular tone. For example, in vivo oxygen
concentration leads to an increase in extracellular adenosine concentration that can promote
vasodilation either through endothelial cells [74, 76] or through A2A adenosine receptor on
SMCs [84]. Finally, the action of prostaglandins-E2 (PGE2) is terminated when astrocyte’s
or neuron’s prostaglandin transporters (PGTs) take up PGE2 by an exchange of intracellular
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lactate. Thereby, extracellular lactate increase through monocarboxylate transporters (MCT)
during neuronal activation (see section below, “modelling brain metabolism”) hinders passive
PGE2 clearance by PGTs and increases extracellular PGE2, which further dilates arterioles [84].
2.2.2.2 Neuronal activity and brain metabolism
One striking brain feature is the tight coupling that exists between neuronal activity and blood
supply for oxygen and carbohydrate. Indeed neuronal activity increases with CBF and also
with CMRglucose, demonstrating a neuro-metabolic coupling. Positron emission tomography
(PET) and other functional brain imaging are based on this correlation between brain activity
and CBF, CMRO2 or CMRglucose [85, 86, 87]. As neurons are the most energy consuming
cells during brain activation, CMRglucose measured by PET with 18F-Fluoro-2-deoxyglucose
was supposed to be a surrogate to neuronal glucose expenditure [86]. Further investigation by
ox and Raichle in the 80s found that even if CBF and CMRO2 were correlated at resting state,
they were not coupled during neuronal activation [88]. Indeed, physiological neuronal activity
increases glucose uptake and cerebral blood ﬂow much more than CMRO2. Glucose uptake is
usually in excess of that consumed by oxidative metabolism [89].
As a result, local temporary mismatch between oxygen supply and consumption leads to less
desaturated hemoglobin in an activated area. Thereby, the increased oxy/deoxy hemoglobin
ratio yields a diﬀerent signal detected by MRI, paving the way to functional MRI measuring
the blood oxygenation level-dependent (BOLD) contrast [87].
These observations rise fundamental questions about the contribution of neurons and astrocytes
to brain glycolysis and oxidative metabolism. The next section will discuss what is known about
the cooperation between these two cell types.
2.2.2.3 Glucose metabolism
Glucose is supposed to be the major energetic fuel of the mammalian brain. Glucose is pas-
sively transmit from blood through glucose transporters (GLUT) and either diﬀuses in the
extracellular space or transfers to astrocytic end-feet (Fig 2). Subsequently interstitial glucose
is passively transferred to neurons and glial cells by a family of membrane-spanning carrier
proteins: the GLUTs [90] (Fig 2). Several GLUT isoforms are present in the brain: GLUT1
is present in all brain cells including the endothelial capillary cells and is consider the main
carrier at the blood–brain barrier (BBB), while GLUT3 is almost restricted to neurons [90].
GLUTs are diﬀerentially express between cell types but may also vary during acute brain injury
thereby inﬂuencing energetic substrate capture [91, 92, 93]: A reduction in endothelial GLUT1
expression has been reported in epileptic human brain [93]; In a diﬀuse TBI rat model neuronal
GLUT3 was found to increase by at least 300% whereas GLUT1 expression did not change [91].
A better understanding of how brain take and consume energetic substrate under pathological
condition is fundamental to further investigate the way we manage carbohydrate supply in the
ICU.
Cellular glucose is either directly exported into the interstitial medium or metabolized to
glucose-6-Phosphate. Glucose-6P can be processed into three main metabolic pathways: gly-
colysis, pentose phosphate or glycogen synthesis (Fig 3). Glycolysis theoretical approach en-
compass two diﬀerent chain reaction whether oxygen is involve or not:
• Anaerobic glycolysis: Glucose-6P is converted during multiple reaction to pyruvate
and subsequently to lactate by lactate dehydrogenase. This chain reaction produces
nicotinamide adenine dinucleotide reduced (NADH) and only 2 ATP molecules.
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Figure 1: Neuro-vascular coupling mechanisms: A. Astrocyte hypothesized to sense glu-
tamate through mGluR increasing intracellular calcium and generating AA from PLA2 which is
converted by COX1 (or 3) to PG and by P450 epoxygenase to EETs. Both PGs and EETs can
relax SMCs. Increasing intracellular calcium can also open KCa and subsequently modify SMCs
tone threw sarcolemma Kir [80]. Endothelial cells can increase their intracellular calcium in
response to receptor (R) binding causing IP3-mediated release of calcium from the endothelial
ER. PLC (or PLA2) can also produce EETs and AA derivatives both of which can drive SMC re-
laxation. Intracellular calcium increases can also lead to endothelial hyperpolarization through
opening of KCa. Endothelial hyperpolarization can spread rapidly to adjacent endothelial cells
through gap junctions and is coupled to encircling SMCs either through MEGJs or some other
EDHF. SMC hyperpolarization causes relaxation through closure of Cav. Adapted from Chen
et al 2014 [74] B. vascular organization of the cerebral cortex, with deeper capillary beds (3) fed
by perpendicularly oriented penetrating arterioles (2) that branch from superﬁcial pial arteries
(1). Confocal laser scanning microscopy, from ﬁxed human brain. Scale-bar = 500μm. adapted
from Alfonso Rodriguez Baeza et al 1998 [67].
Abbreviation : mGluR, Metabotropic glutamate receptor; PLA2, Phospholipase A2; AA,
Arachidonic acid ; PG, Prostaglandins; EETs, Epoxy-eicosatrienoic acid; 20 HETE, 20-
hydroxyeicosatetraenoic acid; SMCs, Smooth muscle cells; R, Receptor; ACh, Acetylcholine;
BK, Bradykinin; ATP, Adenosine triphosphate; ADP, Adenosine diphosphate; UTP, Uridine
triphosphate; IP3, Inositol triphosphate; ER, Endoplasmic reticulum; PLC, Phospholipase C;
DAG, Diacyl-glycerol; NO, Nitric oxide; PGI2, Prostacyclin; KCa, Calcium-dependent potas-
sium channels; MEGJs, Myoendothelial gap junctions; EDHF, Endothelium-derived hyperpo-
larizing factor; Cav, Voltage-dependent calcium channels; Kir, Strong inward rectiﬁer potassium
channels; (?), Potential signaling pathways.
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Figure 2: Brain Nutriment transport A. Diagrammatic representation of potential routes
of glucose diﬀusion from blood Route 1: Glucose traverse the basal lamina whence it is
transported into the astrocytic endfoot. Route 2: Diﬀusion of glucose throughout the basal
lamina, into the interstitium. B. A schematic representation of the cellular localization of
glucose transporter (GLUTs) and monocarboxylate transporters (MCTs) in mammalian brain.
Adapted from Simpson et al 2007 [90]
• Aerobic complete glycolysis: Complete oxidation of glucose whereby pyruvate is con-
verted in acetyl-CoA instead of lactate, and enters mitochondrial tricarboxylic acid cycle
(oxidative pathway). The respiratory chain subsequently produces 30-34 ATP molecules
using NADH molecules.
Glucose can also serve neurotransmitter synthesis such as glutamate, acetyl-choline and γ-
aminobutyric acid. Neurons and astrocytes metabolic speciﬁcity and interactions are still de-
bated (see section below: “Modelling brain metabolism”).
2.2.2.4 Other substrates
Apart from glucose, the brain has the capacity to use other blood-derived energy substrates,
e.g. ketone bodies during development and starvation or lactate during periods of intense
physical activity [94, 85]. Long considered as an end product of anaerobic glycolysis, lactate
is known to act as a “Cell-Cell” shuttle in many organs (e.g. muscle, liver, kidney, heart and
brain) and even as an energetic shuttle between remote organs during exercise. For instance,
during sustained exercise lactate consumption equals or exceeds that of glucose in heart and
muscle [95]. Facilitated transport of lactate across membranes is accomplished by a family
of MCT that account also for pyruvate, acetoacetate, and β-hydroxybutyrate (ketone bodies)
transport. MCTs are diﬀerentially expressed in cells and tissues (e.g. Fig 2 in brain cells)
and their cerebral expression can increase during physiological process (development [96] or
exercise [95]) or during pathological situation such as TBI [97].
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Figure 3: glucose metabolic path-
way: Glucose enters cells through glu-
cose transporters (GLUTs) and is phos-
phorylated by HK to produce glucose-6-
phosphate (glucose-6P). Glucose-6P can
be processed into three main metabolic
pathways. Glycolysis giving rise to pyru-
vate. Pyruvate can then enter mito-
chondria, where it is metabolized through
the tricarboxylic acid (TCA) cycle (ox-
idative pathway), or be reduced to lac-
tate by lactate dehy-drogenase (LDH). Al-
ternatively, glucose-6P can be processed
through the pentose phosphate path-
way, leading to the production of reduc-
ing equivalent in the form of NADPH. Fi-
nally, glucose-6P can also be used to store
glucosyl units as glycogen. Adapted
from Bélanger et al 2011 [85]
Abbreviations : GPI, glucose-6-phosphate isomerase; PFK, phosphofructokinase-1; Fructose-
1,6-P2, fructose-1,6-bisphosphate; DHAP, dihydroxyacetone phosphate; TPI, triose phosphate
isomerase;GA3P, glyceraldehyde 3P; G6PDH, glucose-6-phosphate dehydrogenase; 6-PGL,
6-phosphoglucono-d-lactone; 6-PG, 6-phosphogluconate; 6 PGDH, 6-phosphogluconate de-
hydrogenase; ribulose-5P, ribulose-5-phosphate; ribose-5P, ribose-5-phosphate; xylulose-5P,
xylulose-5-phosphate; TK, transketolase; sedoheptulose-7P, sedoheptulose-7-phosphate; TA,
transaldolase; and erythrose-4P, erythrose-4-phosphate.
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Figure 4: Brain metabolism hypothesis: A. The astrocyte-to-neuron lactate shuttle. B.
The redox switch/redox coupling. Adapted from Cerdán et al 2006 [102]
Abbreviations : Asp, aspartate; Glc, glucose; Gln, glutamine; Glu, glutamate; GLUT1 and
GLUT3, glucose transporters 1 and 3; a-KG, α-ketoglutarate; Lac, lactate; LDH1 and LDH5,
lactate dehydrogenase 1 and 5; Mal, malate; Pp, derived from extracellular monocarboxylates;
Pg, derived from glycolysis.
2.2.3 Modelling brain metabolism
2.2.3.1 Astrocyte-to-neuron shuttle
Understanding metabolic coupling between neurons and astrocytes remains a struggling ques-
tion. In 1994 Pellerin and Magistretti proposed the so called “Astrocyte-to-Neuron lactate
shuttle” [98]. Using primary culture of cerebral astrocytes together with a radioactive glucose
tracer (2-Deoxy-D-[1,2-3H]glucose) they shown that L-Glutamate stimulates glucose uptake
and phosphorylation by astrocytes in a concentration dependent manner (EC50=80μM), with
a release of lactate and pyruvate in the medium. This eﬀect was abolished by the glutamate
transporter inhibitor DL-threo-β-hydroxyaspartate. Together with observations of astrocyte’s
end-feet en-warping brain capillaries, the authors suggested the existence of a cooperative
mechanism whereby glutamate uptake triggers glycolysis in astrocytes (glucose utilization and
lactate production). Lactate once release can be taken-up by neurons and serve as an energy
substrate (Fig 4 A.).
From then on, many in vitro studies support this hypothesis where astrocytes are specialized in
glycolysis and glycogen storage, whereas neurons are more prone to oxidative pathway [85]. For
instance, cultured astrocytes were found to metabolize glucose mainly to lactate and release it
into the external medium, but have limited capacity to oxidise glucose or lactate. In contrast,
neurons released less lactate into the medium and oxidized both glucose and lactate to CO2
far more rapidly than astrocytes [99]. Furthermore, proteomic analysis shows that although
phosphofructokinase mRNA is present in both neurons and astrocytes, the protein is absent in
neurons through post-transcriptional degradation. In these experiments the rate of glucose con-
sumption through the pentose phosphate pathway double the one through glycolysis in neurons
whereas astrocytes depict a substantial glycolysis [100]. Finally by inactivating an astrocyte-
speciﬁc glutamate transporter (GLAST) in vivo, Cholet et al. evidenced a signiﬁcant reduction
in cerebral glucose uptake triggered by a sensory stimulation [101]. However considering the
7.4 fold higher aﬃnity of neuronal GLUT3 compare to astroglial GLUT1, the “astrocyte-to-
neuron” shuttle model fails to predict data from carbohydrate ﬂux on slice or during visual
stimulation [90, 103, 104]. Therefore Simpson et al. published a “neuron-to-astrocyte” shuttle,
lactate being released more by neurons that astrocytes, with good prediction of lactate dy-
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namics during hippocampal stimulation [90, 104]. Moreover in vivo experiments using labelled
glucose found glucose uptake to be even or higher in neuron than in astrocytes [105, 106]. The
high hexokinase level found in neuron’s soma compared to astrocytes by Lungaarg et al. also
support neuronal glycolysis capacity [107].
2.2.3.2 Redox switch/redox coupling
In 2004 Kasischke et al. pave the way to a redox coupling view of astrocytes-neurons interaction,
with a sub-cellular compartmentalization. After hippocampal stimulation, they described a
biphasic NADH response very similar to extracellular lactate modiﬁcations measured with
enzyme-based biosensor [90, 104] (Fig 5). It turns out that this biphasic modiﬁcation include
two anti-localized component [108]:
• An initial neuronal dip in NADH ﬂuorescence, that mostly reﬂect oxidative metabolism
(mitochondrial NADH consumption for ATP production).
• A late astrocytic over-shoot of NADH ﬂuorescence, that reﬂect anaerobic glycolysis with
NADH production.
These results suggest very local coupling between neurons with a high mitochondrial density
and astrocyte’s processes, depending on their NADH/nicotinamide adenine dinucleotide oxi-
dized (NAD+) ratio.
Using U-13C6 glucose and 3-13C pyruvate with primary cultured neurons, it is possible to
discriminate lactate coming from glucose (2,3-13C2) and extracellular pyruvate (3-13C). This
technique allow Cruz et al. in 2001 to evidence two diﬀerent pools of intracellular pyruvate
derive either from extracellular glucose (Pg) or monocarboxylates (Pp) [109]. Together with
Kasischke’s results Cerdán et al. suggest a subcellular compartmentalization of pyruvate and
glutamate in neurons and astrocytes [102], with a “redox switch/redox coupling”: The
subcellular compartmentalization of pyruvate allows neurons and astrocytes to select between
glucose and lactate as alternative substrates, depending on their relative extracellular concen-
tration and the operation of a redox switch. This mechanism is based on the inhibition of
glycolysis at the level of glyceraldehyde-3-phosphate (GA3P) dehydrogenase (GA3P ↔ Pyru-
vate, Fig 3) by NAD+ limitation, under suﬃciently reduced cytosolic NAD+/NADH redox
conditions. Lactate and pyruvate recycling through the plasma membrane allows the return to
the extracellular medium of cytosolic monocarboxylates enabling their trans-cellular, reversible,
exchange between neurons and astrocytes. Together, intracellular pyruvate compartmentaliza-
tion and monocarboxylate recycling result in an eﬀective trans-cellular coupling between the
cytosolic NAD+/NADH redox states of both neurons and glial cells (Fig 4 B.). This coupling
could therefore operate diﬀerently in remote cell compartments (e.g. neuron’s dendrite, axons
and soma).
These two models of metabolic cellular cooperation are not mutually exclusive. In fact during
physiological brain activation, the “redox switch/redox coupling” prediction ﬁt the “astrocyte-
to-neuron” lactate shuttle. However, during pathological process with great metabolic chal-
lenge, the redox cooperation might be diﬀerent.
Most of our knowledge about brain metabolism is based on experiments conducted either in
vitro (i.e. cell culture and brain slices) or in vivo in healthy animals. Yet, these models valid-
ity during pathological processes such as acute brain injury where heterogeneous parameter’s
modiﬁcations will take place is poorly understood. Low oxygen and/or glucose concentration in
brain slice’s medium allow for in vitro brain aggression modeling. Either of this condition will
induce neuronal depolarization (also called anoxic depolarization) that can be recorded in vivo
in human or animal during cardiac arrest. It turns out that neither lactate nor pyruvate, in the
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Figure 5: NADH-NAD+ and lactate
coupling: A. Online extracellular lactate
concentration recordings with an enzymatic
biosensor after hippocampal stimulation in
vivo. Note the initial dip prior to the over-
shoot. The black arrow display the stimula-
tion’s onset. Adapted from Hu et al. [104].
B. NADH dynamic and C. location dur-
ing Schaﬀer pathway stimulation: intrinsic
tissue ﬂuorescence imaging on hippocampal
slice. The initial NADH dip (green) concomi-
tant with the lactate decrease (A.) is located
in the neuropil whereas the following over-
shoot (red) is localized in astrocytes. The
black curve in (B.) represent total NADH
ﬂuorescence. Adapted from Kasischke et al
2006 [108]. Abbreviations: NADH, nicoti-
namide adenine dinucleotide reduced. White
scale bar in C. 50μm.
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presence of oxygen, were able to prevent neuronal depolarization when blocking glycolysis at
the GA3P dehydrogenase level. However glucose infusion seems suﬃcient to sustain energetic
expenditure in the absence of oxygen [110].
During pathological conditions brain tissue can also be challenged by spreading depolarizations:
CSDs. Upon such depolarization the local redox state does not depend on cell types but rather
on their distance to the vasculature: tissues located closer than 8–10 mm from a capillary vessel
wall showed NADH dips, whereas those located further away showed NADH overshoots [111].
2.3 Cerebral perfusion and blood ﬂow alterations
The Scottish anatomist Alexander Monro ﬁrst described the ICP in 1783 [112]. In 1926, Harvey
Cushing, an American neurosurgeon, formulated the doctrine as we know it today, namely that
with an intact skull, the volume of the brain, blood, and CSF is constant. An increase in one
component will cause a decrease in one or both of the other components [113].
Brain blood ﬂow can be modelled with Ohm’s law which states that ﬂow is proportional to
the diﬀerence in inﬂow and outﬂow pressure (ΔP ) divided by the resistance to ﬂow (R): ﬂow
= ΔP/R. In the brain, ΔP is cerebral perfusion pressure (CPP): arterial pressure - pressure
in veins. Systemic venous pressure is normally low (2–5 mmHg) so that brain venous ﬂow is
inﬂuenced directly by ICP. Therefore, CPP is calculated as the diﬀerence between MAP and
ICP.
Under physiological situations CBF range between 46 and 62ml· 100g−1·min−1 in humans [114,
115]. After TBI global CBF is lower [115], and displays heterogeneous distribution because of
edema, contusions and other lesions [116]. Ischemic thresholds that have been determined af-
ter carotid surgery or ischemic stroke (18-20 ml· 100g−1·min−1) [117], lead to the concept of
“penumbra area” between the ischemic core and well perfused remote brain tissue. In trau-
matic brain injury there is increasing evidence for the existence of a “traumatic penumbra”
most at risk of secondary ischemic neuronal injury [116]. However the threshold bellow which
irreversible tissue damages occur, is lower (15ml· 100g−1·min−1 [116]) with an intermediate
oligemic threshold of 33-35ml· 100g−1·min−1 [118, 119].
Blood ﬂow also depends on Poiseuielle’s law that states that ﬂow is directly related to ΔP ,
blood viscosity, and the length of the vessel (assumed to be constant) and inversely related to
vessel’s radius to the fourth power: ﬂow = (8 × η × L)/r4. Radius appears to be the most
powerful determinant of blood ﬂow and even small changes in lumen diameter have signiﬁcant
eﬀects on CBF [120].
At a macroscopic level, auto-regulation of CBF is the ability of the brain to maintain relatively
constant blood ﬂow despite changes in CPP, in the range of ≈60-160 mmHg, mainly by vessels
radius changes. Above and below these limits, auto-regulation is lost and cerebral blood ﬂow
becomes dependent on mean arterial pressure in a linear fashion. Lowering MAP within limits
of auto-regulation may increase vessel’s diameters and thereby cerebral blood volume. If the
brain pressure-volume curve is steep (e.g. during brain edema or intra-cranial mass expansion),
any increase in cerebral blood volume will result in a raise in ICP [121].
During brain aggressions like severe TBI, brain vessels can lost their auto-regulation proper-
ties. In such situation, CBF and subsequently cerebral blood volume, will follow MAP in a
linear relationship. Therefore, correlation between MAP and ICP ﬂuctuation has been used,
in the pressure reactivity index (PRx) calculation, as a surrogate to cerebral autoregulation
ability [122]. PRx is calculated online as the moving Pearson’s correlation coeﬃcients (i.e.
∈ [−1; 1]) between 40 past consecutive 5 second averages of ICP and MAP (i.e. a 5 seconds
moving window). When cerebro-vascular reactivity/autoregulation is intact, PRx has negative
or zero values, otherwise PRx is positive [123, 121].
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Figure 6: NMDA receptor binding sites:
Glutamate will bind the NR2 subunit so as
Zn2+, whereas the glycine binding site is lo-
cated on the NR1 subunit and binds either
D-serine or glycine. Abbreviations: CTD:
C terminal domain, TMD: trans-membrane
domain, ABD: Amino-acid binding domain,
NTD: N terminal domain.
2.4 Excitotoxicity
Glutamate is the main excitatory amino-acid in the central nervous system. It is released in the
extracellular space mainly by neurons, and recaptures through NA+ dependent transporters on
neurons (EEAC-1) or astroglial cells (GLAST, GLT-1) [124]. Aside from its neurotransmitter
action, glutamate is also known to play important roles during both brain development and
pathology.
Glutamate can activate either ionotropic or metabotropic receptors. N-methyl-D-aspartate re-
ceptors (NMDAR) are ionotropic glutamate receptors, permeable to divalent (e.g. Ca++) and
monovalent ions (e.g. Na+). It is a heterodimer composed of two subunits (NR1 and NR2).
The NR1 subunit is ubiquitous whereas the NR2 has diﬀerent subtypes (NR2A, B, C or D)
that are diﬀerentially expressed between brain regions and during development. NMDAR can
be located in the synapse or outside the synaptic cleft. The NR2A-containing NMDAR het-
erodimer subtype is preferentially located at the synapse whereas NR2B-containing NMDAR
is predominant outside the synaptic cleft in the adult cortex [125]. The cell membrane needs to
depolarize and glutamate with a co-agonist (D-serine or glycine) to bind, in order to activate
NMDAR. Glutamate binding site is located on the NR2 subunit, whereas its co-agonist glycine
or D-serine will reach the glycine binding site on the NR1 subunit (Fig 6). As a matter of fact,
inward current through this receptor can be gated by co-agonist extracellular concentrations.
Additional divalent ions binding sites on the NR2 subunit (for Zn2+) or the trans-membrane
domain (for Mg2+, Fig 6) can change NMDAR sensitivity to glutamate.
NMDAR lead to paradoxical actions. On one hand, it plays an important role in neuron
survival since elimination of NMDAR activity in vivo causes widespread apoptosis [126]. On
the other hand, over-activation of NMDAR, by sustained NMDA or glutamate exposure, can
promote neuronal death. This over activation of NMDAR is called excitotoxicity [127, 125]. It
has been proposed that NMDAR location is the main factor that determines their pro-apoptotic
or pro-survival eﬀects. Synaptic NMDAR are admitted to be neuroprotective, whereas extrasy-
naptic receptors over activation will promote cell death [127]. However, the question is still
under debate since recent study shows that blocking extra-synaptic NR2B-containing NMDAR
do not reduce excitotoxicity. Conversely cell death was prevented by reducing D-serine extra-
cellular concentrations (that preferentially binds synaptic NR2A-containing NMDAR) but not
glycine (that preferentially binds extra-synaptic NR2B-containing NMDAR). The authors sug-
gested that synaptic NR2A-containing NMDAR was more prone to induce excitotoxicity [125].
However D-serine is present both inside and outside synaptic cleft, with a 3.1±0.4μM extra-
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cellular concentration measured in vivo with biosensor [128]. These concentrations are much
lower that the one used by Papouin et al. in vitro (0.1-0.5mM) [125], but still way above NM-
DAR glycine binding site ED50 for D-serine or glycine (< 1μM) [129]. Therefore under such
extracellular concentrations the glycine binding site would be saturated.
Evidence about excitotoxic glutamate eﬀect through NMDAR have been demonstrated upon
high concentrations of glutamate or NMDA cell exposure. However the exact threshold of gluta-
mate concentrations or NMDAR inward currents, promoting excitotoxicity are unknown. Even
extracellular in vivo concentrations are still debated. Indeed, glutamate concentrations have
been measured with cMD < 2μM [130, 124] and around 1.2μM with biosensor in vivo [131].
Based on NMDAR inward current recorded in brain slices, some authors even suggested that
lower extracellular concentrations near 25nM are needed to prevent NMDAR opening [132].
Mechanisms as well as glutamate and D-serine concentrations that mediate excitotoxicity
through NMDAR remain to be clariﬁed.
2.5 Inﬂammation
Neuroinﬂammation in brain injury can been viewed as a double-edged sword mediating both
short-term beneﬁcial eﬀects for injured parenchyma and neuronal survival but also adverse
inﬂuences that contribute to secondary brain damage and neuronal loss. Early after brain in-
jury, chemokines release as well as expression of adhesion molecules (I-CAM and V-CAM) by
endothelial cells will drive leukocytes extravasation across the BBB [133, 134, 135, 136]. Mono-
cytes and microglial cells during these pathological conditions encompass diﬀerent phenotypes.
In fact if microglial cells will be involved in injury repair, they can also release toxic agent such
as reactive oxygen species (ROS) [137, 133]. It is well established that microglial form and
function are inextricably linked. In recent years, the traditional view of microglial form ranging
between “ramiﬁed resting” and “activated amoeboid” has been emphasized through imaging
techniques that point to highly dynamic microglial forms. Moreover, microglia adopt interme-
diate forms, with considerable crossover in function and morphologies as they cycle, migrate,
phagocytose, and extend and retract ﬁne and gross processes [138, 139]. Images from brain
slice of moderate to severe TBI survivors suggest that persistent inﬂammation with microglial
activation in white matter promotes degeneration and chronic encephalopathy [140].
Microglia can be looked at from diﬀerent perspectives: their form but also their chemokines
expression. As peripheral tissue macrophages, microglial cells seems to have the capacity for
multiple activation states according to their environment. Their activation spectrum spans sev-
eral stages with diﬀerent functions, between an “M1 pro-inﬂammatory” (with ROS and TNFα
release) to an “M2 anti-inﬂammatory” type (with IL10 and TGFβ production) [141, 142].
Next generation therapeutic acting on neuro-inﬂammation will probably try to promote one
microglial phenotype over the others instead of blocking leukocytes extravasation or use large
anti-inﬂammatory molecules.
Finally the role of inﬁltrating T cells has not received a great interest. Recently Walsh et
al. published evidences that CD4 T-cells mediate neuroprotection after central nervous sys-
tem (CNS) injury that is independent of the major histocompatibility complex and the T-cell
receptor (MHCII/TCR). Conversely, CD4 T-cells produced IL-4 which attenuate damage via
IL-4 receptors on neurons [143].
2.6 Abnormal brain activity
Neuronal activity is usually altered during acute brain injury. Either because of brain aggres-
sion or sedative drugs administered in the ICU. Spontaneous electroencephalography (EEG)
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can for example display transient electrocerebral silence or decrease in alpha rhythm power
(8-12Hz). However these patterns are only surrogates of altered brain condition and might not
be deleterious per se.
Conversely epileptic activity results from excessive and abnormal cortical nerve cell activity,
and is consider a huge energy expenditure [144]. Convulsive seizures can occurs in 11% to 55%
of patients undergoing severe TBI [145] and non-convulsive seizure in 22% of moderate or severe
TBI, 25% of whom will develop a non-convulsive status epilepticus [36]. Such adverse events
are considered part of secondary brain aggressions as they can lead to sustain increase in ICP
or altered brain metabolism (e.g. metabolic crisis with a sustain increase in lactate/pyruvate
ratio) [145, 146]. Moreover epileptic activity has been found to rise brain glutamate concentra-
tion and thereby are considered to generate excitotoxic injury [145, 146].
More recently large waves of depolarizations have been recorded in the human injured brain
with sub-dural electrodes recordings called “Cortical spreading depolarizations”. Those are
waves of electrical silence caused by massive neuronal depolarizations that spread across the
brain, causing a local loss of function. The brain’s electrical activity will eventually recover.
However, with each brain depolarization considered as “tsunami” waves, damage to cells may
worsen. Further insight about their contribution to secondary brain aggressions will be discuss
later in a dedicated chapter 4.
Over the past decades, major achievements have been made in neurological ICU, mainly re-
garding monitoring techniques design to address these secondary brain aggressions. So far these
techniques were mostly evaluated to assess prognosis evaluations. The next neurological ICU
revolution will probably deﬁne a conjunction of surrogate markers based on multi-modal mon-
itoring information (e.g. CBF indexes, MRI, biomarkers and electro-physiological signals) in
order to develop custom therapeutic interventions to act on local secondary brain aggressions.
The next chapter will describe advantages and drawback of diﬀerent monitoring device available
in the ICU.
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Chapter 3
Monitoring techniques and their
implication in clinical course evaluation
3.1 Usual monitoring techniques
3.1.1 Intra-cranial pressure
ICP devices can be implanted during diﬀerent pathological states such as severe TBI, sub-
arachnoid hemorrhage, intra-cranial hematoma, hydrocephalus, central nervous system infec-
tion, malignant stroke. Several diﬀerent invasive methods for measuring ICP exist. Depending
on the technique, ICP measurement can be undertaken in diﬀerent intracranial anatomical lo-
cations: intraventricular, intraparenchymal, epidural, subdural, and subarachnoid.
External ventricular drainage (EVD) is considered the gold standard, and can also be
used for cerebro-spinal ﬂuid (CSF) drainage and administering of medicine intrathecally. In a
meta-analysis Binz et al. found the overall hemorrhage risk associated with ventriculostomy
placement to be 5.7%, but raise to 10% if systematic CT were performed (Clinically signiﬁcant
hemorrhage < 1%) [147]. The infection or colonization rate is hard to asses depending on its
deﬁnition (catheter culture or repeated CSF sample) and range between 2 and 20% [148]. Gram-
positive cocci (consistent with skin ﬂora) such as Staphylococcus epidermidis and Staphylococcus
aureus are the most common pathogens involved. The main risk factors are: non adherence to
rigid insertion and maintenance protocols, leakage of CSF, catheter irrigation and the frequency
of EVD manipulation [148].
Microtransducer ICP monitoring devices include ﬁber-optic devices, strain gauge de-
vices, and pneumatic sensors. Their infection rate is very low (0-8%) like the hemorrhage
one (< 2%) [149]. Fiber optic devices, such as the Camino ICP Monitor, transmit light via
a ﬁber-optic cable towards a displaceable mirror. Changes in ICP will move the mirror, and
the diﬀerences in intensity of the reﬂected light are translated to an ICP value. The Codman
MicroSensor, the Raumedic Neurovent-P ICP sensor, and the Pressio sensor belong to the
group of piezoelectric strain gauge devices. When the transducer is bent because of the ICP,
its resistance changes, and an ICP can be calculated. Pneumatic sensors (Spiegelberg) use a
small balloon in the distal end of the catheter to register changes in pressure, and additionally
allows quantitative measurement of intracranial compliance.
The most widely used ICP microtransducers, are those measuring ICP intraparenchymally, usu-
ally placed in the right frontal region at a depth of approximately 2 cm. However, depending
on known or suspected pressure gradients across intracranial compartments, the placement can
be modiﬁed.
It is important to realize that even with a ventricular catheter, uniformly distributed ICP will
only be observed when CSF circulates freely between all its natural pools. An intraparenchymal
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Figure 7: Visualization of correlation between GOS and average number of ICP
insults per GOS category: Left adult cohort. Right pediatric cohort. Each color-coded
point in the graph refers to a number of episodes of ICP, deﬁned by a certain ICP intensity
threshold (X-axis), and a certain duration threshold (Y-axis). The univariate correlation of
each type of ICP insult with outcome is color-coded: Dark red episodes mean that such ICP
insults are associated with worse outcome; dark blue episodes mean that such ICP insults
are associated with better outcome. The contour of zero correlation is highlighted in black.
Adapted from Güizan et al. 2015 [154]
probe measures local pressure that can be compartmentalized and is not necessarily identical
with intraventricular pressure. Signiﬁcant pressure gradients may exist in patients with in-
tracranial hypertension. For example supratentorial measurements do not necessarily reﬂect
infratentorial pressure and bilateral ICP monitoring has demonstrated large ICP gradients in
patients with expanding mass lesions, subdural hematomas, or even in absence of space occu-
pying lesions [150, 151].
Normal ICP varies with age and body posture but is generally considered to be 5-15 mmHg
in healthy supine adults, 3-7 mmHg in children and 1,5-6 mmHg in infants [152, 149]. Aver-
age ICP > 20mmHg in the ﬁrst 48 h of monitoring is an independent predictor of mortality
and functional 6-month outcome in moderate or severe TBI patients [153, 154]. Recently data
from the “European Union Brain-IT project” showed that the cumulative intracranial pressure-
time burden is independently associated with mortality. In fact ICP above 20 mmHg lasting
longer than 37min in adults, and longer than 8 min in children, are associated with worse out-
comes [154]. But long lasting ICP between 15 and 20 mmHg can also lead to bad outcome [154]
(Fig 7). This highlights that not only ICP threshold is important but other features such as the
time spend above a threshold and the CPP (i.e. mean arterial pressure - ICP) are important.
Diﬀerent patterns of ICP changes are typically observed after TBI:
• Low (< 20 mm Hg) and stable ICP: This pattern is seen after uncomplicated head injury
or during the early hours after severe TBI, before brain swelling evolves.
• High (> 20 mm Hg) and stable ICP: This is the most common pattern seen after severe
TBI.
• ICP waves: These reﬂect reduced intracranial compliance and are discussed in detail
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below.
• ICP changes related to changes in arterial blood pressure: These occur in the presence
of abolished cerebral auto regulatory responses when ICP changes directly with arterial
blood pressure. See details about the PRx below.
• Refractory intracranial hypertension: In the absence of aggressive treatment strategies
this may progress to herniation and death.
In 1965, Lundberg et al. characterized ICP slow waves. “A” waves or “plateau” waves are
steep increases in ICP from baseline to peaks of 50-80 mm Hg that persist for 5-20 min. These
waves are always pathological and may be associated with early signs of brain herniation,
such as bradycardia and hypertension. They occur in patients with intact autoregulation
and reduced intracranial compliance and represent reﬂex, phasic vasodilation in response to
reduced cerebral perfusion. The development of plateau waves leads to a vicious cycle, with
reductions in CPP predisposing to the development of more plateau waves, further reductions
in CPP and irreversible cerebral ischemia. “B” waves are rhythmic oscillations occurring at
0.5-2 waves/min with peak ICP increasing to around 20-30 mm Hg above baseline. They are
related to changes in vascular tone, probably due to vasomotor instability when CPP is at the
lower limit of pressure autoregulation. “C” waves are oscillations occurring with a frequency of
4-8/min and are of much smaller amplitude than B waves, peaking at 20 mm Hg. They occur
synchronously with ABP, reﬂect changes in systemic vasomotor tone, and are of no pathologic
signiﬁcance [155, 152].
As describe in the previous chapter 2, PRx represent a surrogate to cerebral autoregulation. It
is computed online as the correlation between ICP and MAP in a 5 sec moving window [122].
When cerebro-vascular reactivity is intact, PRx has negative or zero values, otherwise PRx is
positive [123]. PRx has been related to patient’s mortality and outcome, and have diﬀerent
thresholds for survival (0.25) and for favorable outcome (0.05) [156]. CPP is also associated
with survival, but the optimal CPP might be diﬀerent between each patients. Therefore, ﬁnding
the ideal CPP that provide suﬃcient energy supply while avoiding edema and increases in ICP
is a key element of severe TBI management in the ICU. Optimal CPP can be deﬁned when the
lowest PRx (i.e. the best autoregulation index) is reached. Patients with a mean CPP close
to their optimal CPP are more likely to have a favorable outcome. Hence, minimal achievable
PRx, have been proposed to guide CPP in head injured patients [157].
3.1.2 Trans-cranial Doppler
Trans-cranial Doppler (TCD) uses ultrasounds applied at each temporal windows of the skull.
It is a bedside non-invasive technique used in the ICU or the emergency room, as well as
out-of-hospital [158]. The ﬁrst mode commonly used is “B-mode” imaging, which displays a
2-dimensional image as seen by the ultrasound probe. The “B-mode” gives anatomical infor-
mation about brain parenchyma and ventricles. Some authors used it for hydrocephalus (third
ventricle size) [159, 160, 161], cerebral hernia (mid-line shift) [162], or intra-cranial hematoma
identiﬁcation [163].
The second mode use color Doppler images to ﬁnd desired blood vessel. Subsequently blood
ﬂow velocities may be measured with a pulsed Doppler eﬀect, which graphs velocities over time
in a small anatomical window. Most commonly insonated in clinical practice is the middle
cerebral artery which is easily accessible [164]. The diﬀerence between systolic and diastolic
ﬂow velocity, divided by the mean ﬂow velocity, is called the pulsatility index (PI, equation (1)).
PI = V s − V d
V m
(1)
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Where Vs is systolic velocity, Vd the diastolic velocity and Vm the mean velocity. Mea-
surements of ﬂow velocity are only estimators of CBF, and changes in ﬂow velocity corre-
late with the changes in CBF only if the angle of insonation and the diameter of the in-
sonated vessel remain constant. Indeed, CBF is related to ﬂow velocity as follows: CBF =
HR × TV I × blood vessel cross − sectional area, where HR is heart rate and TVI is the time
velocity integral (i.e. area under the spectral curve). Blood ﬂow in the basal cerebral arteries,
as in the arteries of other vital organs (liver, kidney, and heart), has a prominent diastolic
component. Vd reﬂects the degree of downstream vascular resistance, whereas Vs depends
on upstream determinants, that is, cardiac output, ipsilateral carotid blood ﬂow, and arterial
blood pressure. Vm is the weighted ﬂow velocity that takes into account the diﬀerent velocities
of the formed elements in the blood vessel insonated, and decreases with low CBF. In TBI
patients, a low Vd, a peaked waveform, and higher pulsatility index values can be observed
during high vascular bed resistance induced by elevated intracranial pressure ICP or hypocap-
nia [165, 166, 164].
After mild to moderate TBI (i.e. GCS 9-15), one of the key management issue in these pa-
tients is to recognize early those at high risk for neurological deterioration despite their initial
reassuring presentation. TCD has been found be a reliable tool to identify such patients when
Vd< 25cm/s and IP> 1.25 [167]. Therefore, TCD on admission may complete CT for accurate
patient evaluation.
After severe TBI TCD has been use to identify and treat brain hypoperfusion (i.e. Vm
< 30cm/s, Vd < 20cm/s or PI > 1.4) [168, 158], that is related to bad outcome [169]. In
such high-risk patients, early TCD goal-directed therapy can restore normal cerebral perfusion
and might then potentially help in reducing the extent of secondary brain injury [168].
3.1.3 Pupil reactivity
The main brain-stem reﬂex that is always assessed by physicians, even during out-of-hospital
management, is pupil reactivity. The photosensitive retinal ganglion cells convey light infor-
mation to the optic nerve. The optic nerve connects to the pretectal nucleus of the upper
midbrain, bypassing the lateral geniculate nucleus and the primary visual cortex. From the
pretectal nucleus, axons connect to neurons in the Edinger-Westphal nucleus, whose axons run
along both the left and right oculomotor nerves. Parasympathetic neurons from the oculomotor
nerve synapse on ciliary ganglion neurons. Finally short ciliary nerves leave the ciliary ganglion
to innervate the iris sphincter muscle of the iris. Under normal conditions, the pupils of both
eyes respond identically to a light stimulus, regardless of which eye is being stimulated. Light
entering one eye produces a constriction of the pupil of that eye, the direct response, as well as a
constriction of the pupil of the unstimulated eye, the consensual response. Lack of the pupillary
reﬂex or an abnormal pupillary reﬂex can be caused by optic nerve damage, oculomotor nerve
damage, brain stem death and depressant drugs, such as barbiturates. Comparing these two
responses in both eyes is helpful in locating a lesion.
Traditionally, pupil measurements have been performed with a pen ﬂashlight to evaluate re-
activity and pupil size. Pupil can be either “reactive”, “slightly reactive” or “non-reactive”.
Anisocoric or bilateral non-reactive pupil has been evaluated in the IMPACT and CRASH TBI
databases with an adjusted OR close to 2 for unfavorable outcome [12].
However these are subjective terms with a signiﬁcant level of inter-examiner variability when
slight reactivity is present. Hence, automated infra-red pupillometer are used daily in the ICU
for brain injury follow-up. Moreover, quantitative pupil reactivity is able to predict cardiac ar-
rest outcome with comparable sensitivity and speciﬁcity than EEG and evoked potentials [170].
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3.2 Brain metabolism assessment methods
PET is broadly use to investigate brain metabolism and perfusion. For instance 18F-2-deoxyglucose
tracer allow for global and local CMRglucose with a spatial resolution in the order of millimeters.
Likewise spectroscopic MRI gives precise information about global and local brain molecules
concentration such as glucose or lactate [171]. Unfortunately, even if those imaging techniques
are of great interest, their application remain limited to research protocols.
Instead global and/or local techniques allow for cerebral metabolism follow-up at the bedside
in the ICU.
3.2.1 Global assessment
3.2.1.1 Oxygen
Venous jugular oxygen saturation (SvjO2) can be used in the ICU to follow the ration between
brain oxygen consumption and supply. SvjO2 needs a retrograde internal jugular catheterization
placed in the jugular bulb to avoid extra-cranial blood contamination. Placement of the catheter
have to be conﬁrmed by lateral skull x-ray [172, 173, 115]. SvjO2 can be measured continuously
with an optic ﬁber (calibration needed each 12-24h, more prone to thrombosis) [174, 115], or
by repeated blood sample (results are dependent on aspiration procedure) [175].
According to the Fick principle, the arterio-venous diﬀerence in oxygen content (avDO2), which
is a surrogate to brain oxygen extraction, is proportional to CMRO2 and CBF :
avDO2 =
CMRO2
CBF
= (SaO2 − SvjO2) × Hb × 1.34 + (PaO2 − PvO2) × 0.03 (2)
Where SaO2 the arterial oxygen saturation, PaO2, arterial oxygen partial pressure, PvO2 jugular
venous oxygen partial pressure and Hb blood haemoglobin. The last part can be neglect leading
to:
SvjO2 = SaO2 − CMRO2
CBF × Hb × 1.34 (3)
SvjO2 average in a normal awake subject, is 62% with a range of 55% to 71%. [176, 177].
According to equation (3), decreased values can come from (1) any numerator increase (e.g.
CMRO2 increase during seizure, consciousness, or fever) or (2) any denominator element de-
crease: insuﬃcient CBF (e.g. during hypotension or increased ICP) or anemia.
Although values ≤ 50% are associated with low GOS in patients with severe TBI [178], the
last “guidelines for the management of severe TBI” from 2007 (build by the brain trauma foun-
dation and the American Association of Neurological Surgeons (AANS) and the Congress of
Neurological Surgeons (CNS)) hold only a level III to SvjO2 monitoring [179].
3.2.1.2 Glucose and lactate
Not only retrograde jugular line is used for SvjO2 measures, but also for global carbohydrate
metabolism evaluation with glucose and lactate blood content. Hence, the arterio-venous dif-
ference in glucose blood content (avDgluc), arterio-venous diﬀerence in lactate blood content
(avDL), or avDO2, gives a global brain metabolism overview.
In 2003 Glenn et al. gives an extensive description of the mean global parameters in healthy
and TBI patients with retrograde jugular line [115] (Table 5). They point out that in sedated
TBI patients both CMRO2, CMRglucose were depressed. In this study, multivariate analysis
shows that the mean parameters most related to the outcome were CMRO2, arterial lactate
levels, arterial glucose levels and a trend for CBF. They also found a CMRlact increase after
TBI, and that episodes of increased lactate uptake occurred most frequently in unfavorable
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Parameter TBI patients healthy volunteers p
CBF (ml. 100g−1.min−1) 40.17 ± 13.2 46.2 ± 10.5 0.01
CMRO2 (ml. 100g−1.min−1) 1.4 ± 0.43 3.10 ± 0.56 0.0001
CMRglc (mg. 100g−1.min−1) 3.43 ± 2.32 4.46 ± 1.16 0.0002
CMRlac (mg. 100g−1.min−1) 0.0355 ± 0.41 −0.18 ± 0.21 0.0001
avDO2 (ml. dl−1) 3.76 ± 1.37 6.89 ± 1.35 0.0001
avDglc (mg. dl−1) 8.94 ± 6.57 9.89 ± 2.92 0.002
avDlac (mg. dl−1) 0.0464 ± 0.94 −0.40 ± 0.48 0.0002
Art glucose (mg. dl−1) 122.7 ± 33.8 82.2 ± 8.3 0.0001
Art lactate (mg. dl−1) 14.05 ± 8.2 6.7 ± 2.1 0.0001
Metabolic Ratio 4.11 ± 2.11 5.83 ± 1.41 0.0001
Jugo2Sat (%) 72.9 ± 8.6 61.7 ± 5.9 0.0001
Arto2Sat (%) 98.5 ± 1.5 97.5 ± 1.2 0.0001
Table 5: Carbohydrate metabolic rate. Adapted from Glenn et al. 2003 [115]
outcome patients (i.e. GOS 1-3) [115].
During hypoxia or ischemia, brain metabolism is altered and increased brain lactate can be ob-
served using cMD or in the CSF [115, 180] and will lead to an increased avDL. Thereby, the ﬁrst
index that can be extracted from these values is the lactate-oxygen index (LOI) (avDL/avDO2).
It is an estimation of the anaerobic brain metabolism. Hence, increased LOI > 0.08 reﬂect a
mismatch between oxygen supply and brain metabolism, and is associated with a bad out-
come [181].
The second parameter is the oxygen-glucose index (OGI) deﬁned by equation (4). The metabolic
ratio (MR) often use as a surrogate is the ration between avDO2 and avDgluc, but omit that
6 oxygen molecules are needed to oxidize one of glucose. This index represents the oxidative
glucose metabolism within the brain.
OGI = avDO26 × avDgluc (4)
Absolute hyperglycolysis is deﬁned as a CMRglucose greater than the 97.5th percentile of normal
for an awake human (i.e. CMRglucose> 6.69mg. 100g−1.min−1, normal = 4.46 ± 1.16, Table 5).
On the other hand relative hyper-glycolysis (i.e. when glucose uptake exceed oxygen consump-
tion) is deﬁned as a MR below the 2.5th percentile of normal values (i.e. MR < 3.44, normal =
5.83 ± 1.41, Table 5) [115, 182]. However even if relative hyperglycolysis appeared to be more
frequent in patients who died, neither episodes of absolute nor relative hyper-glycolysis were
strongly associated with 6 month GOS [115].
At the bedside, following global brain metabolism with retrograde jugular line requires repeated
combine arterial and jugular sample. Aspiration have to be gentle, and samples must be put
immediately in ice. These parameters were the ﬁrst available to measure brain metabolism in
the ICU and have been related to the outcome [181, 115], or ischemic lesions during carotid
surgery in awake patient [183].
However some discrepancy restricted their daily use. For instance, it can be caught oﬀ guard
during anemia and has been shown not to be always correlated with brain lactate concentra-
tion [184]. Finally this monitoring fails during unilateral ischemia, with discrepancies between
both sides leading the authors to conclude that unilateral jugular venous monitoring reliability
monitoring was suspicious [185].
Although it might be useful for diﬀuse TBI monitoring to manage CPP, there is no level I or
II recommendation for its daily use in the ICU.
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3.2.2 Local measures
To overcome jugular measures limitation, such as extra-cranial blood blending or transient
event missing, local techniques have been developed to measure similar parameters (i.e. oxygen
and carbohydrate concentrations) directly within brain tissue. It seems that after diﬀuse head
injury, local monitoring values (i.e. oxygen, CBF or cMD) are correlated to the overall white
matter CBF (R2=0.49) [119]. In the same study, Bouzat et al. found multi-modal monitoring
to better predict CBF than ICP alone, and should be therefore be use to detect oligemic
events [119]. However, this might not be the case when focal lesions take place with huge
metabolic discrepancies over the brain.
3.2.2.1 Brain oxygen partial pressure
In 1997 Charbel et al in were among the ﬁrst to measure PbtO2 continuously in the human
brain with the Paratrend 7TMsystem. This device gives concomitant PbtO2, CO2, pH and brain
bicarbonate concentrations. They found normal PbtO2 to be 33 ± 11mmHg [186], but during
neurosurgery it can range between 12 and 50mmHg in the grey matter [187].
PbtO2 can be measured with diﬀerent techniques: electrochemical (Clark type micro-electrode),
optical with luminescent material, electron paramagnetic resonance, or mass spectroscopy. At
the bedside PbtO2 is measure using either electrochemical (Licox R©, Integra neuroscience) or
optical technology (OxyLab pO2 R©, Oxford optronics, using ruthenium luminescent molecules).
There is a greater body of literature that describes the LicoxR© system. The electrochemi-
cal measurements of oxygen with Clark type micro-electrode is based on oxygen reduction at
a polarized cathode surface, producing an electrical current. In the 1950s, Clark enhanced
the performance and consistency of electrodes for use in biologic ﬂuids and tissues by elec-
trically insulating the anode and cathode with a gas-permeable, but not liquid-permeable,
membrane [188].
Factory probes calibration gives a linear relationship between electrical current and oxygen
concentration. Like all chemical reaction, the reduction of oxygen rate depend on temperature,
so that the relation between PbtO2 and the oxidative current have to be adjusted to brain/body
temperature.
Brain tissue oxygen
PbtO2 is heterogeneous and the PbtO2 at any given point will be a product of highly variable
local factors: the distance from vessels, the PO2 in those vessels, the local diﬀusion coeﬃcient
and the local rate of O2 consumption. Hence, there is no “characteristic oxygen tension”, rather
there is an oxygen tension ﬁeld in brain tissue that range between 6 and 25mmHg [189, 190].
Brain vascular oxygen content
PO2 values in the pial vessels range from approximately 60-110mmHg in arterioles and approx-
imately 35-60mmHg in venules. Using two-photon imaging, Sakadzić et al. measured PO2 in
penetrating arterioles and venules in the cortex, reporting that PO2 in descending arterioles at
the pial surface was approximately 60-70 mmHg, and that of ascending venules was around 40
mmHg. They noted that the vascular PO2 decreased in line with increasing branching order
and depth (≈ 10mmHg between 0-240μm below the pial surface) [189]. Finally PO2 in cap-
illaries was found around 30mmHg whatever the depth [189, 191, 192]. It is very important
to note that vascular O2 content is still debated since these measures are highly dependent on
hematocrite, CBF and region of interest (ROI) location vs red blood cells [192, 189, 191].
PbtO2 in the ICU
Given the large probe size (i.e. 600-800μm) with a sampling area around 14mm2 and the high
density of the capillary bed (Fig 1), PbtO2 measures in the ICU are a mix of capillaries, intra
and extracellular oxygen concentrations. PbtO2 probes are usually implanted in white matter
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parameter Normal values [200, 201] Critical values [202, 203]
Schultz Reinstrup High Low
lactate (mmol/L) 3.06 ± 0.32 2.9 ± 0.9 > 4 > 2.5
Glucose (mmol/L) 2.12 ± 0.15 1.7 ± 0.9 < 0.2 < 1
Pyruvate (μmol/L) 151 ± 11.5 166 ± 47 < 25*
Lactate/Pyruvate (%) 20 ± 2 23 ± 4 > 40 > 25
Glutamate (μmol/L) 14.4 ± 3.3 16 ± 16 > 5*
Glycerol (μmol/L) 81.6 ± 12.4 82 ± 44 > 50*
Table 6: Cerebral Microdialysis parameters: Normal values in anaesthetized patients
during neurosurgery in two studies [200, 201], and critical thresholds deﬁned by Paul Vespa
(hight) [202] or Juan Sahuquillo (low) using the 95 percentile of normal values for lactate and
25% as L/P thresholds [203, 180]; *, were used by Judith Marcoux et al. in 2008 [204].
where normal values range between 25 and 35mmHg [186, 193].
PbtO2 is linked to CBF, arterial oxygen content, oxygen extraction fraction, and CMRO2 [194].
Thereby, a PbtO2 decrease reﬂects either a decrease in CBF, an increase in CMRO2, or a de-
crease in oxygen arterial content.
PbtO2 values < 15mmHg have been related to an unfavorable outcome or death, however
like for ICP, the longer a patient experiences a PbtO2 < 15mmHg, the greater the chance
of death [195]. There is also a critical threshold of 5mmHg below which most patients will
die [195].
3.2.2.2 Carbohydrate brain concentrations
cMD aims at sampling interstitial ﬂuid threw a dialysis membrane in any tissue. It has been
used since the 70s for research purpose in animals brain [196]. The ﬁrst sterile catheter was
designed for human implantation in the 90s (CMA Microdialysis) [197]. After initial use during
epilepsy, it is now used during neurosurgery or in the ICU as part of acute brain injured patient
multi-modal monitoring.
cMD tip is made of a semi-permeable polyamide membrane (10-30mm long, outer diameter
200-600μm). Driven by the gradient between interstitial ﬂuid and the microdialysate, molecule
will diﬀuse through the membrane. Usually the probe cut-oﬀ is around 20kDa allowing to
study small molecules such as glucose, lactate pyruvate or glutamate. The equilibrium of such
molecules is incomplete. The probes yield depend mainly on the membrane cut-oﬀ and mi-
crodialysate perfusion rate. The CMA-70 probes yield (10mm length, 20kDa cut-oﬀ) range
between 70% (at 0.3μl.min−1) and 30% (at 1μl.min−1) [198, 199]. Usually, cMD are use with
a 0.3μl.min−1 perfusion rate, providing a 60min sampling rate [199].
Normal brain concentrations of glucose, lactate, pyruvate as well as the “anaerobic” thresh-
olds, are still quite arbitrary. They are extrapolated from animal studies made in diﬀerent
organs, or from patients who underwent neurosurgical operations for posterior fossa lesions or
epilepsy [200, 201, 203] (Table 6).
Low extracellular brain glucose has been associated with bad outcome during acute brain in-
jury [115, 202]. In 2011 Timofeev et al. found that increased lactate (> 4mmol/L), L/P
(> 25%) and low glucose (< 1mmol/L) were also more frequently observed in patients with
unfavorable outcome after severe TBI [205]. Several interpretations of carbohydrate brain con-
centrations were hypothesized based on glucose metabolism pathways: Anaerobic or anaerobic
glycolysis (Fig 3).
Recently Sahuquillo et al. showed that no relationship exist between L/P and lactate concentra-
tion [203]. Because lactate results from glycolysis, brain lactate concentrations correlates with
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Brain
metabolism
description glucose lactate pyruvate L/P PbtO2
Compensated normal N N/low N/low low Naerobic
hyper-glycolysis low high N/low low N
Altered: MC
type 1 or anaerobic
hyper-glycolysis
(with ischemia)
low high low high low
type 2 or low
pyruvate state
(without ischemia)
low N/low low high N
Table 7: Summary of diﬀerent brain metabolic states as describe by several authors
using cMD, PbtO2 and PET to deﬁne ischemic threshold [203, 202, 206, 207].
Abbreviations: L/P, lactate/pyruvate ratio; N, normal; MC, metabolic crisis.
CMRglucose [202], whereas extracellular pyruvate concentrations dependent on both glycolysis
rate and oxygen consumption (mitochondrial tricarboxylic cycle). Given this, several authors
tried to delineate diﬀerent metabolic patterns depending on brain glucose, lactate, pyruvate,
oxygen and CBF (measured with PET). These diﬀerent deﬁnitions are summarize in the ta-
ble 7.
A linear relationship exists between CMRglucose and the cMD levels of lactate and pyruvate
but not with the L/P [203]. In fact L/P displays a negative correlation with CMRO2 [202],
suggesting that it is more a surrogate of the cellular redox state. It has been postulated that
glycolysis up-regulation in an injured brain indicates a hyper-metabolic state directed toward
restoring perturbed ionic homeostasis or the uptake of high extracellular levels of glutamate.
Increase in CMRglucose in these patients is often indicative of hyperglycolysis and not of a shift
towards anaerobic metabolism. The main diﬀerence between aerobic hyperglycolysis and an
anaerobic proﬁle is that the L/P is signiﬁcantly increased in the latter.
Among anaerobic patterns, the type 1 is the classical ischemic metabolic state where the
NAD+/NADH ratio is shifted toward NADH as a result of mitochondrial oxidative pathway
dysfunction. Then, lactate dehydrogenase reaction is oriented toward lactate formation, with
a subsequent high L/P. However anaerobic hyperglycolytic pattern do not necessarily mean
ischemia but rather that oxygen supply does not ﬁt energetic needs, as described in the type
2 pattern, also called “low pyruvate”. During such situations the PbtO2 and CBF remained in
the rage of normal values [202, 207, 206].
Hypermetabolism following TBI occurs because oxidative phosphorylation normally runs at
near maximal capacity, consequently an increased energy demand should be supplied by an in-
crease in glycolysis [208, 203]. In fact this adapted reaction of aerobic hyperglycolytic pattern
to an aggression is more frequent in patients with good neurological recovery than anaerobic
pattern [208, 209].
Apparently, increments of microdialysis L/P ratio unrelated to ischemia are quite common in
TBI patients [206, 207]. The corresponding “low pyruvate” pattern reported by several au-
thors [203, 206, 204], can be consider as an indicator of type 2 anaerobic metabolism. A few
mechanisms have been proposed to explain this metabolic behavior including a switch from
glycolysis to pentose phosphate pathway or mitochondrial dysfunction. However, additional
studies are needed to conclude, and the impact of “low pyruvate” phenomenon on the outcome
of TBI patients remains to be determined [207].
Although these proﬁles have been related to patient’s outcome, these metabolic patterns are
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the consequence of several secondary brain aggressions that have to be clarify. For instance,
epileptic seizure or reduced CBF are known to impair brain metabolism [146, 210]. But other
pathological events such as CSD are under estimate and could play an important role when
brain homoeostasis is altered.
3.3 Electro-physiology
Head trauma is associated with both “primary” and “secondary” dysfunction, which will give
rise to a complex mixture of focal and diﬀuse lesions. Since secondary brain aggression might
progress over time, the earlier the evaluation, the higher the rate of false, especially over-
optimistic, predictions. EEG examination looks for baseline ongoing activity, epileptic seizure,
electric reactivity to sensory stimulus, or evoked potentials. In 2009, a consensus on the use of
neurophysiological tests in the intensive care unit (ICU) was published in clinical neurophysi-
ology including TBI associated patterns [211] (table 8).
Spontaneous EEG can have non-speciﬁc altered patterns, such as focal or global decrease in
alpha rhythm power (8-12Hz) with increased theta and delta activity. This pattern has been
described for example on continuous EEG during delayed cerebral ischemia following sub-
arachnoid hemorrhage, or decreased CBF [212, 145].
Epileptic events can be recorded in brain injured patients and are called “post traumatic seizure”
after TBI. In the ICU, around 11% to 55% of moderate to severe TBI patients undergo non-
convulsive seizure, 25% of whom will develop a non-convulsive status epilepticus [36, 145].
These episodes of non-convulsive seizure are considered to be part of secondary brain aggres-
sion as they can lead to sustain increase in ICP, metabolic crisis and can raise brain glutamate
concentration [145, 146].
However these markers are not suﬃcient to predict patient’s outcome. Usually more advanced
electro-physiological examination are performed to evaluate functional consequences of anatom-
ical lesions. Early and middle latency evoked-potentials gives information about either somato-
sensory or auditory pathways integrity. On the other hand late evoked potentials are more
determined by pre-attentional and attentional processes. The N100 is the negative potential
generated in the supra-temporal cortex, in response to an auditory “click”. After an infrequent
change in a repetitive sequence of sounds, the N100 amplitude negativity is increased. This
phenomenon is called the “mismatch negativity” (MMN). When present, MMN and the N100
diﬀer from those found in normal subjects in terms of latencies and amplitudes. As a predictor
of return of consciousness MMN had high speciﬁcity and low sensitivity, whereas the N100 had
high sensitivity and low speciﬁcity [213]. P300 is a later response reﬂecting patient’s attentional
focus toward an odd stimulus. In the auditory modality, the P300 can be enhanced using the
subjects own name among others. This late component seems to engage distributed cortical
regions as well as the hippocampus, and reﬂect complex auditory and linguistic processes [214].
The use of P300 elicited by subject’s own name increases the prognostic value of MMN alone
and improves the assessment of comatose patients by demonstrating the activation of higher-
level cognitive functions [215].
However many standard EEG ampliﬁers are built with a high pass ﬁlter (0.5-1Hz cut-oﬀ), in
order to avoid non-speciﬁc large direct current (DC) shifts. Indeed such large baseline mod-
iﬁcations can be of high amplitude and eventually lead to signal saturation. If no baseline
correction is performed, the signal can be lost for long periods of time.
Since the mid-90s, diagnosing CSD have been done in the human brain with speciﬁc ampliﬁer
settings. Indeed these large DC modiﬁcations (≈ 5 − 10 fold that of a status epilepticus) re-
quires ampliﬁers without any high pass ﬁlter (i.e. low cut-of of 0-0.02Hz). Unfortunately, CSD
can-not be speciﬁcally identify on the scalp EEG.
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Prognostic Description Remarks
Death EEG: electrocerebral silence in the
absence of sedative drugs, EP: pat-
tern of brain death
Just conﬁrmatory test
Ominous BAEP: level 2, SEP level 3, (P14
present) EEG: malignant patterns
Pontine involvement in transten-
torial herniation Usually reﬂect
secondary complications (ischemia,
epilepsy, intracranial hypertension)
Uncertain patterns BAEP level 0, SEP level 2 (“mid-
brain pattern”) EEG: uncertain pat-
tern without reactivity
Midbrain dysfunction: uncertain
despite poor clinical examination
(GCS 4/15), requires MRI
Good prognosis EEG: uncertain pattern (Synek)
with variability and/or reactivity
and/or spindles Normal BAEP and
normal SEP or level 1 abnormalities
Best prognosis,
more than 95% of
patients wake up
Preservation of ERP (MMN, P3) Justiﬁes maximal resuscitation
Table 8: Prognostic value of EEG and EP patterns in post-traumatic coma. Adapted
from Guerit et al. 2009 [211, 216, 217, 218]. Abbreviations: EEG: electroencephalography,
EP : evoked potentials, BAEP : brainstem auditory EP, SEP : somatosensory EP, ERP : event-
related potentials, MMN : mismatch negativity. EP modiﬁcations: Level 0: normal, level 1:
inter-peak latency increase, level 2: Distortion without disappearance, level 3: Disappearance.
The next chapter will discuss patho-physiological issues about CSDs during acute brain injury.
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Cortical spreading depolarization
4.1 From bench to bedside
In 1944 Aristides A. Leão was studying, for his doctorate in Harvard University, the propagation
of epileptic activity in the cerebral cortex. He approached the problem by applying electrical
stimulation to the frontal convexity cortex of anesthetised rabbits, and recording from an array
of corticography electrodes posterior to this. Instead of seeing propagating epileptic activity,
he observed a period of electrical silence, which was ﬁrst seen adjacent to the stimulating elec-
trodes, and did propagate from the site of stimulation backwards along the cerebral hemisphere
at a rate of around 3 mm/minute. The phenomenon resolved spontaneously after 5-15 minutes,
with apparently full resumption of cortical electrical activity. He reported his ﬁndings in a
landmark paper entitled “Spreading depression of activity in the cerebral cortex” [219]. A few
years later he described the large depolarization associated with these depressions of cortical
activity and found that they looked like the slow DC shifts he observed after prolonged cere-
bral ischemia (during carotid artery occlusion) [220]. Triggering CSD in diﬀerent conditions,
he already suggested that their development and characteristics were not determined by the
stimuli, but depended on the local characteristics and conditions of the aﬀected regions [220].
The slow potential change of spreading depolarization seems to be invisible in scalp EEG
recordings, whereas the tenfold smaller discharges of epileptic seizures are easily identiﬁed.
This paradox results from the potent capacitive resistance of the dura and skull, which ﬁlters
slow voltage changes but allows high-frequency epileptic activity to pass through. For decades,
this simple physical problem has led to the false conclusion that CSD does not occur in human
brain [221].
In 1977 CSD have been elicited in the human brain (caudate nucleus and hippocampus) seeking
to treat focal epilepsy [222]. Fortunately this has not been replicated and only electrocorticog-
raphy with subdural or depth electrodes has now provided unequivocal evidence that spreading
depolarizations occur in abundance in people with structural brain damage. In 1966, Mayevsky
et al. were the ﬁrst to record CSD correlates in human cortex after TBI (one over 14 patients)
using a multiparametric device with depth electrodes [223]. In 2002 Strong et al. set up a
linear subdural strip, made of 6 platinum electrodes, placed on the cortex after a craniotomy in
order to record both the depolarization and its spread [224]. This subdural strip of electrodes
had become the standard recording technique in the human brain. From now on an interna-
tional group of investigators build the “Cooperative Studies on Brain Injury Depolarization”
(COSBID, http://www.cosbid.org/) to discuss ways to advance these ﬁndings and further
investigate their implications.
Diﬀerent CSD patterns have been described based on their electric signature (Fig 8):
• Cortical spreading depolarization: the generic term for the whole spectrum of waves in
the central nervous system.
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• Terminal depolarization also called anoxic depolarization: spreading depolarization with-
out neuronal repolarization; occurs in the presence of severely noxious conditions such
as anoxia, aglycemia or severe focal or global ischemia. The depression of brain activity
might occur before the depolarization (Fig 8C.).
• Intermediate depolarization also called peri-infact depolarization or sometimes iso-electric
depolarization: Prolonged spreading depolarization with a character between terminal
depolarization and short-lasting spreading depolarization. Intermediate spreading de-
polarizations can occur, for example, under hypoxia, hypoglycemia or in the ischemic
penumbra where they are often referred to as peri-infarct depolarizations. They usually
occur in a cluster of recurrent events, and are associated with persistent depression of
activity between the events (Fig 8B.).
• Spreading depression: As it was the ﬁrst element to be described by Leão in 1944 it
is often use to name CSD. However depression of ongoing electric brain activity during
spreading depolarization is not always present, and CSD has to be refer as spreading
depolarization but not depression. Therefore CSD can be associated with a spreading
depression (Fig 8A.) or not when cortical electric activity is already low (also refers as
isoelectric depolarization, Fig 8B.).
4.2 CSD in brain pathology
To date CSD recording technique needs electrodes to be placed either on the surface or into the
cortex. Therefore the only way to be sure of CSD occurrence in humans is by surgical cran-
iotomy. CSDs have only been recorded in severely brain injured patients after neurosurgery
procedure for intracranial hematoma evacuation, aneurysm clipping or decompressive craniec-
tomy [224]. More recently the same 5mm diameter strip of electrodes have been placed through
an extended burr-hole for EVD [226].
CSDs can be detected among 56% of patients undergoing severe TBI. Moreover, CSD occurrence
appears to be associated with patient’s unfavorable outcome after controlling for conventional
prognostic variables [225]. Among depolarizations events, iso-electric depolarizations were the
one more related to unfavorable outcome (OR=7.58 (2.64–21.8)), whereas CSD without iso-
electric ones had no signiﬁcant eﬀect on outcome (OR=1.56 (0.72–3.37)) [225]. Likewise, CSDs
occur in over 70% of patients with high grade sub-arachnoid hemorrhage (Fischer 3-4). The
CSD pattern again reﬂects the impact it will have on brain tissue. Indeed patients who devel-
oped prolonged depression periods lasting more than 10 min had worse outcome. Moreover,
delayed cerebral deﬁcit ± ischemia was time-locked to new clusters of spreading depolariza-
tions [227].
Finally, CSDs can be recorded in gyrencephalitic brain after an ischemic stroke. In such condi-
tion, peri-infarct depolarization occurrence will expand the hypo-perfused area [228, 229, 230].
In fact, the higher the rate of recurrence of peri-infarct depolarizations, the earlier did the
cortical DC potential convert into terminal depolarization, as an indicator of functional deteri-
oration and infarct growth [231].
To conclude, isolated CSD does not seem to be very harmful, and some authors even suggest
that it can have preconditioning properties [232]. Then when CSD turns into intermediate or
terminal depolarization, they lead to ischemic lesion progression and unfavorable outcome.
44
I 4.2. CSD in brain pathology
Figure 8: Cortical spreading depolarization patterns: A. Cortical depolarization spread-
ing from electrode 1 to 2 with an associated depression [225]. B. Cluster of iso-electric depo-
larization spreading from electrode 1 to 2. Note the absence of ongoing brain activity [225]. C.
One cortical depolarization followed by a terminal depolarization [221].
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4.3 Mechanisms of spreading depolarization
Although brain represents ≈2% of body mass, its energy expenditure reaches ≈20% of total
body consumption. Maintenance of neuronal membrane potential at resting state and during
signaling by the Na+/K+ ATPase pump represents over 50% of grey matter ATP consump-
tion [233]. Nevertheless, the amount of energy being consumed at any moment in time for the
signaling and maintenance of the resting potential and ion gradients is small in relation to the
total electrochemical energy that is already stored up in the system in the form of physiological
ion gradients. This implies that much more energy is required to reboot the system after a
breakdown than to maintain the system [144].
From an energetic point of view, life and subsequently brain homoeostasis is a non-equilibrium
steady state, whereas death incurs no cost by itself. Two pathological states can challenge
this steady state: ictal epileptic activity and spreading depolarization. They are essentially
characterized by an abrupt, partial loss of the ion gradients across the membrane that is much
larger after CSD [144].
Neurons and their proximal dendrites are the main active players of spreading depolarization.
The near complete breakdown of ions gradients that takes place [234] lead to an initial explo-
sive opening of conductance along pyramidal neuron with trans-membrane potential reaching
almost zero, and followed by a wave-like centripetal closure towards the apical dendrites [235]
(Fig 9A and B).
Potassium release with sodium, chlorine and calcium inward current overcome the pumps ca-
pacity and lead to a near complete loss of electrochemical energy with a passive ion distribution
across the membrane. Intracellular hyperosmolality due to charged proteins will lead to cel-
lular swelling and distortion of dendritic spine (Fig 9C). However, in healthy well perfused
cortex sodium ATPase pumps induce a rapid recovery of this ionic breakdown, and restore cell
morphology within minutes. Conversely, clusters of peri-infarct depolarizations induce sustain
dendritic beading, suggesting that energy needs for recovery exceeded energy supply of com-
promised blood ﬂow [236].
Interestingly, it seems that not only neurons are aﬀected and required to recover from a CSD.
In fact, reducing intracellular ATP concentration in astrocytes by blocking their mitochondrial
oxidative cycle with ﬂuorocitrate lead CSD to exceed energy supply and subsequently to neu-
ronal damage [237].
Spreading depolarization typically spread at a rate of 2-6 mm min [221]. Mechanisms of
spreading have not been clearly elucidated. As potassium and glutamate have been found to
be released in the extracellular space during CSD [238, 239, 240], it has been hypothesized
such neuro-active substances will ﬁrst excite and then depress neurons while forcing them to
release more excitatory transmitters acting on surrounding cells [221]. The separate idea that
K+ might diﬀuse slightly further in the extracellular space and cause depolarization in non-
contiguous neurons was explored in detail by Gardner-Medwin et al., who determined a rate
for cortical extracellular diﬀusion of K+ slower than that of CSD propagation [241]. A further
argument against extracellular diﬀusion of K+ as the basis of propagation is that in CSD, no
increase in K+ can be recorded in the cortex prior to the DC depolarization [234, 242].
Another mechanism that has been suggested is a trans-cellular pathway for the reaction/d-
iﬀusion via neuronal and/or glial gap junctions that accounts for prodromal synchronization
ahead of the advancing DC and potassium front [243, 244]. In the case of astrocytes, it is now
abundantly clear that in cultures of astrocytes studied with intracellular calcium-sensitive dyes,
waves of transient increase in intracellular calcium ion can be initiated by glutamate, NO or
mechanical stimulation, and will then propagate across the culture at a rate very similar to
that of CSD in the intact cortex [245, 244].
Last but not least remains the question about mechanisms that initiate CSD. So far, only hy-
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Figure 9: Cortical spreading depolarization mechanism: A.Top, in the healthy brain im-
permanent negatively charged proteins inside the neuron cause small cations such as sodium and
calcium to enter from the extracellular space, producing a small dendrite inward current (Iin,
pink arrow). Compensation for this constant inward current by dendrite outward current (Iout,
green arrow) of the sodium pump. A.Bottom, the core process of spreading depolarization is
failure of sodium and calcium pumps to provide suﬃcient dendritic outward currents to bal-
ance the persistent inward currents through pink and purple channels. If net dendritic current
turns inward (persistent inﬂux of sodium and calcium is more than the out-ﬂux of potassium) a
near-complete loss of electrochemical energy occurs with almost passive ion distribution across
the membrane, intracellular hyperosmolality with cellular swelling and distortion of dendritic
spines. Adapted from Dreier 2011 [221]. B Extracellular ion concentrations changes during a
spreading depolarization represented in grey as its extracellular voltage DC shift. Recording
were made in a healthy cerebellar cortex. Adapted from Kraig et al. 1978 [234]. C Dendrites
in the penumbra of an ischemic stroke undergo a rapid cycle of beading and recovery coinciding
with the passage of CSD. Two photon images of dendrites (green) as well as blood vessels (red;
labelled with Texas Red dextran) from layer I of somatosensory cortex, before and immediately
after a peri-infarct depolarization. Adapted from Risher et al. 2010 [236].
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pothesis have been made about how primary aﬀected regions might have cell destructions with
membrane rupture and massive ion spillage and glutamate release. Indeed, extracellular K+
has been found to increase when CBF drop below 10ml · 100g−1 · min1 [246] or during hypo-
glycemia [247]. Subsequently passive ion diﬀusion across the extracellular space may establish
sustained potential diﬀerences. Lack of oxygen and/or glucose should also be considered as trig-
ger factors, but none is essential, as those potentials also develop in normoxic/normoglycemic
tissues [221].
Recently Daniel von Bornstaädt et al. in 2015 showed that CSD can be initiated in the penum-
bra area of an ischemic stroke by worsening the supply-demand mismatch. In fact tactile stim-
ulation while activating the ischemic hemisphere increases the oxygen extraction and worsen
the supply-demand mismatch. Subsequently the somatosensory stimulation will give rise to a
peri-infarct depolarization originating from its cortical somatotopic representation [248].
4.4 Brain homoeostasis modiﬁcations during CSD
4.4.1 Micro-vascularization changes during CSD
As describe above, restoration of the ionic gradients after CSD is extremely energetically de-
manding, and in the normal brain, the rise in metabolism is matched by a huge increase in CBF.
In 1944 Leão already described a very conspicuous dilatation of the pial arteries that occurred as
the electrical activity become progressively more and more depressed. This hyperemic response
was occasionally followed by, a long period of a relatively much slighter reduction of vessel’s
calibre. The hyperemic vasomotor spread was strictly analogous to that of the depression of the
electrical activity [249]. From now on this pattern has been extensively reproduced and is now
consider as a speciﬁc feature, so that some authors use it as a surrogate to electro-physiologic
recordings for CSD detection [250].
However CSD consequences on micro-vascularization looks more complex in human brain
pathology. Indeed, laser Doppler ﬂowmetry recording’s modiﬁcation range from a classic hy-
peremic response to a ﬂat one or even and ischemic response [226]. Experimentally it has been
shown that systemic hypoxia and/or hypo-tension can modify the hyperemic pattern. Both
systemic aggression will induce a triphasic vascular response with: (1) an initial dip in CBF
which duration was correlated to the length of the depolarization and which amplitude was
correlated to blood pressure or PO2; (2) the subsequent local CBF increase was three times
lower than in normo-tensiv normoxic animals, similarly correlated to systemic blood pressure
and PO2; (3) The following slight hypo-perfusion was not signiﬁcantly impacted by systemic
aggression [251].
Local brain conditions can also play a role on CSD micro-vascular responses. For instance
after middle cerebral artery occlusion in rats, diﬀerent CBF supplies take place depending on
the distance from the ischemic core. If a CSD occurs it will have diﬀerent vasomotor conse-
quences as the depolarization spread across diﬀerentially perfused cortical area [252, 229, 228].
A classic hyperemic patterns can be recorded in normally perfused cortex (remote from the
stroke), whereas in the ischemic core an inverse ischemic response occurs like in terminal depo-
larization [252, 228]. In between (the so called penumbra are), a range of multiphasic patterns
can be observed. Again an initial dip (also called spreading oligemia) occurs, which duration
is related to the depolarization length. This dip is usually followed by a reduced hyperemic
response [252, 228]. In this model, the slope of the hyperemic response was found to correlate
with pre-CSD CBF level [252]. Using laser speckle imaging in a rat model of middle cerebral
artery occlusion, Bere et al. described an extensive overview of vascular response based on
pre-CSD blood supply and CSD feature [253]. Fig 10 describe the vascular responses within
the ﬁrst minutes following CSD depending on CBF supply.
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Figure 10: Overview of various conceptual cerebral blood ﬂow (CBF) responses to
spreading depolarization (SD) in intact cerebral cortex A, and during ischemia B to F.
Solid, black lines depict theoretical CBF responses based on our present and previous obser-
vations. Dotted lines in B to F indicate the physiologic CBF response to SD, for comparison
with those under ischemia. Gray lines and shaded areas stand for ideal SD: short transient in
A to D, intermediate in E, and terminal in F. Baseline CBF (100%) is given as a horizontal
line. Adapted from Bere et al. 2014 [253]
Likewise CSD that occurs after severe TBI can also display such inverse neuro-vascular cou-
pling. In 2014 Hinzman et al. showed that if regional vascular reactivity was preserved, CSD
had a “normal” hyperaemic response. Conversely in case of impaired vascular reactivity, CSD
can have an oligemic inverse response [254].
Finally, in well perfused cortex, CSD can lead to a sustain oligemic or ischemic response when
neuro-vascular coupling needed compound concentrations are modify. For example scaveng-
ing NO with Hb, or decreasing its release with NO synthase inhibitors, under high potassium
concentrations will lead to a prolonged terminal depolarization with a subsequent ischemic vas-
cular response [83, 255]. Together with the fact that CSD set up during neurological worsening
after subarachnoid hemorrhage, these observation drives to the conclusion that such process
underpin delayed cerebral ischemia [227, 221].
4.4.2 Oxygen concentration changes during CSDs
When O2 consumption was ﬁrst evaluated, Leão and Morrison in 1945 found a decreased O2
concentration in blood samples taken from the sagital sinus during CSD [256]. Since the 50s
various techniques has been used to describe local O2 concentration modiﬁcation. However,
as describe in the section 3.2.2.1, brain oxygenation is much more complex to asses, and one
might observe diﬀerent PbtO2 values depending on where and how the recordings are set up.
In fact the early studies (using large electrodes that might record melt signal from penetrating
vessels as well as brain parenchyma) found complex PbtO2 patterns with a ﬁckle initial dip
followed by a subsequent increase, like the multiphasic vascular response described above [257].
More recently thin PO2 electrodes (3-10μm tip) have been developed, allowing more precise
cortical measures, away from large vessels. With such electrodes diﬀerent teams described,
under ketamine or α-chloralose anesthesia, an initial decrease in PbtO2 down to a few mmHg.
The dip duration was increase if there was a pre-existent hypoxemia [111, 258, 82]. The PbtO2
dynamics during CSDs seem to be related to arterial PO2: It will return to the pre-CSD value
when animals breath air or can develop a biphasic pattern (returning to baseline or even in-
creasing, followed by a sustain decrease) when animals breathe a gas mixture with increased
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Figure 11: CSD induce PtO2 modiﬁcation: A. tissue oxygen pressure (PbtO2) in a mouse
ventilated with 100% O2, room air or 15% O2. Adapted from Takano et al. 2007 [111]. B.
Three diﬀerent types of PbtO2 responses are found in the cortex of subarachnoid hemorrhage
patients: Biphasic PbtO2 response with an initial decrease and a secondary increase, monopha-
sic pbtO2 decrease, and monophasic PbtO2 increase. Arrows indicate the onset of CSD in the
electrocorticography channel next to the pbtO2 probe. Adapted from Bosche et at. 2010 [259]
O2 partial pressure [111, 258, 82] (Fig 11A.).
In human brain pathology, PbtO2 can be recorded in the ICU with larger probes (see sec-
tion 3.2.2.1). With such electrodes, CSD-induced PbtO2 modiﬁcations appeared to be somehow
diﬀerent. In fact both in patients with sub-arachnoid hemorrhage or TBI, it looks like PbtO2
patterns displayed a continuum from a monophasic increase, to a monophasic decrease with
biphasic pattern in between (Fig 11B.) [259, 254]. It is likely that these changes reﬂect both
probes technical diﬀerences and distance from vessels, as well as cortex pathological state. A
clear PbtO2 modiﬁcation pattern remains to be clarify.
4.4.3 Glucose and lactate changes during CSDs
As discussed in the chapter 2.2 “brain metabolism”, glucose is the major energetic fuel of the
mammalian brain. During neuronal activation a transient increase in glycolysis with a sub-
sequent extracellular lactate release occurs. Therefore the very large cation shifts that takes
place in CSD make it likely that similar changes in glycolysis would occur.
Recording of such fast dynamic change in glucose and lactate with suﬃcient temporal resolution
is challenging. There are two main strategies for the measurement of neurochemicals in vivo:
implanted biosensors and cMD. Advantage and drawback of each technique will be discussed
in the “Method” part, section 3.4. In 2003 the Biomedical Monitoring Group (Department of
Chemistry) in the King’s college of London, set-up technique combining cerebral cMD with
biosensors (not implanted in the brain though), providing a faster time resolution but loosing
the real concentration information (relative values) [260]. From that time, they were the only
one to publish glucose and lactate dynamics during CSD in both animals and human.
It had become clear that CSD in a normal cortex is followed by a decrease glucose with a release
of lactate in the extracellular space [239, 261]. However the amplitude and duration remains
unclear: sometimes it still transient (5-10 min) with full recovery [239, 260], and sometimes
glucose and lactate remains altered during the whole recording period [261].
In human brain pathology or animals after middle cerebral artery occlusion, the metabolic pat-
terns are more complex since glucose and lactate can have trends independent from CSD [262,
263]. On the hole per-infarct/contusion depolarization lead to a decrease in glucose with a
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release in lactate [264, 263]. Nevertheless, both in animal model and human patients, some will
recover whereas persistent modiﬁcations can occur. Moreover, some patients did not display
any modiﬁcations after CSDs.
This suggests that cortical metabolic responses to an energetic challenge induced by CSDs might
be diﬀerent between cortical areas in pathological conditions. The exact patterns of metabolic
modiﬁcations remains to be clariﬁed in an injured cortex but also in a well fed cortex.
4.4.4 Excitotoxicity and CSDs
The postulate that glutamate is involved in CSD has been initially supported by the observation
that glutamate (≈15mM) applied topically to the rabbit’s cortex can elicits CSD [238]. The
ﬁrst evidence of glutamate release in the extracellular space after CSD were made by Van
Harreveld and Fifková in 1970, eliciting depolarizations on retina in a super-fused chamber
with 14C-glutamate [265]. A transient increase in extracellular glutamate concentration was
conﬁrmed later with rapid sampling cMD in vivo in rats [266]. However hypothesis about
glutamate implications during CSDs have been mainly based on indirect observations, using
NMDAR blockers to stop glutamate transmission. In fact, NMDAR blockers, such as MK-801
or ketamine, are known to decrease CSD occurrence with some kind of tolerance after repeated
injections [267, 268]. This eﬀect was not reproduced with non-NMDAR blocker [268]. An
observational study in acute brain injured patients reported that ketamine was able to decrease
CSD occurrence unlike other general anesthetic drugs [269].
More recently a few studies described glutamate dynamics with a high temporal resolution
during CSD in healthy animals or after middle cerebral artery occlusion. Using ﬂuorescent
probes expressed in vivo on the extracellular surface of either neurons or astrocytes, Enger et
al. in 2015 were able to describe a glutamate wave travelling at 51.7±0.3μm/s (not signiﬁcantly
diﬀerent from the speed of the Ca2+ waves in neurons and glia). This extracellular transient
glutamate increase occurred after the passage of the neuronal Ca2+ wave-front, but before
the arrival of the astrocytic Ca2+ wave [242]. Likewise, a similar glutamate transient release
(11.6±1.3μM) was describe by Hinzman et al. in 2015 with enzyme based biosensors, in healthy
rats that was able to triggered neuronal lesions if glutamate uptake was inhibited [240]. They
also report a glutamate release during anoxic or peri-infarct depolarization which duration was
related to the depolarization length [240]. Based on these observations, the authors suggesting
that CSD can mediate excitotoxicity after brain aggression.
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Over the past decades it has become clear that CSD are fundamental events occurring in
the early period of acute brain injury. Monitoring their occurrence and features can improve
the way clinicians assess patient’s prognosis since CSD are related to unfavorable outcome in all
major severe brain aggression (i.e. TBI, sub-arachnoid hemorrhage or ischemic stroke). More-
over repeated CSD within clusters seems to have the worse consequences on brain condition
and consequently on patient outcome.
CSD vascular consequences have been well explored both in human and animal models. To
date the vascular response is considered as a continuum between a “normal” hyperemic reac-
tion and an inverse ischemic response with intermediate oligemic biphasic pattern in between.
How vascular response will be located in this spectrum is partly attributable to cortical blood
supply: the less blood supply, the worse the response. This has been clearly demonstrated after
middle cerebral artery occlusion where homogeneous vascular modiﬁcations takes place (vs the
distance from the ischemic core), but a little is known in more heterogeneous pathology such
as TBI that namely lead to edema and hemorrhage rather than ischemia.
On the other hand, the cortical metabolic reaction to CSD remains unclear. Even if there is
an emerging pattern resembling hyper-glycolysis (decrease in glucose with subsequent increase
in extracellular lactate), the quantiﬁcation of such modiﬁcations as well as the inﬂuence of
pre-CSD cortical conditions are unknown. Likewise, miscellaneous PbtO2 observations have
been made in animal models and human injured cortex. Therefore, a clear spectrum of brain
oxygen modiﬁcations has also to be deﬁned based on brain energetic supply.
Finally CSDs are supposed to mediate excitotoxicity through extra synaptic glutamate release.
However recent studies indicates rather transient glutamate increase, and it is unclear whether
it will lead to NMDAR over-activation with excitotoxic consequences.
Based on these observations we made the hypothesis that CSDs have diﬀerent neuro-chemical
consequences in healthy tissue compared to a “traumatic penumbra” where neuronal death is
expected to occur. Our second hypothesis was that clusters of CSDs will have worse conse-
quences after TBI that isolated CSDs.
Our main goal was to describe the changes in micro-vasculature, metabolism and glutamate
concentrations elicited by CSD that occurred after a severe experimental TBI. We chose to
use an animal model of TBI (1) to improve injury reproducibility and (2) to have access to
continuous highly sensitive techniques such as biosensors for neuro-chemical recordings that are
not available in humans.
Our objectives were to:
• Describe the metabolic (glucose, lactate, PbtO2) and micro-vascular patterns observed
during and after CSDs in a healthy cortical tissue.
• Report how these patterns are altered during spontaneous isolated CSDs after severe TBI.
• Determine if cluster of CSDs will have worse consequences.
However, these goals requires preliminary studies:
• Due to TBI heterogeneity, and considering CSD as a promoter of neuronal death, our
main goal requires the delineation of brain regions where neuronal death occurs in order
to record CSD in this area.
• We had also to check for the biosensor reliability in brain parenchyma, as in vivo condi-
tions could be far away from the standard in vitro procedures for biosensor’s calibration.
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The ﬁrst part of my experimental plan was devoted to mapping neuronal and glial injury in
the LFPI model of severe TBI (part IV). Then, we were able to deﬁne the aﬀected areas within
which we would implant diﬀerent monitoring probes (i.e. PbtO2, biosensors, laser Doppler
ﬂowmetry (LDF)) for CSD neuro-chemical recordings.
The second part was devoted to the characterization of oxidase-based electrochemical biosensor
recordings, especially the validation of electrochemical monitoring during changes in PbtO2 and
temperature (part V).
Finally, I will describe our results on neuro-chemical consequences of CSDs in healthy and in-
jured cortex in part VI entitled “Metabolic and micro-vascular consequences of cortical spread-
ing depolarizations, in a normal or injured brain”.
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Part III
Methods
J. Heyrovsky, 1959 Nobel Prize in Chemistry for the discovery and development
of polarographic methods of analysis.
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Chapter 1
Modeling traumatic brain injury:
Choosing the right model
1.1 Diﬀerent animal models
Pre-clinical studies are usually needed prior phase one clinical trial. In view of the heterogeneous
nature of the clinical situation in TBI, numerous animal models of such injury have been
developed. Although larger animals are closer in size and physiology to humans, rodents have
become the main species in biomedical research over the past decades, owing to a modest cost,
a good reproducibility and standardized techniques available to study their physiology and
behavior. Likewise head injury models have been mainly developed in rats, sometimes in mice,
and only very few studies in larger animals such as pigs or cats.
Addressing TBI outcome being the main purpose of a clinical or pre-clinical studies, behavioral
surrogates have been developed in rodents. Whereas mortality is easy to asses and is mainly
due to respiratory arrest [270, 271], long term cognitive dysfunction is more subtle. Sensory and
motor deﬁcits can be assessed by a composite neurological score (involving clinical examination
of how the animal moves and behaves), the adhesive removal test (that measures the duration
an animal takes to remove adhesive tape on his paw), or the foot fault test (which counts how
many rung are missed by a rat walking on an horizontal ladder). Memorization and learning
ability can be assessed by the Morris water maze test in which animals have to memorize a
platform location in a circular swimming pool, and anxiety can be assessed by the WET where
animals have to explore a pool without escape [272].
Although functional deﬁcits due to TBI exposure are the principal health problem in modern
warfare, rats do display only light deﬁcits from mild or moderate head injury so that many
studies focus on tissue destruction rather than functional deﬁcits. For that matter, the present
study will address anatomical modiﬁcations at the cellular levels of both neurons and glial cells.
TBI models include two diﬀerent approaches, either closed head injury or open skull injury
after surgery.
1.1.1 Closed head injury models
A so-called “Diﬀuse Brain Injury” model was developed in 1994 by Marmarou et al. to produce
diﬀuse lesions like those observed after falls or car accident trauma [270]: the controlled head
injury (CHI). Head injury device consists of a sectioned brass weight set that falls freely from a
designated height through a tube. In anesthetized rats with skull exposure made by a mid-line
incision, a stainless steel disc is mounted with glue to the skull mid-line between lambda and
bregma to prevent skull fracture, but some author used a lateral percussion [273] (Fig 12E).
The more the height, the more the lesions and the mortality [270]. To generate axonal lesions
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Figure 12: Experimental set-ups for the animal models of TBI: A-LFPI : The lateral
ﬂuid percussion injury device uses rapid injection of a ﬂuid pulse into the epidural space; B-
CCI: The controlled cortical impact injury model uses an air or electromagnetic driven piston
to penetrate the brain at a known distance and velocity; C-PBBI: The penetrating ballistic-
like brain injury involves the transmission of projectiles with high energy (transmission of a
metal rod or expansion of the probe’s elastic balloon); D-Weight-drop: weight-drop model,
a free weight is released directly onto the exposed dura; E-CHI: Closed head injury uses a
metal disk is placed over the skull to prevent bone fracture; F-Blast: Blast brain injury can be
caused by the primary injury related to the blast and other mechanisms. Adapted from Xiong
et al 2013 [271]
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the weight must be at least 450g and dropped from a height of 1.5-2 meter. This model yields
a 40-70% mortality rate, reduced to 10-25% with artiﬁcial ventilation [270].
CHI is characterized by widespread and bilateral damage of neurons, axons, dendrites and
microvasculature as well as extensive diﬀuse white matter injury, particularly in the corpus
callosum, internal capsule, optic tracts, cerebral and cerebellar peduncules, and the long tracts
in the brainstem [271, 274]. At a cellular level, these macroscopic lesions are associated with
activated microglia and astrocytes as well as degenerating neurons [275]. Diﬀuse brain edema
seen with MRI is associated with microcirculatory collapse due to astrocyte swelling [276]. The
subsequent functional deﬁcit include sensory-motor and cognitive deﬁcits such as diﬃculties
with beam walking and memory [270, 275, 271].
A blast-induced TBI rat model that mimics real blast-induced mild TBI seen in recent military
conﬂicts has been developed (Fig 12F). This recent model is in the way of its full description
of behavior, MRI and neurochemical consequences. Non-impact blast injury is characterized
by diﬀuse cerebral brain edema, extreme hyperemia and a delayed vasospasm. Diﬀuse axonal
injury was the most prominent feature during the initial 2 weeks [277, 271].
1.1.2 Open skull experimental models
1.1.2.1 Lateral ﬂuid percussion injury
LFPI models have been designed in the Virginia University by Thompson and McIntosh to repli-
cate human TBI without skull fracture [278, 279]. The insult is inﬂicted by a pendulum striking
the piston of a reservoir of ﬂuid to generate a ﬂuid pressure pulse to the intact dura through a
craniotomy. The craniotomy can be made either centrally around the mid-line between bregma
and lambda, or laterally over the parietal bone between bregma and lambda [278, 271] (Fig 12A,
see methods, chapter 1 for further details).
The site of craniotomy is crucial in determining the extent and location of tissue injury pro-
duced. The mid-line percussion model was initially developed for use in cats and rabbits,
subsequently adapted for use in rats and then modiﬁed to produce the lateral percussion model
in rodents.
The location and severity of the neurological lesions that can be generated by LFPI has not
received a great deal of systematic study [280, 281]. LFPI appears to produce a complex pat-
tern of widespread lesions throughout the injured hemisphere, which encompass intra-cranial
hemorrhage, brain swelling and gray matter damage. These grey matter damage have been
described in cortical, hippocampal, and thalamic brain regions [282, 281]. Interestingly, the
sites of the most intense neuronal loss are often remote from the site of impact. For example,
maximal damage is usually observed in the temporal cortex or deep in the thalamus [280, 283].
LFPI produces neurobehavioural and cognitive deﬁcits that are commonly seen in patients with
TBI: diﬃculties with movement and vestibular function as well as memory and cognitive deﬁcit
as measured by the Morris water maze test [284]. Cognitive dysfunction and neurological im-
pairments persist for more than a year following severe LFPI [285].
LFPI models have high mortality compared with other models, which is probably due to the
brainstem-compromised prolonged apnea. LFPI severity can be assessed by measuring the du-
ration of initial respiratory arrest and the latency of the righting reﬂex recovery [286]. In our
experiments 3 ATA was considered as moderate with an apnea < 30sec, a lack of response to
tail pinch for at least 2 min and a suppression of righting reﬂex lasting between 25 and 35 min.
A 3.8 ATA LFPI induced prolonged apnea necessitating artiﬁcial ventilation for at least 30-45
min and was considered a severe TBI.
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1.1.2.2 Control cortical impact
The controlled cortical impact (CCI) model uses a pneumatic or electromagnetic impact device
to drive a rigid impactor onto the exposed, intact dura. The controlled impact is delivered to
the intact dura through a unilateral craniotomy lying most often between bregma and lambda,
which causes deformation of the underlying cortex [271] (Fig 12B). The advantage of this injury
model over other TBI models is the ease with which mechanical factors, such as time, velocity
and depth of impact, can be controlled.
The histopathological lesions mimics cortical tissue loss, acute subdural hematoma, axonal in-
jury, concussion and BBB dysfunction. The subsequent functional deﬁcits observed in CCI
encompass cognitive impairments (which have been detected in the Morris water maze test),
sensory-motor deﬁcit or emotional and anxiety behavior (as quantiﬁed in the WET test), and
even coma [287, 288, 271].
The functional deﬁcits observed are highly related to both the depth of deformation and the
velocity of the impact. After deep deformation there almost always exists a penetrating le-
sion [289, 290], making this model closer to a penetrating wound TBI.
1.1.2.3 Weight drop injury
In weight-drop models, the skull is exposed to a free falling, guided weight. Injury severity in
these models can be altered, like in the CHI model, by adjusting the mass of the weight and
the height from which it falls which was often the tenth of those used in the CHI model [271]
(Fig 12C).
Morphologically, these injuries progress from hemorrhages in white matter directly under the
contused cortex during the ﬁrst few hours after injury to the development of a necrotic cavity
by 24 hours. The cavitation appears to expand over the subsequent 2 weeks [291, 271].
1.1.2.4 Penetrating ballistic-like brain injury
Penetrating ballistic-like brain injury is caused by transmission of projectiles with high energy
and a leading shock-wave, which produces a temporary cavity in the brain that is many times
the size of the projectile itself [292] (Fig 12C). The outcome in this model is directly related
to the anatomical path of the projectile and the degree of energy transfer. Several pathophys-
iological characteristics are similar to those reported in other models, including the presence
of hemispheric swelling, increased ICP, remote white matter injury and neuro-inﬂammation.
However, it causes extensive intra-cerebral hemorrhage throughout the primary lesion [271].
1.2 Which model suits best our needs?
TBI models include two diﬀerent approaches, either closed head injury or open skull injury,
as described above. LFPI is one of the most widely used TBI animal model, even if there is
a recent resurgence of interest in mid-line ﬂuid percussion and CHI because of the increased
interest in diﬀuse brain injury associated with sport and blasts [278, 271].
Our main interest was to compare CSD neurochemical consequences in a healthy cortical matter
to an injured “traumatic penumbra” area like a peri-contusional cortex. For that matter we
needed a TBI model giving rise to both diﬀuse and focal lesions like open skull animal models.
We chose the LFPI model over the others because: (1) it is the most extensively described
model in the literature and (2) it will produce a complex pattern of lesions with neuronal loss
in the temporal cortex [280, 293, 282, 283]. Nevertheless precisely mapping the lesions produced
by LFPI appears a prerequisite to choose the cortical area of interest for CSD neuro-chemical
study. Therefore the ﬁrst part of our study will focus on mapping LFPI induces injury (Part
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“anatomical modiﬁcation”).
Although CSDs have been recorded in patients undergoing a severe TBI, only few studies
reported CSD occurrence after experimentally induced TBI in the literature. One explanation
would be the low rate of CSD events after moderate LFPI (i.e. < 2 in 5 hours post trauma) [294].
Similar results have been reported using either CCI [295] or ballistic models [296], so that some
authors triggered additional CSD with potassium cortical apposition [295, 232]. Nevertheless,
increasing LFPI intensity up to 5 ATA will lead to further increase in ICP and in CSD frequency,
up to 4/hours [294].
Therefore, we chose to perform a severe LFPI and kept the animals for 5 hours post injury
under light anesthesia for spontaneous CSDs recordings. In another set of experiments clusters
of CSDs have been triggered with cortical potassium apposition. This model, as described
below, requires a surgical window on the parietal bone to expose the dura, which makes easier
sensors implantation for brain metabolism follow-up.
1.3 LFPI experimental setup
Animals were anesthetized with isoﬂurane and placed in a stereotaxic frame (Stoelting, Dublin,
Ireland) with their body temperature maintained around 37 oC with a homeothermic blan-
ket (Harvard apparatusR©). A subcutaneous inﬁltration of 0.5 mL of 3 mg/ml ropivacaine
(Naropeine R© 7.5mg·ml−1 in saline) was performed prior to scalp opening. A circular cran-
iotomy (5 mm diameter) located 3.8 mm caudal to Bregma and 3.0 mm lateral from the
mid-line was then performed under aseptic conditions. A hollow plastic cap, the “injury cap”,
was ﬁrst attached to the skull using cyanoacrylate, then secured with dental acrylic. A 1 mm
diameter stainless steel screw, inserted into the skull, served as an anchor for the dental acrylic
and the injury cap was ﬁlled with sterile saline. The animal was then removed from the stereo-
taxic frame and brought to the lateral ﬂuid percussion device (Custom Design and Fabrication,
Virginia Commonwealth University Richmond, Virginia, USA, Fig 13). Rats received a single
20 ms ﬂuid percussion pulse of 3.0 or 3.8 ATA under light anesthesia, in which the animal was
removed from the anesthesia mask and the LFPI impact was administered at the ﬁrst signs of a
hind limb response to a gentle toe pinch. The cap was then removed, anesthesia was resumed,
and the scalp was sutured.
To avoid respiratory arrest after severe TBI, mechanical ventilation (Harvard apparatusR©, Is-
pra MA1 55-7058, Vt = 6ml· kg−1, breath rate = 60·min−1, Peep = 5cm H20) was performed
through a 16 gauge tracheal catheter placed prior to TBI (induction with 5% isoﬂurane in O2).
Figure 13: Lateral ﬂuid percussion de-
vice, Custom Design and Fabrication, Vir-
ginia Commonwealth University Richmond.
A freely moving hammer is drop on a water
ﬁlled cylinder transmitting the pressure wave
to the dura on the other side. Adapted from
Thomson et al. 2005 [278]
Animals were then kept under light anesthesia (0.8-1.5% isoﬂurane with 30% O2 in air)
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for brain metabolism study, or ventilated until they recovered spontaneous breathing for his-
tological analysis. In that case animals were single-housed for 7 days, with assisted drinking
and feeding if necessary. Buprenorphine 0.05 mg/kg was administered twice at 12h interval
after surgery. Exclusion of animals was decided if mechanical ventilation could not be resumed
within the ﬁrst 45 min post-TBI or if animals lost more than 25% of their initial body weight.
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Chapter 2
Mapping brain cells injury
2.1 How to assess cells injury after TBI?
As in human brain pathology, experimental TBI induces heterogeneous macroscopic and mi-
croscopic lesions that can be assessed by diﬀerent techniques. Morphological MRI (T1, T2,
T2*, ﬂair sequences) makes it easy to map brain injury over the whole brain and gives macro-
scopic information on hematoma, cerebral hernia, intra/extra cranial hemorrhage, or edema.
Moreover advanced sequence such as DTI MRI gives additional information about white matter
injury, and arterial spin labeling about CBF. However even if the spatial resolution is <1mm,
these imaging techniques does not reach that of cell visualization.
Unlike in patients, animal models allow reproducible histological analyses that are required
for closer microscopic evaluation. Diﬀerent approaches are needed to address either global
overview or perform precise analysis on speciﬁc regions. Whole brain histological imaging can
be challenging and time consuming, even without stereologic reconstruction. For that matter,
automated slice scanning methods are now available to process large numbers of histological
slices.
Several cell types compose the brain tissue and can be damaged following LFPI. Since neurons
are considered the primary signaling cells in a living brain, we ﬁrst focused our analysis on neu-
ronal injury. Injured neurons can be identiﬁed by staining brain sections with several methods.
A ﬁrst approach consist in neurons counting using diﬀerent dye: (1) Nissl staining typically
marks the endoplasmic reticulum due to ribosomal RNA as well as the nucleus and other ac-
cumulations of nucleic acid [280]; (2) hematoxylin and eosin is one of the principal stains in
histology. Hematoxylin colors cell’s nuclei in blue, whereas the eosin counter-staining colors
eosinophilic structures in various shades of red, pink and orange [297, 298]. Degenerating neu-
rons can also be detected based on cell shrinkage and hyperchromatism (pyknosis), as well as
by vacuolation of the cytoplasm. However, these methods can easily produce false positives or
fail to detect degenerating neurons [299].
Other approaches used several dye targeting speciﬁcally dying neurons. Indeed, neurons with
terminal damages displays a cytoplasm with a selective aﬃnity for acid dyes such as acid
fuchsin, which persist until lysis of the cell [280, 300]. Likewise, Fluoro-Jade stains are highly
acidic anionic derivatives of ﬂuorescein. Among them Fluoro-Jade C exhibits the greatest sig-
nal to background ratio, as well as the highest resolution and has been used to assess neuronal
damage after brain injury [283, 282]. These methods stains all degenerating neurons regardless
of speciﬁc insult or mechanism of cell death. However, the mechanism by which they labels
degenerating neurons is unknown thus creating some controversy to the actual physiological
condition of the labeled cells.
Finally TUNEL (Terminal Deoxynucleotidyl Transferase dUTP Nick End) detect fragmented
DNA resulting from apoptotic mechanisms by staining nucleic acid end chain [301]. However
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TBI involves both necrotic and apoptotic mechanisms. Fluoro jade-C is currently regarded to
be a superior method for detecting degenerating neurons, although the mechanism by which
this reagent labels injured cells is unknown, and there is a debate regarding whether all Fluoro-
Jade positive neurons ultimately die, or if some may recover [299, 302]. Moreover, only a few
dying neurons are usually detected in each section at a given time, and the signiﬁcance of such
small numbers of labeled neurons in a given brain structure is diﬃcult to interpret.
Thus, quantifying the overall neuronal density several days after injury appears to be the best
strategy, as it directly estimates the extent of cumulated neuronal death. Neuronal density is
typically assessed by manual cell counts in a delineated brain sections [303, 304, 305, 306], some-
times followed by stereological reconstruction of the brain structure [293, 307, 308]. However,
these techniques are slow and time-consuming. We recently developed an automated method
based on the open source ImageJ software. This macro quantiﬁes neuronal density in brain
sections based on immunoreactivity to the nuclear neuronal marker NeuN and stained with the
ﬂuorescence DNA dye 4’,6’-diamidino-2-phenylindole (DAPI) [309]. Our ﬁrst step analysis was
to determine neuronal density modiﬁcation using this automated analysis on confocal images,
after selecting region of interest base on whole slide NeuN images. NeuN immuno-reactivity
stains the nuclei of most neuronal cell types in both the central and peripheral nervous systems,
with some exceptions, but has not been observed in glial cells. It was not until 17 years after its
discovery that NeuN was identiﬁed as the RNA splicing regulator Rbfox3 [310]. To date it has
been shown that NeuN immuno-reactivity (trough Rbfox3 expression) can vary both during
physiological neuronal activity and subsequently to pathological process [311]. Therefore, neu-
ronal loss cannot be address by measuring staining intensity modiﬁcations but require manual
or automated counts.
Based on our observations about the pattern of neuronal loss, we then addressed the question of
how glial cells are aﬀected by LFPI. Likewise, we labeled glial cells using astrocytes or microglia
speciﬁc antigens, to approach their number and morphology.
Expression of glial ﬁbrillary acidic protein (GFAP) has become a prototypical marker for im-
munohistochemical identiﬁcation of astrocytes. Nevertheless, it is important to recognize the
appropriate uses and limitations of GFAP as an astrocyte marker. GFAP was ﬁrst isolated
as a protein highly concentrated in old demyelinated plaques from multiple sclerosis patients
and was then found to be associated immunohistochemically with reactive astrocytes in such
plaques and in other pathological contexts. In line with this original mode of identiﬁcation,
GFAP expression can be regarded as a sensitive and reliable marker that labels most, if not
all, reactive astrocytes that are responding to CNS injuries. However, GFAP is not an abso-
lute marker of all non-reactive astrocytes and is often not immunohistochemically detectable
in astrocytes in healthy CNS tissue or remote from CNS lesions [312].
Microglia can be visualized in human and animal brain tissue sections and in cultures by a
variety of cell surface-associated or intracellular/cytosolic molecules. Usually the molecules
targeted by staining have an established function as receptors, adhesion molecules, or enzymes
in macrophages. For example the CD11b/CD18 integrin, which we used in our study, binds
complement C3b. Like with astrocyte, the expression level of many of these molecules, such as
for example CD11b, mostly increases with microglial activation [138]. Finally, while microglial
cells can be easily distinguished from other brain cells, this is not always possible with respect
to non-CNS monocytes that also exhibit the same antigens [138].
2.2 Immuno-ﬂuorescence
Staining a molecule at the surface or within cells or tissue with a primary antibody is called
immuno-chemistry. Immuno-ﬂuorescence techniques use a second antibody, from another species,
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Figure 14: ﬂuorescent dye excitation and emission spectrum: dashed lines represent
excitation and solid lines emission spectrum of DAPI (blue), Alexa Fluor 488 (green) and
Alexa Fluor 633 (red).
targeting the primary antibody’s heavy and/or light chain. Several secondary antibodies can
bind the primary one, thus magnifying the signal. This secondary antibody is coupled with a
ﬂuorescent molecules characterized by a wavelength of excitation and emission (Fig14). The
emitted light has a longer wavelength, and therefore lower energy, than the absorbed radiation
(excitation wavelength).
Several characteristics are noteworthy:
• Fluorescence excitation spectrum: Optimum instrument setup should deliver excitation
light as close as possible to the peak of the excitation spectrum of the ﬂuorophore.
• Fluorescence emission spectrum describe light density emitted after excitation by a radi-
ation within the ﬂuorescence excitation spectrum.
• Stoke shift: the diﬀerence (in wavelength or frequency units) between positions of the
band maxima of the absorption and emission spectra. The more the stroke shift, the
easier the discrimination between excitation and emission wavelength.
• Fluorescence lifetime: the average time the molecule stays in its excited state before emit-
ting a photon. Usually in nanoseconds it has to be the shortest for repeated excitations.
• Quantum yield: It gives the eﬃciency of the ﬂuorescence process, and is deﬁned as the
ratio of the number of photons emitted to the number of photons absorbed. The maximum
ﬂuorescence quantum yield is 1.0 (100%); each photon absorbed results in a photon
emitted. Compounds with quantum yields of 0.10 are still considered quite ﬂuorescent.
In our experiments we performed multiple labeling on rat brain slices (20-30μm thick). It
was important to choose ﬂuorescent molecules with ﬂuorescent spectra as diﬀerent as possible
to distinguish between the diﬀerent markers that we stained (e.g. NeuN, GFAP or CD11b).
Therefore cell nuclei were stained with the intercalating agent DAPI, and neurons with a mice
primary antibody targeting NeuN protein. NeuN is a protein localized in neuron nucleus and
perikarion. In another set of experiments, our primary antibodies targeted against the GFAP or
CD11-b, with secondary antibody conjugated respectively with Alexa FLuor 488 or Alexa Fluor
633 (Fig 14). Sequential acquisitions were performed for each ﬂuorescent molecule in order to
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avoid possible interferences. DAPI ﬂuorescence was assessed at an excitation wavelength of 405
nm and emission wavelengths of 418-473 nm, while the signal for Alexa Fluor 488 was assessed
at an excitation wavelength of 488 nm and emission wavelengths of 510-613 nm, and Alexa
FLuor 633 was assessed at an excitation wavelength of 621 nm and emission wavelengths of
650-750 nm.
2.3 Imaging brain slices
2.3.1 Whole slide imaging
In order to have slide overview, one have usually to manually image small parts of the slide
and merge them afterwards. This is time consuming and can lead to homogeneous images due
to contrast and or brightness diﬀerences at the edge of small images even if optic parameters
remains constant.
The “Centre d’Imagerie Quantitative de Lyon Est” (CIQLE, http://ciqle.univ-lyon1.fr)
has recently acquired a slide scanner: Axio Scan.Z1 (Zeiss). The Axio Scan provide automatic
slide imaging with a coarse focus matrix, followed by a ﬁne focus one. Sequential ﬂuorescence
images are then performed for each ﬂuorochrome excitation wavelength, illuminated with LED
light. Images are automatically merged resulting in on global image of the slide. The optic
magniﬁcation goes up to 40X.
One of the main problems of conventional light and ﬂuorescence microscopy, is out-of-focus
blur degrading the image by obscuring important structures of interest. In fact not only is
the plane of focus illuminated, but much of the specimen above and below this point is also
illuminated resulting in out-of-focus blur from these areas. This raises several issues: (1) the
background noise is magniﬁed by ﬂuorescent light coming from diﬀerent z-planes, and (2) the
focus still merge the slide thickness limiting the image resolution. These technical issues can
be a problem for molecule co-localization.
2.3.2 Confocal microscopy
To improve the z-plane resolution, optical sectioning can discard unwanted out-of-focus ﬂuo-
rescence. The light from above focal-plane is focused before the pinhole and is blocked away
by the pinhole. Only the light from focal plane is focused at the pinhole thus can reach the
image detector (Fig 15A).
In addition, the use of lasers in confocal microscopy provides light at discrete wavelengths and
has very high intensity which is advantageous for ﬂuorescence excitation. A point-like light
source is achieved by using a laser light passing through an illumination pinhole. The point-
like illumination is then scanned over the specimen by the help of a scanner. The reﬂected
emission light passes through the detecting pinhole and forms a point-like image on detector
PMT (photon multiply tube) that converts detected photon into electron (Fig 15). PMT has
a high dynamic range, and a high refresh rate (nanosecond level).
Thereby confocal microscopy combines several technical improvements over conventional mi-
croscopy:
• A point light source for illumination
• A point light focus within the specimen
• A pinhole at the image detecting plane
These three points are optically conjugated together and aligned accurately to each other in
the light path of image formation, justifying the term “confocal”. Confocal eﬀects result in
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A. B.
Figure 15: Confocal microscopy principle: A schematic representation of confocal optical
sectioning. B Schematic representation of scanning mirrors providing x-y direction scan.
suppression of out-of-focal-focus light and stray light in the ﬁnal image. True, three-dimensional
data sets can be recorded. Scanning the object in x/y-direction as well as in z-direction (along
the optical axis) allows viewing the object from all sides. Finally due to the small dimension of
the illuminating light spot in the focal plane, stray light and photo bleaching are minimized.
2.4 Cell counts
Neuronal counts can be performed manually or semi-automatically using specialized image
analysis software but are always time consuming. For example, neuronal density has been
analyzed stereologically in the hippocampus of animals after a status epilepticus or TBI, but
has seldom been analyzed in other brain regions. Moreover, neuronal counts based on NeuN
immuno-labeling has important drawbacks, especially because the expression or antigenicity
of NeuN protein can vary after brain injury [313]. Therefore Woeﬄer et al. in our laboratory
developed in 2014 an automated procedure for detecting and counting neuronal nuclei, based on
the analysis of confocal images of brain sections stained with DAPI and antibody to NeuN [309].
Cell density was deﬁned as the total number of DAPI-stained nuclei per mm2 of tissue in
diﬀerent regions that were deﬁned based on slide scan overview (i.e. parietal cortex, temporal
cortex, CA1, CA3, hilus, dentate gyrus, and thalamus). Neurons were identiﬁed using confocal
images, as DAPI-stained nuclei present in a NeuN-positive region of the optical section. This
identiﬁcation was performed on the central optical section within the z-stack of each imaged
region (deﬁned as the optical section with the most intense NeuN staining). Each neuronal
nucleus was then conﬁrmed in at least 2 contiguous sections out of the four optical sections
that surrounded the central one (1 μm interval [309], Fig 16).
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Figure 16: Schematic representation of
neuronal density quantiﬁcation on a
single optical section.
A Processing of NeuN-positive regions. (A1)
Original image of a brain section (cortex) in
the 510–613 nm channel (NeuN-Alexa 488
staining). (A2) Digital ﬁltering using band
pass ﬁlter in the Fourier domain. (A3) Im-
age dichotomization using an autothreshold.
(A4) Removal of particles smaller than 50
square pixels. (A5) Object closure using
morphomath. (A6) NeuN-positive objects
are merged into a single selection. B Pro-
cessing of DAPI-positive regions. (B1) Orig-
inal image in the 418–473 nm channel (DAPI
staining). (B2) Digital ﬁltering using a band
pass ﬁlter in the Fourier domain. (B3) The
center of each nucleus is represented by a
cross at the maximum ﬂuorescence inten-
sity. C Each cross present in the green posi-
tive region represents a neuronal nucleus. D
Schematic representation of the NeuN/DAPI
conﬁguration leading to the recognition of a
neuronal nucleus. E Example of an object
treated as a non-neuronal nucleus. Adapted
from Woeﬄer-Maucler 2014 [309].
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Chapter 3
Brain metabolism recordings during
CSDs
Our main goal was to describe the changes in micro-vasculature, metabolism and glutamate
concentrations elicited by CSDs that occurred after a severe experimental TBI. To address
this question we were able to measure CBF, PbtO2, as well as glucose lactate and glutamate
extracellular concentrations. We used several methods that are discussed in the next sections.
Cerebral metabolic rate (CMR) of oxygen and glucose are also commonly used to compare brain
metabolism in normal and pathological conditions. Usually the diﬀerences between arterial
and venous blood contents are used to compute these CMR at steady state (see Introduction
section 3.2). However we did not have access to such parameters, and therefore we had to deduce
these CMR from our extracellular measurements. Assumptions and models that underpin these
calculations will be discuss in a following section 3.5.
3.1 Cortical spreading depolarization
3.1.1 Recording techniques
The historical method used by Leão in the 40s consisted in a silver-chloride Ringer-agar elec-
trodes applied on the surface of the pial matter [220]. As silver is considered toxic these
electrodes could not be transposed to clinical practice. Therefore an alternative device was de-
veloped by Strong et al. in 2002. It was made of 6 subdural platinum-iridium electrodes placed
on the cortex, thereby bypassing the signal-distorting skull and intermediate tissue [224]. To
date, this device became the gold standard method for CSD recordings in the human brain.
In animals small intra-cortical metal, glass or silicon electrodes are used to record neuronal
activity from the extracellular space. It was ﬁrst described in 1875 by Richard Caton who
studied electrical brain activity with a galvanometer electrode [314]. This kind of electrode
gives diﬀerent information: On one hand the signal >500 Hz is related to neurons action po-
tentials spikes, close to the electrode tip. On the other hand, signal ﬂuctuation <300Hz, called
local ﬁeld potential (LFPot), represent ionic modiﬁcations around the probe and are related to
spatiotemporal neuronal activity synchronization [315]. Finally, membrane potential changes
in non-neuronal cells, such as glia, may also give rise to extracellular potentials. Recent studies
on neuron-glia interactions have indicated that the glial syncytium may contribute to slow and
infraslow (<0.1Hz) ﬁeld patterns [315, 316].
Therefore LFPots are indicative of the response of a large population of neurons to a stimulus
or represent their ongoing oscillations. Unlike intracellular recordings LFPot are not a stan-
dardized method but will change depending on experimental preparation.
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Low impedance electrodes (i.e. 1-3MΩ) are required to record CSD with a good DC signal.
In our experiments, LFPot electrodes were made with an Ag/AgCl wire inserted into a pulled
3-5 μm tip glass capillary (Harvard Apparatus, Edenbridge, U.K.), ﬁlled with a mix 2M NaCl,
1M Na citrate solution (1:1 ratio). A subcutaneous silver chloride reference was placed in the
neck of the animal. These electrodes were inserted close to biosensors between 500 and 1000μm
deep inside the cortex. The signal acquisition was made by a near-DC octal bioAmp ampliﬁer
(ADInstrument, Oxford, United Kingdom) with an analogue build-in 0.02 Hz high-pass ﬁlter
and a 100Hz low-pass ﬁlters. Analogue-digital conversion was made by a 16 bit PowerLab 16/35
with Labchart 7 (ADInstrument).
This set-up allows us to detect CSDs but not to determine their essential features such as
amplitude or duration, because we do not have real DC recording. In fact such analogue high-
pass ﬁlters cut the depolarization “ultra-slow” component and modiﬁes its onset, as well as its
amplitude (Fig 17, A and B).
The biosensors used for neuro-chemical recordings during CSDs are also electrodes made of
platinum. The signals of these biosensors result from: (1) the currents due to the enzymatic
oxidation of a metabolite or a neurotransmitter on the surface of the electrode (see below sec-
tion 3.4), and (2) currents produced by local ﬁeld potentials by induction . In our laboratory, the
high frequency component of the signal (typically >2Hz) can be converted into local ﬁeld poten-
tials using a resistor-capacitor circuit-based model [317]. However, unlike Ag/AgCl electrodes in
which current can freely pass through by a reversible redox reaction (AgCl+e−  AgCl+Cl−),
platinum electrodes are considered “polarizable”. Indeed, platinum does not react with elec-
trolytes in the medium but instead the medium will “shield” the charged/polarized metal with
layers of ions that act like a capacitor. The amount of charge that can be stored in these ion
layers will increase when a potential is applied to the electrode, like during our recordings. As
a consequence, DC potential modiﬁcations will be ﬁltered out by these ion layers so that the
biosensor does not record the depolarization of a CSD (Fig17, C). Nevertheless, the decrease
in local ﬁeld potentials amplitude (i.e. the depression) can be recorded (Fig17, C grey curve).
The low frequency component (typically <1Hz) recorded from these biosensor can therefore
be related to extracellular concentration of molecule of interest in the interstitial medium. To
completely identify the DC component of the biosensor signal, control or null biosensors coated
with albumin (no enzymatic activity) can identify non speciﬁc interference from (1) a low fre-
quency component of local ﬁeld potentials that has not been completely ﬁltered out by the
electrodes, (2) the oxidation of other endogenous molecules like ascorbic acid or uric acid, and
(3) local pH changes. If a signal is present of the control biosensor, it must be subtracted from
that recorded by the enzymatic biosensor in order to obtain the speciﬁc oxidation current of
the molecule of interest.
3.1.2 How to trigger CSDs?
CSDs can be triggered experimentally by many cortical stimuli. Leão carried out his experiment
with “tetanizing” shocks delivered for a period of 3 to 5 seconds through a ﬁne silver wire
electrode [249]. Glutamate and potassium that are released in the extracellular space during
CSDs, are also known to trigger such depolarization when injected in the cortex [234]. In recent
studies CSDs are triggered either by potassium apposition or by a pin prick (sometimes with
needle ﬁlled with a potassium chloride solution), on a site remote from the recorded area.
In our experiments we triggered CSDs with a transient increase in potassium concentration
of the saline solution that was infused at the cortical surface, by stirring a drop of 1M K+.
Therefore we were able to control that only one depolarization was triggered, with a continuous
ﬂow of saline solution. However K+ infusion induced a global depolarization of the parenchyma
facing the entire cranial window, which was slightly diﬀerent from a propagating CSD (for
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Figure 17: Local ﬁeld potential recording during a single CSD with an LFPot glass
micro-pipette connected to either a DC ampliﬁer (A) or an near-DC ampliﬁer (B).
(A) An LFPot glass micro-pipette is connected to an extracellular ampliﬁer (EXT 10-2F, NPI
Electronics). The grey curve represent the AC signal component (i.e. 0.5-30 Hz), black curve
the DC signal (i.e. 0-30 Hz). The red curve represent the DC signal with an additional 0.02 Hz
high pass digital ﬁlter (butterworth, second order); (B) The same kind of glass micro-pipette
is connected to a bioAmp (ADInstrument) with a 0.02 Hz analogue build-in high ﬁlter. Black
and grey curve represent also the DC and AC components.
(C) A control biosensor (without the enzymatic layer) is connected to a VA-10 ampliﬁer, and
polarized at +500mV. Black and grey curve represent also the DC and AC components. The
red curve represent the simultaneous signal recorded from the glass micro-pipette (as in (B)).
example by a pin prick at distance) that is usually considered to better mimic the CSDs
observed in brain injured patients. CSDs were deﬁned by a large slow depolarization, with a
subsequent vascular response. A depression of ongoing cortical activity was currently observed
in healthy animals. In our model of severe TBI with LFPI, CSDs were observed spontaneously
during the recorded period (i.e. 20min to 5hours post injury), and also characterized by a large
slow depolarization with a subsequent vascular response. A depression of the ongoing activity
can also be observed if not already depressed by the injury.
3.2 Cerebral blood ﬂow
CBF can be measured using diﬀerent techniques computing either absolute or relative values.
Absolute values of CBF are usually obtained at steady state using a lipophilic tracer injected
IV (e.g. 133Xenon) crossing the BBB, therefore we have to wait for the tracer to be cleared from
brain before another measurement can be performed. Radiation can be measured using single
photon emission computed tomography or scalp detectors, and related to local CBF [115]. H152 O
tracer has been used with PET imaging to measure CBF in diﬀerent experimental conditions
during functional imaging studies. Finally, MRI “continuous arterial spin labeling” sequence
can also extract CBF local information [318]. However these measures of absolute CBF are
static, requiring long lasting acquisition time, and not adapted for CSD induced dynamic
modiﬁcations.
Conversely, optical techniques using backscattered light from illuminated cortical surface gives
real time information. Laser speckle contrast imaging gives a 2D blood ﬂow representation of
the illuminated cortical surface through a microscope. Hence, it becomes diﬃcult to implant
multiple electrode inside the cortex with the lens focusing on the same brain area.
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Therefore, in our experiments, blood cell perfusion in the microvasculature of brain tissues
was measured with a pencil Probe connected to blood Flow meter (1mm tip, MNP100XP,
ADInstrument, Oxford, United Kingdom). Analog signals were acquired a 16 bit PowerLab
16/35 with Labchart 7 (ADInstrument).
The Blood FlowMeter determines the blood ﬂow perfusion by illuminating the surface of the
cortex with laser light (830 nm wavelength, visible red light) and measuring the backscattered
light. The returned signal is a combination of the original light and backscattered light which
results in a signal with a varying frequency content. When the tissue is illuminated by a
coherent, low powered laser, light is scattered by both moving and static structures within
the microcirculatory beds. Photons, scattered by moving blood cells are spectrally broadened
according to the Doppler Eﬀect. Maximum Doppler shifts occur when blood cells are moving
in a direction parallel to the incident light beam. The detected light (scattered light) from the
cells is detected in a direction opposite to its origin. This varying signal content is the signal
of interest as it represents the Doppler shift as a result of light being backscattered oﬀ moving
blood cells.
LDF produces an output signal in blood perfusion unit (BPU) that is proportional to the blood
cell perfusion (or ﬂux). This represents the transport of blood cells through microvasculature
and is deﬁned as:
Microvascular perfusion = Number of blood cells × Mean velocity (5)
Microvascular perfusion, therefore, is the product of the mean cell velocity and mean blood cell
concentration present in the small volume of tissue under illumination from the laser beam (5).
The LDF has been factory calibrated with a constant known motility standard so that, for a
given perfusion situation, all probes will read the same value of BPU. However BPU is not an
intrinsic physiological deﬁnition of blood perfusion, even though it can be traced to a physical
standard, the measurements expressed in BPU must be considered as strictly relative.
Thus median BPU measured during the ﬁrst 5min of each experiment was considered as 100%
and after animals were euthanized as 0%.
3.3 Tissue oxygen concentration
Brain oxygen concentration can be measured with a wide range of techniques and the values
they give are highly dependent on experimental conditions such as anesthesia or the brain region
of interest monitored [192]. Two Photon microscopy has been used to describe O2 concentration
in both brain vessels and tissue, however it is hard to have simultaneous electrophysiological
and biosensor recordings under a microscope due to spatial organization. What’s more, our
model of LFPI induces a subdural hemorrhage that might interfere with the photon tissue
penetration.
Hence, we chose to measure PbtO2 using an electrochemical (Clark-type) micro-sensor con-
nected to an ampliﬁer with a constant potential of -0.8V (OX-10, Unisense, Aarhus, Denmark).
This technique is minimally invasive (10μm tip) with a high temporal resolution. The cathode
is polarized against the internal Ag/Cl reference. Driven by external partial pressure, oxygen
diﬀuses from the environment through a silicone membrane and is reduced at the gold cathode
surface. The OX-10 oﬀers the association of a very small tip (10 μm) with a short reaction time
(≤ 0.1sec). Sensor oxygen consumption is also very low (2.5−25.0×10−7 μg·min−1) compared
to brain oxygen consumption (i.e. 2.19 ± 0.14 μmol· g−1·min−1 ↔ 70.08 × μg· g−1·min−1
under α-chloralose anesthesia and normocapnia in rats [319], Table 9).
The oxygen micro-sensor has an internal guard cathode that removes oxygen in the electrolyte,
thus minimizing zero-current and pre-polarization time. Oxygen sensors respond linearly in the
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range of 0 to 100% (i.e. oxygen % in the bubbled gas) allowing to convert linearly the signal
to oxygen partial pressure (PO2). Like all chemical reactions, the rate of oxygen reduction
depends on temperature, so that the relationship between PbtO2 and the oxidative current
has to be adjusted to brain/body temperature. Hence, calibration was conducted in a 37oC
saline (0.9%) solution, to match animals in vivo body temperature. atmospheric and anoxic
conditions were obtained by bubbling 0.5L·min−1 of either air or N2 in a home-made chamber.
3.4 Glucose, lactate and glutamate concentrations
3.4.1 Imaging
PET is broadly used to investigate brain metabolism and perfusion. For instance 18F-2-
deoxyglucose tracer allow for global and local CMRglucose with a millimeter of spatial resolution.
Likewise spectroscopic MRI gives precise information about global and local concentrations of
brain metabolites such as glucose or lactate [171]. However these imaging techniques gives
static images, that cannot be reproduce over time with a temporal resolution needed for the
study of dynamic process such as CSD. Moreover these measurements average the vascular,
intracellular and extracellular concentrations. Thereby interpreting experimental modiﬁcations
of glucose or lactate detected by PET can be challenging because of their multiple possible
origins.
3.4.2 Tissue measurements
3.4.2.1 Microdialysis
Although chemical signaling has a key role in every brain function, relatively few techniques
allow the direct measurement of transmitters and metabolite’s extracellular concentrations and
the monitoring of their dynamic changes over time. Among them, cMD has been broadly used
both in animal models since the 70s [196] and in the ICU since the 90s for the monitoring of
acutely brain injured patients [197].
Molecules present in the interstitial ﬂuid diﬀuse across a polyamide dialysis membrane into the
perfusion ﬂuid inside the catheter. The low membrane cut-oﬀ (e.g. 6-35kDa, MAB probes, Mi-
crobiotech, Sweden) permits small molecules, such as glucose, lactate or amino-acids, detection.
If the membrane is long enough, the size and polarity of the molecule small enough, and the
dialysate ﬂow slow enough, the concentration in the dialysate will approach the concentration
in the interstitial ﬂuid. The usual perfusion rate ranges between 0.3 and 1 μl·min−1 with a
30-60 min sampling rate. With CMA-70 probes (10mm length, 20kDa cut-oﬀ) micro-dyalisate
concentrations are around 70% their true value in the interstitial ﬂuid. Overall, the temporal
resolution is insuﬃcient to detect the dynamic changes that challenge the tissue during CSD.
Recently the team led by MG Boutelle developed a rapid sampling MD technique [320]. Brieﬂy
the assay comprised a custom built valve that allows rapid ﬂow injection of small volumes of
dialysate into two separate enzyme beds (either glucose or lactate sensitive biosensors) systems
at a 30 sec intervals (Fig 18). With a 2 μl·min−1 continuous ﬂow rate the authors could not
compute the in vivo recovery and were unable to quantify the glucose and lactate extracellular
concentrations (i.e. in vivo recovery of the probe/ﬂow-rate). Thus values of glucose and lactate
levels are reported in terms of their concentrations in the dialysate.
Despite its impressive analytical power, cMD is limited on the one hand by the large size of
the probes (i.e. 200-600 μm) used to collect brain samples. In particular, implantation of cMD
probes into the CNS often causes lesions that impair the physiological processes taking place
around the probe [321, 322]. Moreover, cMD probes are too large to be inserted into brain
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Figure 18: Schematic of rapid-sampling microdialysis system
Dialysate stream from the patient’s MD probe (CMA, Microdialysis, Sweden) ﬂows continu-
ously into the custom built valve. The computer switches the valve between the 2 positions to
inject a 200 nL samples alternately into the glucose and lactate assays. Adapted from Parkin
et al 2005 [262]
slices or small structures of rat or mouse CNS.
On the other hand, the slow diﬀusion of molecules through the dialysis membrane leads to a
30-60 min sampling rate to approximate the real extracellular concentrations. When trying
to reach continuous measurements real cerebral concentrations cannot be quantiﬁed and are
reported in terms of the dialysate concentrations. Because extracellular concentrations of neu-
rotransmitters and metabolites can vary with fast kinetics, especially during CSD, it is essential
that detection take place with a faster temporal resolution in the order of seconds.
3.4.2.2 Microelectrode biosensors
To overcome these technical limitations, a more recent avenue of research has developed micro-
electrode biosensors that are sensitive to a speciﬁc molecule through electrochemical detection.
In 1959 J. Heyrovsky received the Nobel Prize in Chemistry for the discovery and development
of polarographic methods of analysis. A dropping mercury electrode, which consists of mercury
ﬂowing through a capillary and emerging from the oriﬁce as a continual series of mercury drops,
is polarized at a ﬁxed potential. Such electrodes have been used in analytical chemistry for
the detection of electro-active species (i.e. can be made to oxidize or reduce). The potential of
the electrode is controlled so that the chemical species are oxidized or reduced. The potential
can be thought of as “electron pressure” which either forces a species in solution to gain an
electron (reduction) or lose an electron (oxidation). As the potential of the electrode becomes
more negative, it becomes more strongly reducing. Conversely, as the potential becomes more
positive, it becomes more strongly oxidizing. Therefore, the redox reaction taking place on the
electrode can be controlled by controlling the electrode potential. The polarographic analyzer
controls the potential of the electrode against a silver chloride reference, and measures the cur-
rent at the electrode that is proportional to the electro-active molecule concentration around
the electrode.
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This principle has been used to design microelectrodes for brain analysis, in which the dropping
mercury electrode can be made of carbon, graphite, gold or platinum. These materials have
been used to design microelectrode biosensors that can work within a tissue, whereas dropping
mercury electrodes can only work in liquid solutions.
The ﬁrst molecules to be detected in the central nervous system with carbon ﬁber micro-
electrodes were directly oxidizable (dopamine, nor-epinephrine, serotonin, or their metabo-
lites) [323]. Other non-electro-active molecules can be detected by microelectrode biosensor
based on their recognition by an enzyme belonging to the class of oxidoreductases that is di-
rectly immobilized on the surface of the microelectrode. Most oxidases utilized for biosensors
have ﬂavin adenine dinucleotide (FAD) as their co-factor and use O2 as an electron acceptor to
catalyze oxidation reaction of the type:
Substrate + Enzyme − FAD → OxidizedProduct + Enzyme − FADH2 (6)
Followed by:
Enzyme − FADH2 + O2 → Enzyme − FAD + H2O2 (7)
The main interest of this type of enzymes is the production of hydrogen peroxide (H2O2), be-
cause it can be subsequently oxidized on the electrode surface. Enzymatic activity depends on
oxygen as a co-substrate that is supposed to be available in non-limiting concentration in the
brain. It is also sensitive to temperature and pH, so that these parameters can limit detection
capabilities. Oxygen and temperature issues will be discussed in the part V “Electrochemical
measurement validation”. Depending on micro-electrode electrochemical scheme (e.g. polymer
use for enzyme immobilization) and on the applied working potential used for detection, un-
wanted oxidation of endogenous electroactive molecules like ascorbic acid, catecholamines, uric
acid or serotonin has to be considered. To prevent such interference, screening layers such as
poly-m-phenylenediamine (PPD) and/or naﬁon can be added (Fig 19).
Diﬀerent electrochemical methods can be used with biosensors:
• Cyclic voltammetry: The working electrode potential is ramped linearly versus time.
After the set potential is reached the potential is ramped in the opposite direction to
return to the initial one. These cycles of ramps in potential may be repeated at a high
frequency (up to 10Hz) and the current at the working electrode is plotted versus the
applied voltage to give the cyclic voltammogram trace.
• Constant-Potential Amperometry (used in our experiments): A ﬁxed potential is applied
between the working electrode and the reference. The measured current changes as the
electroactive-analyte is oxidized (e.g. H2O2). The applied potential can be adjusted
to maximize the response for the analyte of interest while minimizing the response for
interfering analytes. Unlike voltametric techniques, constant-potential amperometry gives
a continuous signal related to the concentration of a molecule around the tip of the
electrode. For oxidase based biosensors, the sampling rate is thus dependent on (1)
enzymatic reaction kinetics and (2) oxidation kinetics on the electrode surface. The
oxidases we used for biosensors manufacturing (i.e. glucose oxidase, lactate oxidase or
glutamate oxidase) are coated on a platinum wire polarize at +500mV for optimal H2O2
oxidation against a silver-chloride reference [323]. This set up oﬀers a 1-2 sec temporal
resolution (Fig 19).
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Figure 19: Glucose sensitive biosensor principle.
A. biosensor micro-image and B. schematic representation of the diﬀerent layers of the biosen-
sor. In the center; Enzymatic reaction allowing for glucose detection by its oxidation with H2O2
production. On the right: time-response to a 1μM glucose concentration increase.
3.5 Cerebral metabolic rate calculations
3.5.1 CMRO2 calculation
CMRO2 is traditionally computed from CBF and avDO2 (see equation (2) in introduction,
section 3.2). However such measures made at steady-state and are not appropriate for fast
dynamic modiﬁcation monitoring. In our experiments we measured PbtO2 and CBF modiﬁca-
tions and seek to determine also CMRO2 from these values. However, using LDF and PbtO2
probes imposed several assumptions:
• Since LDF only gives relative perfusion data, the absolute CBF (in ml· g−1·min−1) rely
on data from the literature. Thereby, only relative modiﬁcations of CMRO2 can be
interpreted.
• Since our probe is located in the extracellular space, we have to assume that extra-cellular
oxygen concentration equal intracellular and mitochondrial concentrations.
• We have also to consider the arterial oxygen content to be constant.
Using PET imaging with a 15O-oxygen inhaled tracer to measure CMRO2 and an H152 O injected
tracer to measure CBF, Gjedde et al. published in 1997 a model of the relationship between
CBF and oxygen delivery during neuronal excitation [324]. According to this model, the tension
of oxygen in mitochondria being negligible compared to the average capillary tension, the mean
oxygen tension in the capillary drives the oxygen delivery and consumption in the tissue.
This model has been tested using the same PET approach during both visual stimulation [324]
and CBF decrease with indometacine infusion [114]. Oxygen being a small molecule, it is
supposed to diﬀuse within the tissue independently from its architecture. Therefore the authors
assumed that oxygen diﬀusion coeﬃcient remains constant.
Based on this model, Henning Piilgaard and Martin Lauritzen in 2009 proposed a similar
algorithm to compute CMRO2 based on CBF measured by an LDF probe and PbtO2 measured
using implanted electrochemical probes [258]. They used Gjedde’s relation assuming that PbtO2
equals mitochondrial oxygen concentration [114]:
PbtO2 = P50· h
√
2·Ca·CBF
CMRO2
− 1 − CMRO22·L (8)
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Where P50 is the half-saturation tension of the oxygen-hemoglobin dissociation curve, h the
Hill’s coeﬃcient of the same dissociation curve, Ca the arterial oxygen concentration, and L
the eﬀective diﬀusion coeﬃcient of oxygen in brain tissue.
To calculate the eﬀective diﬀusion coeﬃcient of oxygen in brain tissue (L) standard values of
P50 (34 mmHg [325]) and h (2.7), were combined to Ca from our experiments (7.2 mmol·mL−1,
calculated with equation (9)), CBF and CMRO2 from the literature.
CaO2 = (Hb × 13.4 × Sat O2100 ) + (PaO2 × 0.031) (9)
As reported in table 9, CBF and CMRO2 are highly dependent on species and anesthesia. In
rats under isoﬂurane, that is very similar to our experimental conditions, Baughman et al.
reported a CBF of 1.35 ml· g−1·min−1 and a CMRO2 of 3.57 μmol· g−1·min−1 [326]. Using
equation (8) with these parameters we computed an L value of 5.1 μmol· g−1·min−1·mmHg−1.
We calculate “oﬀ-line” CMRO2 from simultaneously recordings of PbtO2 and CBF using an L
value of 5.1 μmol· g−1·min−1·mmHg−1, and Ca of 7.2 mmol·mL−1.
In our experiment, baseline values of PbtO2 and CBF were taken as the median of a 5 min
period starting the experiments, after stabilization. Baseline BPU recorded by the LDF probe
was considered as 100% of initial absolute CBF, and the BPU value after the animal was eu-
thanized as 0%.
In healthy animals, initial absolute CBF value (i.e. 100% BPU) was taken from Baughman
et al. (1990) as for the L calculation: 1.35 ml· g−1·min−1 [326]. After LFPI Hayward et al.,
using ALS MRI sequence, reported a 54% decrease in CBF in the temporal cortex near the area
where we have implanted our electrodes [318]. Therefore in animals undergoing severe LFPI
we used 54% × 1.35 = 0.729 ml· g−1·min−1 as initial absolute CBF value.
Equation (8) was then encrypted in “R ” (see chapter 4 “Statistical analysis and signal pro-
cessing”) with CBF as a relative value (percentage from baseline level of BPU measured with
the LDF probe) as follow:
1 CMRO2. func <− f unc t i on (CMR, CBF, TPO2, P50 , h , Ca , L , cb fbase )
2 {
3 cb f <− cb fbase ∗ CBF/100
4 P50 ∗ ( (2 ∗Ca∗ cb f /CMR)−1)^(1/h) − (CMR/ (2 ∗L) ) − TPO2
5 }
Subsequently CMRO2 calculations were conducted using the uniroot() function (package stats)
to determine the CMRO2 value that gives the root of equation 8. CBF and PbtO2 recordings
were divided into 1 sec epochs, to compute second by second variations of CMRO2 after CSDs:
1 f o r ( i in 1 : nrow ( data ) ) {
2 CMRO2[ i ] <− un i root (CMRO2. func , c (0 , maxindex ) , data$LDF[ i ] , data$TPO2[ i
] , P50 , h ,Ca ,L , cb fbase ) $ root
3 # c (0 , maxindex ) d e f i n e the CMRO2. func equat ion i n t e r v a l o f v a l i d i t y .
$
4 }
3.5.2 CMRglucose calculation
Like for CMRO2, CMRglucose is usually calculated from avDgluc and CBF. For the same rea-
sons we had to compute CMRglucose from extracellular glucose concentrations, measured with
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Table 9: Values of CBF and CMRO2 for diﬀerent anesthesia and species from the
literature [327, 328, 329, 326, 330, 331, 319, 114, 115]. Calculated from their data with 1 ml
O2 = 44.64 mmol, and an average brain density of 0.99 g/cm3 [332]
Reference spieces Condition CBF
(ml· g−1·min−1)
CMRO2
(μmol· g−1·min−1)
Nilsson and Siesjo
(1975)
rat conscious 1.4 5.00
50 mg/g phenobarbital 1.11 4.05
150 mg/kg phenobarbi-
tal
0.79 2.95
250 mg/kg phenobarbi-
tal
0.6 2.6
Harp et al. (1976) rat 70% N2O, 1.2%
halotane
0.8 3.36
Berntman et al.
(1979)
rat 70% N2O 1.11 4.00
Baughman et al.
(1990)
rat isoﬂurane 1.5% 1.35 3.57
isoﬂurane 2.8% 1.08 1.9
Poulsen (1997) pig midazolam, ketamine 0.37 1.69
Hyder et al. (2000) rat morphine 50 mg/kg,
70% N2O
0.75 3.15
α-chloralose 80mg/kg,
70% N2O
0.4 1.51
Zhu et al. (2002) rat α-chloralose 15mg/h 0.53 2.19
Gjedde et al. (2005) healthy
volun-
teers
conscious 0.62 1.47
Glenn et al. (2003) healthy
volun-
teers
conscious 0.46 1.38
TBI pa-
tients
sedation and ventila-
tion
0.4 0.62
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biosensors. However unlike oxygen, glucose is a much larger molecule that does not diﬀuse
uniformly in brain tissue. Conversely its diﬀusion depends on both extracellular space tortuos-
ity and transporters kinetics. Glucose transport across membranes is mediated by a family of
membrane-spanning passive carrier proteins, the GLUTs. The repartition of several isoforms
among brain cells is discussed in the introduction section 2.2.
Since GLUT1 are similarly distributed at the luminal and abluminal membranes of the endothe-
lium, BBB can be modeled as a single membrane system in terms of glucose transport [333].
Therefore brain glucose concentration reﬂects the relative transport capacity at the BBB and
CMRglucose (Fig 20B).
However, using extracellular glucose concentration to compute CMRglucose imposed several as-
sumptions:
• We have to assume that the arterial blood glucose concentration remains constant.
• Since our biosensors are located in the extracellular space, we have to assume that extra-
cellular equal intracellular concentrations. Indeed, considering the high concentrations
of GLUT 3 and 1 on neurons and astrocytes, the diﬀusion of glucose across their mem-
brane is not limiting and allows fast equilibrium. Accordingly, unlike other metabolite
(N-acetylaspartate, choline, creatine, myo-inositol, and taurine), intra and extra-cellular
glucose concentrations are very close [334]. The largest glucose gradient being at the
BBB.
• Likewise, the high concentrations of GLUT 3 and 1 on cell’s membranes lead to the
hypothesis that glucose repartition in brain tissue is homogeneous and independent of
extracellular tortuosity.
• The transport kinetics of the BBB have also to be constant. However transport kinetics
as measured in vivo by MRI spectroscopy has been mostly determined under steady-state
conditions, compatible with suﬃcient measurement time required for glucose equilib-
rium [333, 335, 336]. This might not be the case during fast glucose modiﬁcations on one
side of the BBB.
• Last but not least, modeling glucose transport across BBB and CMRglucose, for example
with a reversible Michaelis-Menten equation, does not include CBF values.
Under Steady-state conditions, a near linear relationship between brain and plasma glucose
has been experimentally determined and described by a reversible Michaelis-Menten model of
enzyme kinetics [333]. However, a reversible model is unable to account for GLUT transport
kinetics adaptation to asymmetric glucose concentrations across BBB [337]: Transaccelera-
tion and iso-inhibition describes respectively how glucose transport rate from blood (Gblood)
to brain tissue (Gbrain) can be increase by Gblood or decrease by Gbrain [336, 337]. Therefore a
“four-state” model has been developed to account for the diﬀerent GLUT1 conformations at the
BBB (Fig 20A). The best description of experimental observations by this “four-state” model in-
cluded symmetric rather than asymmetric glucose carriers across BBB (i.e. KGbraint = K
Gplasma
t ,
Fig 20) [336, 337]. Therefore, the relationship between glucose concentrations in brain (Gbrain)
and plasma (Gplasma) at steady-state can then be described by equation (10):
Gbrain = Vd
(
Tmax
CMRgluc
− 1
)
× Gplasma − Kt
Tmax
CMRgluc
+ 1 + Gplasma
Kii
(10)
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reference method,
species,
anaesthesia
Kt (mM) Tmax (μmol ·
g−1 · min−1)
CMRgluc (μmol ·
g−1 · min−1)
Gruetter 1998 MRS, human,
awake
0.6 ± 2 0.69 ± 0.09 0.3*
De graaf 2001 MRS, human,
awake
1.2 ± 0.62 0.57 ± 0.15 0.27 ± 0.07
grey matter 1.1 ± 0.66 0.65 ± 0.13 0.36 ± 0.07
white matter 1.7 ± 0.88 0.24 ± 0.13 0.11 ± 0.06
Choi 2001 MRS, rat,
αchloralose
3.3 ± 0.1 Tmax/CMRgluc=2.7 ± 0.13
Choi 2002 MRS, rat,
pentobarbital
3.3 ± 0.1 Tmax/CMRgluc=5.0 ± 0.24
Morgenthaler
2006
brain extrac-
tion, rat,
isoﬂurane or
αchloralose
1.4 ± 0.7 Tmax/CMRgluc=2.3 ± 0.1
Table 10: Glucose kinetic parameters according to a reversible Michaelis-Menten model
(equation (11)) [333, 338, 339, 340, 341]. Abbreviations: MRS Magnetic resonance spec-
troscopy; * CMRglucose was assume to remain constant.
Where Vd is the the physical distribution space volume of glucose in the brain (0.77mL · g−1),
Tmax denotes the apparent maximal transport rate across the BBB (μmol ·g−1 ·min−1), Kt and
Kii denote the apparent Michaelis and inhibition constants (in mM). Adding a fourth endothelial
compartment did not improve the model when confronted to diﬀerent datasets [336].
It was noteworthy that Kt was on the order of a few mM, as previously determined from
the reversible model. Moreover, since Kii largely exceeds Gplasma, iso-inhibition (i.e. transport
inhibition by Gbrain) is unlikely to be of substantial importance for plasma glucose below 25
mM. As a consequence, the reversible Michaelis-Menten model (equation (11)) can account
for most experimental observations under normo-glycemia and moderate cases of hypo and
hyperglycemia [336, 333]:
Gbrain = Vd
(
Tmax
CMRgluc
− 1
)
× Gplasma − Kt
Tmax
CMRgluc
+ 1
(11)
Therefore, brain glucose concentration at steady-state appears to be well deﬁned by the ratio
of Tmax to CMRglucose, assuming that other parameters remain constant. Several authors cal-
culated Michaelis-Menten constants for glucose transport from a reversible model using either
spectroscopy MRI or PET (Table 10). However, it is noteworthy that the spatial resolution of
these imaging techniques is not enough to depict the diﬀerence between capillaries, extracellu-
lar space and intracellular compartment. Therefore, brain glucose concentrations measured by
magnetic resonance spectroscopy are higher than those obtained with micro-electrode biosen-
sors (2.2-4.1 [342] vs 0.59±0.3mM [343]).
Another caveat is that all these kinetic parameters have been determined assuming a con-
stant CMRglucose. Some authors even evaluate the ratio between Tmax and CMRglucose as a
surrogate to Tmax, with huge variations depending on anesthesia or plasma glucose concentra-
tions [339, 344]. To our knowledge, there is no evidence about how these parameters behave
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Figure 20: Glucose transport models: A. Schematics representation of the alternating
conformation kinetics of the glucose carrier. In the absence of glucose (Gout or Gin), the carrier
can exist in two inter-converting isomers that are ready to bind glucose either outside (Cout)
or inside (Cin) the membrane. When loaded, the carrier can also assume two isomeric forms
favoring glucose release to the outer (CoutG) or inner (CinG) side of the membrane. The rate
constants k1 and k−3 deﬁne glucose binding while k−1 and k3 deﬁne its dissociation from the
carrier. The rate constants k2 and k−2 or k4 and k−4 reﬂect the isomerisation of the loaded or
unloaded carrier. B. Shows the simplest model of bidirectional glucose transport (Tf and T r)
which represents the forward and reverse ﬂuxes of glucose diﬀusion through the BBB that was
considered as a single membrane. C. The compartment composed by the endothelial cells was
included and thus four unidirectional ﬂuxes (T) are required to describe glucose ﬂow through
the BBB. The glucose consumption rate CMRglc was considered as a metabolic compartment
in the system. Adapted from Duarte et al. 2009 [336]
The four-state exchange model parameters can be describe as follow:
Gbrain = Vd
(
Tmax
CMRgluc
− 1
)
× Gplasma − KGplasmat
Tmax
CMRgluc
+ K
Gplasma
t
KGbraint
+ Gplasma
KGbrainii
Tmax = G
k2k3k4
(k4k2 + k4k−2 + k3k4 + k2k3)
KGbraint =
(k4 − k−4)(k−1k−2 + k2k3 + k3k−1
k−3(k−1k−2 + k−2k−4 + k2k−4 + k−1k−4)
K
Gplasma
t =
(k4 − k−4)(k−1k−2 + k2k3 + k3k−1
k−1(k2k4 + k−2k4 + k3k4 + k2k3)
KGbrainii =
k1(k4k2 + k4k−2 + k3k4 + k2k3)
k−3(k2k−2 + k1k2)
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during dynamic process such as brain activation or injury, therefore we had to consider them
as constant.
In 2006, Morgenthaler et al. shown that the relationship between brain and blood glucose was
not inﬂuenced by the anesthetic agent: isoﬂurane or αchloralose [341].
Moreover, a reversible Michaelis-Menten model gave a good description of their data. In
our experiment we calculated CMRglucose using a reversible Michaelis-Menten equation, with
Morgenthaler parameters of Kt and Tmax/CMRglucose. To extrapolate Tmax from the ratio
Tmax/CMRglucose, we used CMRglucose from the literature, corresponding to our experimental
condition: anesthetized rats under low doses of Isoﬂurane (0.8-1.5%). Indeed CMRglucose is in-
ﬂuence by the depth of anesthesia, ranging from 0.44μmol ·g−1 ·min−1 under 2% Isoﬂurane and
nitrous oxide [345] to 0.55 μmol · g−1 · min−1 under 1.5% Isoﬂurane alone [346]. A CMRglucose
of 0.55 μmol · g−1 · min−1 lead to a Tmax of 2.3 × 0.55 = 1.27 μmol · g−1 · min−1.
Therefore, the equation (11), was encrypted in “R”, using a Kt=1.4, a Tmax=1.27 and a
Vd=0.77:
1 CMRGluc <− f unc t i on (CMRG, Gbrain , Vd=0.77 , Kt=1.4 , Tmax=1.27 , Gplasma
=7.3)
2 {
3 (Vd∗ ( ( ( (Tmax/CMRG)−1)∗Gplamsa − Kt ) / ( (Tmax/CMRG) + 1) ) ) − Gbrain
4 }
Like CMRO2, CMRglucose was calculated using the uniroot() function (package stats) to de-
termine the value that gives the root of equation 11, assuming that other parameters remains
constant during the experiment.
1 f o r ( i in 1 : nrow ( data ) ) {
2 CMR[ i ] <− un i root (CMRGluc, c ( 0 . 0001 , maxindex ) , Gbrain [ i ] ,Vd,Kt ,
Tmax, Gplamsa ) $ root # c (0 . 0001 , maxindex ) d e f i n e the CMRGluc
func equat ion i n t e r v a l o f v a l i d i t y . $
3 }
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Chapter 4
Statistical analysis and signal
processing
Many software are available to perform statistical analysis and/or signal processing. Among
them “R” is a powerful and widely used open-source (GNU General Public License) program-
ming language and software environment for statistical computing, graphics and data analysis.
It is currently developed by the “R development core team” (http://www.R-project.org/; R
Foundation for Statistical Computing, Vienna, Austria). We performed our analysis in RStudio
(version 0.98.1103 – c©2009-2014), also a free and open source integrated development environ-
ment (IDE) with “R” (version 3.2.0, 2015-04-16).
The capabilities of “R” are extended through user-created packages, which allows specialized
statistical techniques, graphical devices, import/export capabilities, reporting tools . . . In our
analysis we used the following additional packages:
• graphics: graphics (Paul Murrel, Aukland university), ggplot2 (Hadley Wickham and
Winston Chang, Rice university) and gridExtra (Baptiste Auguie, Wellington university)
• signal processing: signal (actual maintainer: Uwe Ligges, Dortmund university)
• data processing: dplyr (actual maintainer: Hadley Wickham, RStudio)
• model and statistical analysis: stats (R Core Team and contributors worldwide) and
nlstools (actual maintainer: Florent Baty, COPSAC, Gentofte university).
Likewise, I wrote a package dedicated to biosensor and brain metabolism analysis that is
available on GitHub for download (https://github.com/balanca/BrainMetabolism.git, the
documentation is in appendix VIII). It includes functions for biosensor calibration and signal
conversion to corresponding substrate concentration, CMRO2 and CMRglucose calculations, and
a few signal processing function. This package has been used in our analysis in order to save
time, and the scripts that are included will be described along my thesis.
As we usually had a few samples in each group, a normal data distribution could not be assumed.
Therefore our data will be presented as median and interquartile range [25th percentile;75th
percentile].
Group comparisons were performed by a Wilcoxon rank sum test. When there were more than
two groups to compare (histological analysis), a Kruskal-Wallis test was performed. A Wilcoxon
rank sum test (with bonferroni p value adjustment) was used for post-hoc comparisons when
the Kruskal-Wallis showed a signiﬁcant eﬀect.
A p value < 0.05 was considered as signiﬁcant.
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,QVHUP8&156805/\RQ1HXURVFLHQFH5HVHDUFK&HQWHU$QL5$1HXURFKHP
7HFKQRORJLFDO3ODWIRUP)/\RQ)UDQFH
WKHVHDXWKRUVFRQWULEXWHGHTXDOO\WRWKLVZRUN
&RUUHVSRQGLQJDXWKRU6WpSKDQH0DULQHVFR3K'/\RQ1HXURVFLHQFH5HVHDUFK&HQWHU7HDP
:$.,1*$YHQXH5RFNHIHOOHU/\RQ&HGH[
(PDLOVWHSKDQHPDULQHVFR#XQLYO\RQIU
5XQQLQJWLWOHTXDQWLI\LQJQHXURQDOORVVIROORZLQJ7%,LQUDWV
.H\ZRUGVLPPXQRKLVWRFKHPLVWU\1HX1ODWHUDOIOXLGSHUFXVVLRQKLSSRFDPSXVFRUWH[
$%B$%B
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$EVWUDFW
7UDXPDWLFEUDLQLQMXU\FDXVHVZLGHVSUHDGQHXURORJLFDOOHVLRQVWKDWFDQEHUHSURGXFHGLQDQLPDOV
XVLQJWKHODWHUDOIOXLGSHUFXVVLRQ/)3PRGHO7KHFKDUDFWHUL]DWLRQRIWKHSDWWHUQRIQHXURQDO
GHDWKJHQHUDWHGLQWKLVPRGHOUHPDLQVXQFOHDULQYROYLQJERWKFRUWLFDODQGVXEFRUWLFDOEUDLQ
UHJLRQV+HUHVHYHQGD\VIROORZLQJPRGHUDWHDWPRVSKHUHVDEVROXWH$7$RUVHYHUH
$7$/)3ZHHVWLPDWHGQHXURQDOORVVXVLQJLPPXQRKLVWRFKHPLVWU\WRJHWKHUZLWKDQFRPSXWHU
DVVLVWHGDXWRPDWHGPHWKRGIRUTXDQWLI\LQJQHXURQDOGHQVLW\LQEUDLQVHFWLRQV1HXURQDOFRXQWV
ZHUHSHUIRUPHGLSVLODWHUDOWRWKHLPSDFWLQWKHSDULHWDOFRUWH[YHQWUDOWRWKHVLWHRISHUFXVVLRQ
WKHWHPSRUDOFRUWH[WKHGRUVDOWKDODPXVDQGWKHKLSSRFDPSXV7KHVHUHVXOWVZHUHFRPSDUHGWR
WKHFRXQWVREVHUYHGDWVLPLODUDUHDVLQVKDPDQLPDOV:HIRXQGWKDWQHXURQDOGHQVLW\ZDV
VHYHUHO\GHFUHDVHGLQWKHWHPSRUDOFRUWH[LQWKHGRUVDOWKDODPXVDQGLQDUHD&$
RIWKHKLSSRFDPSXVRILQMXUHGDQLPDOVFRPSDUHGWRFRQWUROVEXWZDVQRWVLJQLILFDQWO\
PRGLILHGLQWKHFRUWLFHVORFDWHGLPPHGLDWHO\YHQWUDOWRWKHLPSDFW7RWDOFHOOXODUGHQVLW\
LQFUHDVHGLQEUDLQVWUXFWXUHVGLVSOD\LQJQHXURQDOGHDWKVXJJHVWLQJWKHSUHVHQFHRIJOLRVLV7KH
LQFUHDVHLQWKHVHYHULW\RI/)3GLGQRWFKDQJHWKHSDWWHUQRIQHXURQDOLQMXU\7KLVDXWRPDWHG
PHWKRGVLPSOLILHGWKHVWXG\RIQHXURQDOORVVIROORZLQJWUDXPDWLFEUDLQLQMXU\DQGDOORZHGWKH
LGHQWLILFDWLRQRIDSDWWHUQRIQHXURQDOORVVWKDWVSUHDGVIURPWKHGRUVDOWKDODPXVWRWKHWHPSRUDO
FRUWH[ZLWKWKHPRVWVHYHUHOHVLRQVEHLQJLQEUDLQVWUXFWXUHVUHPRWHIURPWKHVLWHRILPSDFW
6LJQLILFDQFHVWDWHPHQW
7UDXPDWLFEUDLQLQMXU\7%,LVRQHRIWKHPDLQFDXVHVRIGLVDELOLW\OHDGLQJWRPDMRUHFRQRPLF
DQGVRFLDOEXUGHQV$EHWWHUXQGHUVWDQGLQJRIWKHPHFKDQLVPVXQGHUO\LQJQHXURORJLFDO
G\VIXQFWLRQIROORZLQJ7%,LVWKHUHIRUHRILPSRUWDQFH/DWHUDOIOXLGSHUFXVVLRQ/)3LVRQHRI
WKHPRVWZLGHO\XVHG7%,DQLPDOPRGHOVKRZHYHUWKHFKDUDFWHUL]DWLRQRIWKHSDWWHUQRIQHXURQDO
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GHDWKJHQHUDWHGLQWKLVPRGHOUHPDLQVLQFRPSOHWH,QWKHSUHVHQWVWXG\ZHGHVFULEHDSDWWHUQRI
QHXURQDOORVVVHYHQGD\VDIWHU/)3WKDWVSUHDGVIURPWKHGRUVDOWKDODPXVWRWKHWHPSRUDOFRUWH[
7KLVGHVFULSWLRQSDYHVWKHZD\IRUPRUHWKRURXJKHYDOXDWLRQVRIIXWXUHWKHUDSHXWLFLQWHUYHQWLRQV
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,QWURGXFWLRQ
7UDXPDWLFEUDLQLQMXU\7%,LVDOHDGLQJFDXVHRIGLVDELOLW\DPRQJ\RXQJSHRSOHOHDGVWR
PDMRUHFRQRPLFDQGVRFLDOEXUGHQVDQGDUHFRQVLGHUHGWRLQFUHDVHZRUOGZLGH$EHWWHU
XQGHUVWDQGLQJRIWKHPHFKDQLVPVXQGHUO\LQJQHXURORJLFDOG\VIXQFWLRQIROORZLQJ7%,DVZHOODV
KRZWRLPSURYHSDWLHQWRXWFRPHVDUHWKHUHIRUHRIPDMRULPSRUWDQFH7%,RIWHQFDXVHV
ZLGHVSUHDGQHXURQDOLQMXU\WRWKHFHQWUDOQHUYRXVV\VWHPLQFOXGLQJKHPRUUKDJHQHXURQDOORVV
DQGZKLWHPDWWHUOHVLRQVZLWKD[RQDOLQMXU\0DWKpHWDO/HYLQHHWDO7KLV
KHWHURJHQHLW\FRPSOLFDWHVWKHGHYHORSPHQWRIQHXURSURWHFWLYHVWUDWHJLHVDLPHGDWLPSURYLQJ
SDWLHQWRXWFRPH.DEDGLHWDOD
$QLPDOPRGHOVRI7%,DOORZUHVHDUFKHUVWRJHQHUDWHGDPDJHLQDUHSURGXFLEOHPDQQHU
DQGDUHFULWLFDOWRDQLPSURYHGXQGHUVWDQGLQJRIWKHPHFKDQLVPVXQGHUO\LQJWKHGHYHORSPHQWRI
QHXURORJLFDOOHVLRQV/DWHUDOIOXLGSHUFXVVLRQ/)3LVRQHRIWKHPRVWZLGHO\XVHGPRGHOVWKDW
DOORZVLQGXFLQJPRGHUDWHWRVHYHUHLQMXU\E\PRGXODWLQJWKHLQWHQVLW\RIWKHVKRFNZDYH/LHWDO
7KHORFDWLRQDQGVHYHULW\RIWKHQHXURORJLFDOOHVLRQVWKDWFDQEHJHQHUDWHGE\/)3KDVQRW
UHFHLYHGDJUHDWGHDORIV\VWHPDWLFVWXG\+LFNVHWDO.DEDGLHWDOE7KHUHIRUH
SUHFLVHO\PDSSLQJWKHOHVLRQVSURGXFHGE\/)3DSSHDUVDSUHUHTXLVLWHIRUERWKXQGHUVWDQGLQJWKH
PHFKDQLVPVXQGHUO\LQJEUDLQLQMXU\LQWKLVPRGHODQGGHYHORSLQJQHXURSURWHFWLYHWUHDWPHQWV
SRWHQWLDOO\DSSOLFDEOHWRKXPDQSDWLHQWV
6HYHUDOVWXGLHVKDYHVRXJKWWRGHILQHWKHFKDUDFWHULVWLFVRIQHXURQDOORVVIROORZLQJ/)3LQ
UDWV7KLV7%,PRGHODSSHDUVWRSURGXFHDFRPSOH[SDWWHUQRIZLGHVSUHDGOHVLRQVWKURXJKRXWWKH
LQMXUHGKHPLVSKHUHZKLFKHQFRPSDVVFRUWLFDOKLSSRFDPSDODQGWKDODPLFEUDLQUHJLRQV+LFNV
HWDO*UDG\HWDO6DWRHWDO,QWHUHVWLQJO\WKHVLWHVRIWKHPRVWLQWHQVH
QHXURQDOORVVDUHRIWHQUHPRWHIURPWKHVLWHRILPSDFWIRUH[DPSOHPD[LPDOGDPDJHKDVEHHQ
REVHUYHGLQWKHWHPSRUDOFRUWH[RUGHHSLQWKHWKDODPXVIROORZLQJSHUFXVVLYHLPSDFWWRWKH
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LSVLODWHUDOVXUIDFHRIWKHEUDLQ+LFNVHWDO.DEDGLHWDOE7ZRPDMRUVWUDWHJLHVKDYH
EHHQXVHGWRGHWHUPLQHWKHSDWWHUQRIWKHVHEUDLQOHVLRQV7KHILUVWRQHFRQVLVWVRIDVVHVVLQJWKH
QXPEHURILQMXUHGQHXURQVVWDLQHGE\LQMXU\PDUNHUVVXFKDV)OXRUR-DGH&5DJKXSDWKLHWDO
%HQW]HUHWDORUWHUPLQDOGHR[\QXFOHRWLG\OWUDQVIHUDVHG873QLFNHQGODEHOLQJ
781(/5DJKXSDWKLHWDORUE\WKHQXPEHURIYLVXDOO\LGHQWLILHGK\SHUFKURPDWLFRU
VKUXQNHQQHXURQV+LFNVHWDO%HQW]HUHWDO+RZHYHUWKHVHPHWKRGVFDQ
SRWHQWLDOO\JHQHUDWHKLJKQXPEHUVRIIDOVHSRVLWLYHVRUIDOVHQHJDWLYHV6FKPXHGHWDO
6FKPXHGHWDO$OWHUQDWLYHO\EUDLQOHVLRQVFDQEHGHILQHGE\WKHGHQVLW\RIQHXURQVWKDW
UHPDLQVHYHUDOGD\VIROORZLQJWKH7%,6XFKVWXGLHVDUHW\SLFDOO\SHUIRUPHGXVLQJYLVXDODQDO\VLV
DQGPDQXDOFHOOFRXQWVDQGDUHWKHUHIRUHKLJKO\ODERULQWHQVLYH)RUWKLVUHDVRQWKH
FRPSUHKHQVLYHTXDQWLILFDWLRQRIQHXURQDOGHQVLW\KDVWRGDWHEHHQOLPLWHGWRIHZEUDLQ
VWUXFWXUHV0F,QWRVKHWDO.DEDGLHWDOE*LYHQWKHFRPSOH[DQGZLGHVSUHDG
QDWXUHRIQHXUDOOHVLRQVIROORZLQJ/)3LQMXU\WKHUHLVDSUHVVLQJQHHGIRUVLPSOHUDQGUDSLG
PHWKRGVIRUTXDQWLI\LQJQHXURQDODQGFHOOXODUGHQVLWLHVLQEUDLQVHFWLRQV
:HUHFHQWO\GHYHORSHGDQDXWRPDWHGPHWKRGEDVHGRQ,PDJH-VRIWZDUHWKDWTXDQWLILHV
QHXURQDOGHQVLW\LQEUDLQVHFWLRQVLPPXQRUHDFWLYHIRUWKHQXFOHDUQHXURQDOPDUNHU1HX1DQG
VWDLQHGZLWKWKHIOXRUHVFHQFH'1$G\H

GLDPLGLQRSKHQ\OLQGROH'$3,*UDG\HWDO
+HUHZHDSSOLHGWKLVWHFKQLTXHWRWKHEUDLQVRI:LVWDUUDWVVXEMHFWHGWRPRGHUDWH$7$
RUVHYHUH$7$/)3WRTXDQWLI\QHXURQDOGHQVLW\LQVHYHQEUDLQUHJLRQVLQFOXGLQJWKH
SDULHWDOFRUWH[LPPHGLDWHO\YHQWUDOWRWKHVLWHRISHUFXVVLRQLPSDFWHGFRUWH[WKHWHPSRUDO
FRUWH[SULPDU\VRPDWRVHQVRU\FRUWH[DQGVHFRQGDU\DXGLWRU\FRUWH[WKHGRUVDOWKDODPXVDQG
WKHKLSSRFDPSXVDUHDV&$DQG&$GHQWDWHJ\UXVDQGKLOXV
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0DWHULDOVDQGPHWKRGV
$QLPDOV
0DOH:LVWDUUDWVZHLJKLQJJZHUHREWDLQHGIURP(OHYDJH-DQYLHU/H*HQHVW6DLQW,VOH
)UDQFH$OOH[SHULPHQWDOSURWRFROVZHUHDSSURYHGE\WKHORFDOFRPPLWWHHRQDQLPDOVLQUHVHDUFK
DWWKH8QLYHUVLW\&ODXGH%HUQDUG/\RQ,DSSURYDOQXPEHU%+DQGZHUHSHUIRUPHGLQ
DFFRUGDQFHZLWK(XURSHDQGLUHFWLYH(87KHUHZDVQRVLJQLILFDQWGLIIHUHQFHLQERG\
ZHLJKWEHWZHHQFRQWURODQLPDOVDQGWKRVHVXEMHFWHGWRPRGHUDWHRUVHYHUH/)3&RQWUROV
JPRGHUDWH/)3JVHYHUH/)3JS 
/DWHUDOIOXLGSHUFXVVLRQLQMXU\/)3PRGHO
$QLPDOVZHUHDQHVWKHWL]HGZLWKLVRIOXUDQHDQGSODFHGLQDVWHUHRWD[LFIUDPH6WRHOWLQJ
'XEOLQ,UHODQGZLWKWKHLUERG\WHPSHUDWXUHPDLQWDLQHGDURXQG&ZLWKDKRPHRWKHUPLF
EODQNHW/6,/HWLFD%DUFHORQD6SDLQ$VXEFXWDQHRXVLQILOWUDWLRQRIP/RIPJPO
URSLYDFDLQH1DURSHLQHPJPOLQVDOLQHZDVSHUIRUPHGSULRUWRVFDOSRSHQLQJ$FLUFXODU
FUDQLRWRP\PPGLDPHWHUORFDWHGPPFDXGDOWR%UHJPDDQGPPODWHUDOIURPWKH
PLGOLQHZDVWKHQSHUIRUPHGXQGHUDVHSWLFFRQGLWLRQV$KROORZSODVWLFFDSZDVILUVWDWWDFKHGWR
WKHVNXOOXVLQJF\DQRDFU\ODWHWKHQVHFXUHGZLWKGHQWDODFU\OLF$PPGLDPHWHUVWDLQOHVVVWHHO
VFUHZLQVHUWHGLQWRWKHVNXOOVHUYHGDVDQDQFKRUIRUWKHGHQWDODFU\OLFDQGWKHSODVWLFFDSZDV
ILOOHGZLWKVWHULOHVDOLQH7KHDQLPDOZDVWKHQUHPRYHGIURPWKHVWHUHRWD[LFIUDPHDQGEURXJKWWR
WKHODWHUDOIOXLGSHUFXVVLRQGHYLFH&XVWRP'HVLJQDQG)DEULFDWLRQ9LUJLQLD&RPPRQZHDOWK
8QLYHUVLW\5LFKPRQG9LUJLQLD86$5DWVUHFHLYHGDVLQJOHPVIOXLGSHUFXVVLRQSXOVHRI
RU$7$XQGHUOLJKWDQHVWKHVLDLHWKHDQLPDOZDVUHPRYHGIURPWKHDQHVWKHVLDPDVNDQGWKH
/)3LPSDFWZDVDGPLQLVWHUHGDWWKHILUVWVLJQVRIDKLQGOLPEUHVSRQVHWRDJHQWOHWRHSLQFK7KH
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FDSZDVWKHQUHPRYHGDQHVWKHVLDZDVUHVXPHGDQGWKHVFDOSZDVVXWXUHG7KHDQLPDOVZHUH
VLQJOHKRXVHGIRUGD\VZLWKDVVLVWHGGULQNLQJDQGIHHGLQJLIQHFHVVDU\%XSUHQRUSKLQH
PJNJZDVDGPLQLVWHUHGWZLFHDWKLQWHUYDODIWHUVXUJHU\
7RDYRLGUHVSLUDWRU\DUUHVWIROORZLQJVHYHUH/)3PHFKDQLFDOYHQWLODWLRQ+DUYDUG
$SSDUDWXV,VSUD0$9W PONJEUHDWKUDWH PLQ3HHS FP+2ZDV
SHUIRUPHGIROORZLQJ$7$/)3XQWLODQLPDOVUHFRYHUHGVSRQWDQHRXVEUHDWKLQJ7R
DFFRPSOLVKWKLVDQLPDOVZHUHLQWXEDWHGZLWKDJDXJHFDWKHWHUIROORZLQJWKHLQGXFWLRQRI
DQHVWKHVLDDQGEHIRUH/)3$QLPDOVZKRVHPHFKDQLFDOYHQWLODWLRQFRXOGQRWEHUHVXPHGZLWKLQ
WKHILUVWPLQSRVW/)3DVZHOODVDQLPDOVWKDWORVWPRUHWKDQRIWKHLULQLWLDOERG\ZHLJKW
LQWKHSRVWSURFHGXUHSHULRGZHUHH[FOXGHGRIWKHVWXG\&RQWURODQLPDOVGLGQRWUHFHLYHVXUJHU\
%UDLQIL[DWLRQDQGUHPRYDO
6HYHQGD\VIROORZLQJWKH/)3PHGLDWHGLQGXFWLRQRI7%,DQLPDOVZHUHGHHSO\
DQHVWKHWL]HGZLWKDQLQWUDSHULWRQHDOLQMHFWLRQRIVRGLXPSHQWREDUELWDOPJNJ&HYD
/LERXUQH)UDQFHDQGLQWUDFDUGLDOO\SHUIXVHGILUVWZLWKP/RID5LQJHUVROXWLRQZLWK
KHSDULQDWURRPWHPSHUDWXUHWKHQZLWKP/RIDQLFHFROGIL[DWLYHVROXWLRQFRQWDLQLQJ
IUHVKO\GHSRO\PHUL]HGSDUDIRUPDOGHK\GHLQ0SKRVSKDWHEXIIHU3%S+ 7KHEUDLQV
ZHUHUHPRYHGSODFHGLQDVXFURVHVROXWLRQ3%0S+ IRUKDQGIUR]HQLQD
VROXWLRQRILVRSHQWDQHDW&EHIRUHVWRUDJHDW&IRUIXUWKHUDQDO\VLV
)OXRUHVFHQWGRXEOHODEHOLQJLPPXQRKLVWRFKHPLVWU\
1HX1LPPXQRODEHOOLQJZDVSHUIRUPHGDFFRUGLQJWRWKHPHWKRGGHVFULEHGE\:RHIIOHU
0DXFOHUHWDO)UR]HQUDWEUDLQVZHUHFXWLQWRPWKLFNVHFWLRQVXVLQJD+020
PLFURWRPH0LFURP)UDQFKHYLOOH)UDQFHDQGEUDLQVHFWLRQVZHUHSODFHGLQDVROXWLRQRI
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P0SKRVSKDWHEXIIHUHGVDOLQH3%6S+ 6LJPD$OGULFK6W4XHQWLQ)DOODYLHU)UDQFH)RU
LPPXQRKLVWRFKHPLVWU\WLVVXHVHFWLRQVZHUHILUVWSHUPHDELOL]HGZLWKDVROXWLRQRI3%6
7ULWRQ;DQGJRDWVHUXP6LJPD$OGULFK6W4XHQWLQ)DOODYLHU)UDQFHIRUPLQ
ZDVKHGIRUPLQZLWK3%6DQGWKHQWKUHHPRUHWLPHVIRUPLQZLWK3%6DQG7ZHHQ
3%676LJPD7KHVHFWLRQVDQDO\]HGLQWKLVVWXG\ZHUHORFDWHGEHWZHHQDQGPPFDXGDO
IURP%UHJPD3D[LQRVDQG:DWVRQ%UDLQVHFWLRQVZHUHLQFXEDWHGRYHUQLJKWDW&ZLWKD
PRXVHPRQRFORQDODQWLERG\GLUHFWHGDJDLQVWWKH1HX1SURWHLQ0$%0LOOLSRUH
0ROVKHLP)UDQFH55,'$%BLQ3%67ZLWKJRDWVHUXP7DE$IWHUWKUHH
PLQZDVKHVZLWK3%67WKHVHFWLRQVZHUHLQFXEDWHGIRUKZLWKJRDWDQWLPRXVH,J*DQWLERG\
FRXSOHGWR$OH[D)OXRU,QYLWURJHQ6DLQW$XELQ)UDQFH55,'$%BDQG
'$3,6LJPD$OGULFK6DLQW4XHQWLQ)DOODYLHU)UDQFHLQ3%67FRQWDLQLQJJRDW
VHUXP7DE7KHVHFWLRQVZHUHWKHQZDVKHGIRUPLQLQ3%67IROORZHGE\DPLQZDVKLQ
3%67KHVHFWLRQVZHUHWKHQPRXQWHGRQWRSUHFOHDQHGPLFURVFRSHVOLGHV*URXQG(GJHV
0HQ]HOJODVHU%UDXQVFKZHLJ*HUPDQ\XVLQJ0LOOLSRUHZDWHUDQGFRYHUVOLSSHGXVLQJ
)OXRURPRXQWPRXQWLQJPHGLXP6LJPD$OGULFK6DLQW4XHQWLQ)DOODYLHU)UDQFHDQGVWRUHGDW
&LQWKHGDUN
$QWLERG\FKDUDFWHUL]DWLRQ
0RQRFORQDODQWLERGLHVUDLVHGDJDLQVW1HX1RULJLQDWHIURPWKHVLQJOH$FORQHDQGKDYHEHHQ
VKRZQWRVSHFLILFDOO\UHFRJQL]HWKHVRFDOOHG1HX1HSLWRSHRQWKHVSOLFLQJIDFWRU5EIR[
0D[HLQHUHWDO6HFRQGDU\DQWLERGLHVZHUHSXULILHGXVLQJWKHLUDIILQLW\IRUPRXVH
LPPXQRJOREXOLQV7KH\VSHFLILFDOO\WDUJHWHGPRXVHJDPPDLPPXQRJOREXOLQVKHDY\DQGOLJKW
FKDLQVZLWKOLPLWHGFURVVUHDFWLYLW\DJDLQVWERYLQH,J*JRDW,J*UDEELW,J*UDW,J*KXPDQ,J*
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,J*+/6HFRQGDU\$QWLERG\3RO\FORQDO$
&RQIRFDOPLFURVFRS\
6OLGHVZHUHLPDJHGDWWKH&,4/(,PDJLQJ)DFLOLW\8QLYHUVLWp&ODXGH%HUQDUG/\RQ/\RQ
)UDQFHXVLQJD/HLFD63FRQIRFDOODVHUVFDQQLQJPLFURVFRSH&/60ZLWKDîREMHFWLYH
1$7KHLPDJHVZHUHDFTXLUHGE\DWZRVWHSSURFHVVSRVLWLYLW\IRU'$3,ZDVDVVHVVHGDW
DQH[FLWDWLRQZDYHOHQJWKRIQPDQGHPLVVLRQZDYHOHQJWKVRI±QPZKLOHWKHVLJQDO
IRU$OH[D1HX1LPPXQRUHDFWLYLW\ZDVDVVHVVHGDWDQH[FLWDWLRQZDYHOHQJWKRIQPDQG
HPLVVLRQZDYHOHQJWKVRI±QP$]VHULHVFRQVLVWLQJRI±RSWLFDOVHFWLRQVZLWKD
PLQWHUYDOZHUHLPDJHGZLWKLQHDFKUHJLRQRILQWHUHVW,QGLYLGXDOLPDJHVZHUHDYHUDJHGWKUHH
WLPHVIRU1HX1LPPXQRUHDFWLYLW\$OH[DDQGWZLFHIRU'$3,,PDJHDQDO\VLVZDV
SHUIRUPHGXVLQJ,PDJH-VRIWZDUHYHUVLRQSKWWSLPDJHMQLKJRYMDYDYHUVLRQB
ELWLQFOXGLQJWKHIROORZLQJSOXJLQV5*%*UH\PHUJH/2&,SOXJLQ*UDQILOWHUNPHDQ
FOXVWHULQJPD[LPXPHQWURS\WKUHVKROGPL[WXUHPRGHOLQJDQGDQDXWRPDWHGFXVWRPPDGH
PDFURGHYHORSHGDWWKH&HQWUH&RPPXQGH4XDQWLPpWULH8QLYHUVLW\&ODXGH%HUQDUG/\RQ
/\RQ)UDQFH:RHIIOHU0DXFOHUHWDO2YHUDOOFHOOXODUGHQVLW\ZDVGHILQHGDVWKHWRWDO
QXPEHURI'$3,VWDLQHGQXFOHLSHUPPRIWLVVXH1HXURQVZHUHLGHQWLILHGDV'$3,VWDLQHG
QXFOHLSUHVHQWLQD1HX1SRVLWLYHUHJLRQRIWKHRSWLFDOVHFWLRQ7KLVLGHQWLILFDWLRQZDVSHUIRUPHG
RQILYHFRQVHFXWLYHRSWLFDOVHFWLRQVVSDFHGE\PZLWKWKHFHQWUDORQHEHLQJWKHRSWLFDO
VHFWLRQZLWKWKHKLJKHVWIOXRUHVFHQFHLQWHQVLW\XVXDOO\ORFDWHGWKHWKDQGWKHWKRSWLFDOVHFWLRQ
RIWKHVOLFH(DFKQHXURQDOQXFOHXVKDGWREHLGHQWLILHGZLWKLQD1HX1SRVLWLYHUHJLRQLQWKH
RSWLFDOVHFWLRQRIKLJKHVWLQWHQVLW\DQGLQDWOHDVWRQHRIWKHIRXURSWLFDOVHFWLRQVWKDWVXUURXQGHG
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1HX1QHJDWLYHUHJLRQV%UDLQUHJLRQVFKDUDFWHUL]HGE\VSDUVHQHXURQDOFHOOERGLHVQHRFRUWH[
KLOXVWKDODPXVZHUHSURFHVVHGXVLQJWKH0RPHQWVDXWRWKUHVKROGPHWKRGZKHUHDVRWKHUDUHDV
GLVSOD\LQJGHQVHO\SDFNHGQHXURQV&$&$DQGGHQWDWHJ\UXVZHUHGLFKRWRPL]HGXVLQJWKH
/LDXWRWKUHVKROGPHWKRGVHH:RHIIOHU0DXFOHUHWDOIRUDFRPSOHWHGHVFULSWLRQRIWKH
PHWKRG1HXURQDOFRXQWVZHUHWKHUHIRUHSHUIRUPHGZLWKRXWKXPDQLQWHUYHQWLRQ
,PDJLQJRIZKROHEUDLQVHFWLRQVZDVSHUIRUPHGXVLQJD=HLVV$;,26FDQ=VOLGH
VFDQQHUZLWKDîREMHFWLYH1$DQGDQ2UFD)ODVKFDPHUD([FLWDWLRQDQGHPLVVLRQ
ZDYHOHQJWKVZHUHQPDQGQPIRU'$3,DQGQPDQGQ0IRU$OH[D
IOXRUUHVSHFWLYHO\
6WDWLVWLFDODQDO\VHV
5HVXOWVDUHSUHVHQWHGDVPHGLDQDQG LQWHUTXDUWLOH UDQJH1HXURQDODQGFHOOXODUGHQVLWLHV
ZHUHH[SUHVVHGDVWKHQXPEHURIQHXURQVDQGQXFOHLSHUPPðLQGLIIHUHQWDQLPDOVFRQWUROV
 LQ$7$/)3JURXSDQG LQ$7$/)3JURXS'HQVLWLHV LQDJLYHQ UHJLRQRI LQWHUHVW
ZHUHDVVHVVHGLQGLIIHUHQWEUDLQVOLFHVDQGDYHUDJHGIRUHDFKDQLPDO'DWDZHUHWKHQFRPSDUHG
EHWZHHQWKHWKUHHJURXSVE\D.UXVNDO:DOOLVUDQNVXPWHVWZLWKLQVHYHQEUDLQUHJLRQVXVLQJWKH
5 VRIWZDUH  5 'HYHORSPHQW &RUH 7HDP KWWSZZZ5SURMHFWRUJ 5 )RXQGDWLRQ IRU
6WDWLVWLFDO &RPSXWLQJ 9LHQQD $XVWULD 3DLUZLVH FRPSDULVRQV XVLQJ :LOFR[RQ UDQN VXP WHVW
ZLWK %RQIHUURQL S YDOXH DGMXVWPHQW ZDV XVHG WR FRPSDUH JURXSV ZKHQ WKH .UXVNDOO:DOOLV
VKRZHGDVLJQLILFDQWHIIHFW*UDSKLFVZHUHPDGHXVLQJWKHJJSORWOLEUDU\$SYDOXHZDV
FRQVLGHUHGDVVLJQLILFDQW
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5HVXOWV
$FXWHEHKDYLRUDOHIIHFWVRI/)3LQMXU\
)ROORZLQJDPRGHUDWH/)3$7$Q DQLPDOVH[KLELWHGDORVVRIFRQVFLRXVQHVV
FKDUDFWHUL]HGE\DODFNRIUHVSRQVHWRWDLOSLQFKIRUDWOHDVWPLQ6KRUWDSQHDODVWLQJOHVVWKDQ
VZDVHYLGHQWDQGWKHULJKWLQJUHIOH[ZDVUHFRYHUHGEHWZHHQDQGPLQSRVWLQMXU\2QH
UDWRIVDPSOHGLHGRIDFXWHFDUGLRUHVSLUDWRU\IDLOXUH2YHUDOOWKHVHDFXWHEHKDYLRUDOHIIHFWV
IROORZLQJPRGHUDWH/)3ZHUHFRQVLVWHQWZLWKGHILQLWLRQRIPRGHUDWH7%,LQWKLVPRGHO$R\DPD
HWDO%DRHWDO6KXOW]HWDO
:HVXEMHFWHGHLJKWDQLPDOVWRVHYHUH/)3$7$$WWKLVLQWHQVLW\WKHUHVXOWDQWDSQHD
QHFHVVLWDWHGDUWLILFLDOYHQWLODWLRQIRUDWOHDVWPLQ$IWHUPLQDQLPDOVGLGQRW
UHFRYHUVSRQWDQHRXVEUHDWKLQJDQGGLHG7KHUHIRUHLQRXUKDQGV/)3DW$7$SURGXFHG
V\PSWRPVFRQVLVWHQWZLWKVHYHUH7%,$R\DPDHWDO%DRHWDO6KXOW]HWDO
'HILQLWLRQRIWKHUHJLRQVRILQWHUHVW
&RURQDOVOLFHVRIEUDLQVIURPPRGHUDWHRUVHYHUH/)3LQMXUHGUDWVZHUHILUVWREVHUYHG
XVLQJDVOLGHVFDQQHUWRREWDLQDSUHOLPLQDU\HVWLPDWHRIWKHUHJLRQVRIPRVWLQWHQVHQHXURQDOORVV
)LJ$6HYHUHQHXURQDOORVVZDVHYLGHQWLQWKHWHPSRUDOFRUWH[LHSULPDU\VRPDWRVHQVRU\
FRUWH[DQGVHFRQGDU\DXGLWRU\FRUWH[DQGLQWKHGRUVDOWKDODPXVEHFDXVH1HX1
LPPXQRUHDFWLYLW\KDGGUDPDWLFDOO\GHFUHDVHGOHDYLQJDQDSSDUHQW'$3,VWDLQLQJRQWKHLPDJHV
)LJ$
%DVHGRQWKLVSUHOLPLQDU\DQDO\VLVZHGHILQHGVHYHQEUDLQUHJLRQVIRUFRQIRFDOLPDJLQJ
DQGIRUWKHGHWHUPLQDWLRQRIQHXURQDOGHQVLWLHV)LJ%7KHVHZHUHWKHLPSDFWHGFRUWH[LH
SDULHWDODVVRFLDWLRQFRUWH[LPPHGLDWHO\XQGHUQHDWKWKHVLWHRIWKHIOXLGLPSDFW
PPð)LJ%DUHDWHPSRUDOFRUWH[WRWDODUHDLPDJHG PPð)LJ%DUHD
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GRUVDOWKDODPXVPPð)LJ%DUHD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PPð)LJ%DUHD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&$PPð)LJ%DUHDGHQWDWHJ\UXVPPð)LJ%DUHDKLOXV
PPð)LJ%DUHD7KHUHZDVQRVLJQLILFDQWGLIIHUHQFHEHWZHHQWKHDUHDVRIWKH
UHJLRQVRILQWHUHVWLQFRQWUROUDWVDQGLQWKRVHVXEMHFWHGWRPRGHUDWHRUVHYHUH/)3GI 
.UXVNDO:DOOLVWHVWIRULPSDFWHGFRUWH[ȋ S WHPSRUDOFRUWH[ȋ S &$
ȋ S &$ȋ S GHQWDWHJ\UXVȋ S KLOXVȋ S 
WKDODPXVȋ S 
(IIHFWVRIPRGHUDWH$7$/)3RQQHXURQGHQVLWLHV
6XUSULVLQJO\ QR FKDQJH LQ QHXURQDO GHQVLW\ FRXOG EH HYLGHQFHG LQ WKH FRUWH[ WKDWZDV
LPSDFWHG E\/)3  >@ QHXURQV SHUPP LQ FRQWUROV YV  >@ QHXURQV SHU
PP DIWHU /)3$7$ 7DE )LJ$ ȋ    GI    S    Q  +RZHYHU QHXURQDO
GHQVLW\VKRZHGDGHFUHDVH LQ WKH WHPSRUDOFRUWH[ ORFDWHG ODWHUDO WR WKH LPSDFW>
@QHXURQVSHUPPLQFRQWUROVYV>@QHXURQVSHUPPDIWHU/)3$7$7DE
)LJ%ȋ GI S Q ,QWKHGRUVDOWKDODPXVQHXURQDOGHQVLW\ZDVGHFUHDVHG
E\    >@ QHXURQV SHUPP LQ FRQWUROV YV  >@ QHXURQV SHUPPð DIWHU
/)3$7$7DE)LJ&ȋ GI S Q 
7KHKLSSRFDPSXVZDV OHVV LPSDFWHGE\/)32QO\DUHD&$VKRZHGDVLJQLILFDQW
GHFUHDVHLQQHXURQDOGHQVLW\>@QHXURQVSHUPPLQFRQWUROVYV>@DIWHU
/)3$7$ 7DE )LJ% ȋ    GI    S    Q  7KHUH ZHUH QR VLJQLILFDQW
GLIIHUHQFHV LQQHXURQDOGHQVLW\ LQRWKHUKLSSRFDPSDO UHJLRQV &$>@YV
>@QHXURQVSHUPP 7DE)LJ$ȋ  GI  S  Q  GHQWDWH J\UXV
>@YV>@QHXURQVSHUPP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GI S Q 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(IIHFWVRIPRGHUDWH$7$/)3RQWRWDOFHOOGHQVLWLHV
,QFRQWUDVWWRWKHGHFUHDVHLQQHXURQVSHFLILFGHQVLWLHVZHREVHUYHGDQLQFUHDVHLQWRWDO
QXFOHLGHQVLW\LQWKHWHPSRUDOFRUWH[>@QXFOHLSHUPPLQFRQWURO
DQLPDOVYV>@QXFOHLSHUPPðDIWHU/)3$7$7DE)LJ%ȋ GI S
 Q 7RWDOFHOOXODUGHQVLW\ZDVDOVRLQFUHDVHGLQWKHWKDODPXV>@
QXFOHLSHUPPLQFRQWURODQLPDOVYV>@QXFOHLSHUPPðDIWHU/)3$7$7DE
)LJ&ȋ GI S $VLPLODUHIIHFWZDVHYLGHQWLQDUHD&$RIWKH
KLSSRFDPSXV>@QXFOHLSHUPPLQFRQWURODQLPDOVYV>@
QXFOHLSHUPPðDIWHU/)37DE)LJ%ȋ GI S 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
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@QXFOHLSHUPPðDIWHU
/)37DE)LJ%ȋ GI S 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VXPWHVWXVHGIRUSRVWKRFDQDO\VLVZDVLPSDFWHGE\DQLPSRUWDQWGDWDGLVSHUVLRQDQGGLGQRW
UHDFKVLJQLILFDQFHLQWKHWHPSRUDOFRUWH[S WKHWKDODPXVS DQGWKHKLOXVS 
1RVLJQLILFDQWGLIIHUHQFHLQWRWDOFHOOXODUGHQVLW\ZDVREVHUYHGLQRWKHUKLSSRFDPSDODUHDV&$
>@YV>@QXFOHLSHUPP7DE)LJ$GHQWDWHJ\UXV
>@YV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7DE)LJ$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>@YV>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
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7HPSRUDOFRUWH[
>@PRGHUDWH/)3YV>@QXFOHLSHUPPVHYHUH/)3S WKDODPXV
>@PRGHUDWH/)3YV>@VHYHUH/)3S &$>
@PRGHUDWH/)3YV>@VHYHUH/)3S DQGKLOXV>@
PRGHUDWH/)3YV>@VHYHUH/)3S 7KHUHIRUHWKHSDWWHUQRIQHXURQDOORVV
ZDVVLPLODUDIWHUPRGHUDWHRUVHYHUH/)3DOWKRXJKDQRQVLJQLILFDQWWUHQGIRUUHGXFHGQHXURQDO
GHQVLWLHVZDVDSSDUHQWDIWHUVHYHUH/)3
0HDVXUHPHQWVRIFRUWLFDODQGKLSSRFDPSDOVXUIDFH
1HXURQDOORVVLQDJLYHQEUDLQVWUXFWXUHLVQRWRQO\GHSHQGHQWRQQHXURQDOGHQVLW\EXWDOVRRQLWV
YROXPH7KLVLVHVSHFLDOO\LPSRUWDQWLQWKHKLSSRFDPSXVDQGLQWKHLPSDFWHGFRUWH[LQZKLFK
QHXURQDOGHQVLW\ZDVQRWVLJQLILFDQWO\DIIHFWHG:HWKHUHIRUHPHDVXUHGWKHVXUIDFHRIWKHVHEUDLQ
VWUXFWXUHVRQRXUVOLFHVXVLQJWKHLPDJHVRIZKROHEUDLQVHFWLRQVSURYLGHGE\WKHVOLGHVFDQQHU
)RUWKHSDULHWDOFRUWH[WKHVXUIDFHZDVGHILQHGE\WKHFRUWLFDOWKLFNQHVVPHDVXUHGEHWZHHQSLD
PDWHUDQGFRUSXVFDOORVXPPXOWLSOLHGE\PPLHWKHZLGWKRIWKHFRUWH[LPSDFWHGE\/)3
)RUWKHKLSSRFDPSXVZHPHDVXUHGWKHWRWDOVXUIDFHRIWKHZKROHKLSSRFDPSDOIRUPDWLRQ
HQFRPSDVVLQJDUHDV&$WR&$DQGGHQWDWHJ\UXV
:HIRXQGQRVLJQLILFDQWFKDQJHVLQWKHLPSDFWHGFRUWH[FRQWUROVPPð>±@$7$
PPð>±@$7$PPð>±@.UXVNDO:DOOLVFKLVTXDUHG 
GI SYDOXH RULQWKHKLSSRFDPSXVFRQWUROVPPð>±@$7$
PPð>@$7$PPð>±@.UXVNDO:DOOLVFKLVTXDUHG GI 
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SYDOXH 7KHUHIRUHLQWKHLPSDFWHGFRUWH[DUHD&$RIWKHKLSSRFDPSXVGHQWDWH
J\UXVDQGKLOXVLQZKLFKQHXURQDOGHQVLW\ZDVQRWVLJQLILFDQWO\DIIHFWHGWKHVXUIDFHRIWKHWLVVXH
ZDVQRWVLJQLILFDQWO\DIIHFWHGHLWKHUVXJJHVWLQJWKDWQHXURQDOORVVZDVQRWSUHVHQWLQWKHVH
VWUXFWXUHV
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'LVFXVVLRQ
,QWKLVVWXG\ZHREVHUYHGDVLJQLILFDQWUHGXFWLRQLQQHXURQDOGHQVLW\IROORZLQJPRGHUDWHRU
VHYHUH/)3LQMXU\LQWKHWHPSRUDOFRUWH[ORFDWHGODWHUDOWRWKHLPSDFWLQWKHLSVLODWHUDOGRUVDO
WKDODPXVDQGLQDUHD&$RIWKHLSVLODWHUDOKLSSRFDPSXV6XUSULVLQJO\WKHLPSDFWHGFRUWH[DUHD
&$RIWKHKLSSRFDPSXVGHQWDWHJ\UXVDQGKLOXVZHUHQRWDIIHFWHGE\/)3QHLWKHULQQHXURQDO
GHQVLW\QRULQWKHRYHUDOOVXUIDFHRIWKHVWUXFWXUH2YHUDOOWKHVSDWLDORUJDQL]DWLRQRIWKHEUDLQ
OHVLRQVGHWHFWHGDIWHUPRGHUDWHRUVHYHUH/)3FDQEHUHSUHVHQWHGDVDOLQHH[WHQGLQJIURPWKH
GRUVDOWKDODPXVWRWKHWHPSRUDOFRUWH[SULPDU\VRPDWRVHQVRU\FRUWH[DQGVHFRQGDU\DXGLWRU\
FRUWH[DQGHQFRPSDVVLQJDUHD&$RIWKHKLSSRFDPSXV)LJ7KHSDWWHUQRIWKHVHOHVLRQV
DQGWKHREVHUYHGGHFUHDVHVLQQHXURQDOGHQVLW\ZHUHQRWGLIIHUHQWEHWZHHQWKHPRGHUDWHDQGWKH
VHYHUH/)37KHUHODWLYHVLPSOLFLW\RIRXUDXWRPDWHGSURFHGXUHDOORZHGXVWRVDPSOHVHYHQEUDLQ
UHJLRQVZKLFKUHSUHVHQWHGDSSUR[LPDWHO\WZRVTXDUHPLOOLPHWHUVRIJUH\PDWWHULQWKHUDWEUDLQ
SURYLGLQJRQHRIWKHPRVWH[WHQVLYHTXDQWLILFDWLRQRIQHXURQDOGHDWKIROORZLQJH[SHULPHQWDO
WUDXPDWLFEUDLQLQMXU\
:HKDYHFKRVHQWKHDQDWRPLFDOSODQHRILQWHUHVWEDVHGXSRQWKHNQRZOHGJHRIWKHORFDWLRQRIWKH
PD[LPXPRIQHXURQDOOHVLRQVIROORZLQJ/)3LQMXU\+LFNVHWDO6XUSULVLQJO\ZKLOH
GLIIHUHQFHVEHWZHHQVKDPDQG/)3DQLPDOVZHUHHYLGHQFHGQRGHFUHDVHRIQHXURQDOGHQVLW\ZDV
REVHUYHGLQWKHVHYHUHLQFRPSDULVRQWRPRGHUDWH/)3LQMXU\DQLPDOV7KH/)3WKUHVKROG
LQWHQVLW\DWZKLFKVXFKOHVLRQVDSSHDULVWKHUHIRUHEHORZ$7$DQGLWZRXOGLQWHUHVWLQJWR
LQYHVWLJDWHZKHWKHUPLOG7%,FRXOGDOVRLQGXFHVLJQLILFDQWGHFUHDVHVLQQHXURQDOGHQVLWLHV,W
VKRXOGEHQRWHGKRZHYHUWKDWVHYHUH/)3PLJKWKDYHLQGXFHGJUHDWHUQHXURQDOORVVLQDGMDFHQW
DQGUHPRWHDQDWRPLFDOSODQHV,QDGGLWLRQRXUVWXG\ZDVOLPLWHGWRWKHTXDQWLILFDWLRQRIQHXURQDO
GHQVLWLHVZKLFKDSSHDUHGWREHDIIHFWHGRQO\RQWKHVLGHRIWKHEUDLQLSVLODWHUDOWR/)3,WLV
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SRVVLEOHWKDWPRUHGLIIXVHOHVLRQVVXFKDVHGHPDD[RQDOLQMXULHVRUZKLWHPDWWHUOHVLRQVFRXOG
DOVREHSUHVHQWRQWKHFRQWUDODWHUDOVLGHRIWKHEUDLQ7KHVHLVVXHVZDUUDQWFODULILFDWLRQVLQIXUWKHU
VWXGLHV
6HYHUDORWKHUVWXGLHVKDYHHVWLPDWHGWKHH[WHQWRIQHXURQDOORVVLQWKHEUDLQRIUDWV
VXEMHFWHGWR/)37KHVHHIIRUWVKDYHSULPDULO\XWLOL]HGWZRVWUDWHJLHVWKDWHLWKHUDVVHVVWKH
QXPEHURILQMXUHGQHXURQVRUTXDQWLI\WKHGHQVLW\RIUHPDLQLQJQHXURQVLQGLIIHUHQWEUDLQUHJLRQV
DWDJLYHQWLPHIROORZLQJLQMXU\,QMXUHGQHXURQVFDQEHLGHQWLILHGE\VWDLQLQJEUDLQVHFWLRQVZLWK
1LVVOVWDLQV+LFNVHWDOKHPDWR[\OLQDQGHRVLQ%HQW]HUHWDO=KDQJHWDO
DFLGIXFKVLQ+LFNVHWDO)OXRUR-DGH&.DEDGLHWDOE6DWRHWDORUE\
SHUIRUPLQJ781(/ODEHOLQJ5DJKXSDWKLHWDO+HPDWR[\OLQDQGHRVLQ+	(DVZHOODV
1LVVOVWDLQVODEHODOOFHOOVDQGGHJHQHUDWLQJQHXURQVFDQEHGHWHFWHGEDVHGRQFHOOVKULQNDJHDQG
K\SHUFKURPDWLVPS\NQRVLVDVZHOODVE\YDFXRODWLRQRIWKHF\WRSODVP+RZHYHUWKHVH
PHWKRGVFDQHDVLO\SURGXFHIDOVHSRVLWLYHVRUIDLOWRGHWHFWGHJHQHUDWLQJQHXURQV6FKPXHGHWDO
)OXRURMDGH&LVFXUUHQWO\UHJDUGHGWREHDVXSHULRUPHWKRGIRUGHWHFWLQJGHJHQHUDWLQJ
QHXURQVDOWKRXJKWKHPHFKDQLVPE\ZKLFKWKLVUHDJHQWODEHOVLQMXUHGFHOOVLVXQNQRZQDQGWKHUH
LVDGHEDWHUHJDUGLQJZKHWKHUDOO)OXRUR-DGHSRVLWLYHQHXURQVXOWLPDWHO\GLHRULIVRPHPD\
UHFRYHU6FKPXHGHWDO0RUHRYHURQO\DIHZG\LQJQHXURQVDUHXVXDOO\GHWHFWHGLQ
HDFKVHFWLRQDWDJLYHQWLPHDQGWKHVLJQLILFDQFHRIVXFKVPDOOQXPEHUVRIODEHOHGQHXURQVLQD
JLYHQEUDLQVWUXFWXUHLVGLIILFXOWWRLQWHUSUHW7KXVTXDQWLI\LQJWKHRYHUDOOQHXURQDOGHQVLW\
XVLQJYDULRXVVWDLQLQJPHWKRGVVHYHUDOGD\VDIWHULQMXU\DSSHDUVWREHWKHEHVWVWUDWHJ\DVLW
GLUHFWO\HVWLPDWHVWKHH[WHQWRIDFFXPXODWHGQHXURQDOGHDWK1HXURQDOGHQVLW\LVW\SLFDOO\
DVVHVVHGE\PDQXDOFHOOFRXQWVLQEUDLQVHFWLRQV6DQGHUVRQHWDO&KHQH\HWDO
(QRPRWRHWDO:LWJHQHWDOVRPHWLPHVIROORZHGE\VWHUHRORJLFDOUHFRQVWUXFWLRQRI
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WKHEUDLQVWUXFWXUH*UDG\HWDO6HOZ\QHWDO/XRHWDO+RZHYHUWKHVH
WHFKQLTXHVDUHVORZDQGWLPHFRQVXPLQJ
1HXURQDOORVVIROORZLQJH[SHULPHQWDO7%,KDVEHHQLQYHVWLJDWHGXVLQJERWKRIWKHVH
VWUDWHJLHVLHWKHODEHOLQJRIG\LQJQHXURQV+LFNVHWDO.DEDGLHWDOE6DWRHWDO
RUWKHPDQXDOFRXQWLQJRIUHPDLQLQJQHXURQV*UDG\HWDO=KDQJHWDO
6HOZ\QHWDO/XRHWDO2YHUDOOORVVRIQHXURQVIROORZLQJ7%,LQGXFWLRQE\/)3
KDVFRQVLVWHQWO\EHHQREVHUYHGLQWKHWHPSRUDOFRUWH[+LFNVHWDO.DEDGLHWDOE
6DWRHWDO5DJKXSDWKLHWDO%HQW]HUHWDO%DRHWDO=KDQJHWDO
WKDODPXV+LFNVHWDO.DEDGLHWDOE6DWRHWDO/XRHWDODQG
DUHD&$RIWKHKLSSRFDPSXV+LFNVHWDO.DEDGLHWDOE*UDG\HWDO6DWRHW
DO=KDQJHWDO6DQGHUVRQHWDO/XRHWDO+RZHYHUVHYHUDO
GLIIHUHQFHVVKRXOGEHQRWHGEHWZHHQRXUILQGLQJVDQGWKRVHRIHDUOLHUVWXGLHV)RUH[DPSOH
QHXURQDOORVVLQWKHKLSSRFDPSXVVRPHWLPHVHQFRPSDVVHVDUHD&$6DWRHWDO&$
*UDG\HWDO/XRHWDOGHQWDWHJ\UXV.DEDGLHWDOE/XRHWDO
DQGRUKLOXV+LFNVHWDO*UDG\HWDOZKLFKZHUHQRWDIIHFWHGLQRXUVWXG\:H
VKRXOGQRWHWKDWQHXURQDOORVVLQWKHVHKLSSRFDPSDODUHDVZDVREVHUYHGLQ6SUDJXH'DZOH\UDWV
ZKHUHDVWKHSUHVHQWZRUNZDVSHUIRUPHGLQ:LVWDUUDWV,WLVSRVVLEOHWKDWYDULDWLRQLQWKH
VXVFHSWLELOLW\RIGLIIHUHQWUDWVWUDLQVFDQDFFRXQWIRUWKHVHGLVFUHSDQFLHV6FKHIIDQG6XOOLYDQ
)XMLPRWRHWDO)RUH[DPSOHGLIIHUHQWVWUDLQVRIPLFHFDQGLVSOD\GLIIHUHQWOHYHOVRI
H[FLWRWR[LFFHOOGHDWKIROORZLQJNDLQLFDFLGLQIXVLRQRUGLIIHUHQWLQIODPPDWRU\UHVSRQVHVWR
LVFKHPLD6WHZDUGHWDO6XFKVWUDLQGLVFUHSDQFLHVFRXOGSRWHQWLDOO\KDYHLPSRUWDQW
LPSOLFDWLRQVIRUWKHUHSURGXFLELOLW\RIQHXURGHJHQHUDWLRQIROORZLQJ7%,$QRWKHUPDWWHURI
GHEDWHLVWKHH[LVWHQFHRIQHXURQDOORVVLQWKHLPSDFWHGFRUWH[ZKLFKFRPHVLQWRFRQWDFWZLWKWKH
ZDWHUFROXPQWKDWWUDQVPLWVWKHSHUFXVVLRQZDYH:KLOHPRVWVWXGLHVLQFOXGLQJRXUVUHSRUWQR
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RYHUWQHXURQDOLQMXU\DWWKLVVLWH+LFNVHWDO6DWRHWDO*UDGLHWDO6DWRHW
DO5DJKXSDWKLHWDO%HQW]HUHWDO6DQGHUVRQHWDORWKHUVLQGLFDWH
VLJQLILFDQWQHXURQDOORVV.DEDGLHWDOE6KXOW]HWDO/XRHWDO7KH/)3
SURWRFROKDVWKHSRWHQWLDOWRLQGXFHGLUHFWGDPDJHDWWKHSHUFXVVLRQVLWHZKLFKFRXOGLQFOXGH
VXEDUDFKQRLGKHPRUUKDJHRUWHDULQJRIWKHGXUDWKDWFRXOGSURGXFHQHXURQDOLQMXU\LPPHGLDWHO\
XQGHUQHDWKWKHZDWHUFROXPQLQDQRQUHSURGXFLEOHPDQQHU,QRXUKDQGVKRZHYHU/)3GLGQRW
SURGXFHFRUWLFDOFDYLWDWLRQWKDWZRXOGVXJJHVWGXUDPDWHUOHVLRQDQGZDWHULQWUXVLRQLQWRWKH
FRUWH[DQGQHXURQDOORVVZDVQRWGHWHFWDEOHLQWKHLPSDFWHGUHJLRQ
6RPHKDOOPDUNVRIQHXURQDOOHVLRQVIROORZLQJH[SHULPHQWDO7%,XVLQJ/)3DUHWKHLU
ZLGHVSUHDGQDWXUHDQGWKHIDFWWKDWWKHPRVWVHYHUHQHXURQDOORVVDSSHDUVLQEUDLQUHJLRQVWKDW
DUHUHPRWHIURPWKHVLWHRILPSDFW+LFNVHWDO7KLVSDWWHUQRIGDPDJHOLNHO\UHIOHFWVWKH
FRPSOH[LW\RIWKHIRUFHVWKDWDUHWUDQVPLWWHGWKURXJKWKHEUDLQSDUHQFK\PDIROORZLQJSHUFXVVLRQ
,WLVSRVVLEOHIRUH[DPSOHWKDWWKHLPSDFWHGFRUWH[LVVXEMHFWHGPRVWO\WRDFRPSUHVVLRQ
GHFRPSUHVVLRQZDYHDWWKHWLPHRIWKHLPSDFWRIWKHIOXLGFROXPQZKLOHUHPRWHVLWHVVXFKDVWKH
WHPSRUDOFRUWH[RUWKHWKDODPXVVXIIHUIURPVKHDUVWUHVVWKDWFRXOGEHPRUHGHVWUXFWLYHIRU
QHXURQDOFHOOV7KHWHPSRUDOFRUWH[PD\DOVRLPSDFWWKHVNXOOERQHLQUHVSRQVHWRWKHSHUFXVVLRQ
ZDYH7KHH[DFWQDWXUHRIWKHIRUFHVWKDWDUHWUDQVPLWWHGZLWKLQWKHEUDLQSDUHQFK\PDUHPDLQV
SRRUO\XQGHUVWRRG+RZHYHULWVHHPVOLNHO\WKDWWKHEUDLQUHJLRQVLQZKLFKPD[LPDOQHXURQDO
ORVVLVGHWHFWHGVHYHQGD\VIROORZLQJ/)3DUHDOVRWKRVHZLWKPD[LPDOSULPDU\LQMXU\
LPPHGLDWHO\DIWHUWKHSHUFXVVLRQ$GGLWLRQDOO\VXEVHTXHQWLQIODPPDWLRQFRXOGGHYHORSDWWKHVLWH
RISULPDU\LQMXU\DQGDJJUDYDWHQHXURQDOORVVRYHUWLPHVHFRQGDU\LQMXU\.XPDUDQG/RDQH

,QVXSSRUWRIDQLPSRUWDQWUROHIRULQIODPPDWLRQLQSRVW/)3QHXURQDOORVVZHGHWHFWHGD
VLJQLILFDQWLQFUHDVHLQWKHWRWDOQXPEHURIQXFOHLZKLFKZDVFRUUHODWHGZLWKGHFUHDVHG1HX1
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SRVLWLYHFHOOXODUGHQVLW\LQWKHWHPSRUDOFRUWH[DQGLQDUHD&$RIWKHKLSSRFDPSXVIROORZLQJ
ERWKPRGHUDWHDQGVHYHUH/)37KLVLQFUHDVHLQQRQQHXURQDOFHOOXODUGHQVLW\OLNHO\UHIOHFWV
JOLRVLVDQGLQIODPPDWLRQLQWKHVHEUDLQUHJLRQV,QIDFW6HOZ\QHWDOIRXQGWKDWPLFURJOLDO
LQYDVLRQZDVDVVRFLDWHGZLWKDVWURF\WHDFWLYDWLRQLQWKHVHUHJLRQVIROORZLQJ/)3LQMXU\7KH
SUHFLVHIXQFWLRQRILQIODPPDWLRQLQWKHFRQWH[WRIWUDXPDWLFEUDLQLQMXU\LVVWLOODWRSLFRIPXFK
GHEDWHDQGLQWHUHVWEXWDQXPEHURIVWXGLHVDJUHHWKDWUHGXFLQJWKHUHOHDVHRISURLQIODPPDWRU\
PROHFXOHVOLNHLQWHUOHXNLQȕ,/ȕRUEORFNLQJSURWHLQVSHUWDLQLQJWRLQIODPPDWRU\FDVFDGHV
VXFKDVH[WUDFHOOXODUUHJXODWHGNLQDVH(5.RUF\FOLQGHSHQGHQWNLQDVHV&'.VFDQEH
EHQHILFLDOWREUDLQUHFRYHU\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Chapter 2
Glial modiﬁcation
2.1 Methods
2.1.1 Animals
As a matter of conformity to the majority of TBI studies, and to prior results on glial modiﬁ-
cations within our laboratory, these experiments have be conducted in Sprague Dawley instead
of Wistar rats (250-400g) obtained from Elevage Harlan (Gannat, France). All experimental
protocols were approved by the local committee on animals in research at the University Claude
Bernard Lyon I (approval number: DR2014-31-V2 MESRverif), and were performed in accor-
dance with European directive 2010/63/EU. There was no signiﬁcant diﬀerence in body weight
between control animals and those subjected severe LFPI.
During this experiment, we compare brain slices from control animals (without any surgery), to
animals subjected to a severe LFPI (3.8ATA). As during the other experiments, animals were
intubated prior to LFPI and ventilated until they recover suﬃcient spontaneous ventilation.
LFPI was performed as described in the methods part section 1.3, and animals received
Buprenorphine 0.05 mg/kg twice at 12h interval after surgery.
2.1.2 Brain ﬁxation and removal
Seven days after TBI, animals were deeply anesthetized with an intraperitoneal injection of
sodium pentobarbital (150mg· kg−1, Ceva R©, Libourne, France) and intracardiacally perfused,
ﬁrst with 150 mL of a Ringer solution with 0.1% heparin at room temperature, then with
500 mL of an ice-cold ﬁxative solution containing 4% freshly depolymerized para-formaldehyde
(PFA) in 0.1 M phosphate buﬀer (PB) (pH = 7.4). The brains were removed, post-ﬁxed for
2 hours in 4% PFA and placed in a 30% sucrose solution (PB, 0.1 M, pH = 7.4) for 48-72 h.
Brains were then frozen in a solution of isopentane at -50oC before storage at -80oC for further
analysis.
2.1.3 Glial cells labelling
Rat brains were cut frozen into 30 μm thick sections using a HM 500 OM microtome (Microm,
Francheville, France), brain sections were placed in a solution of 10 mM phosphate buﬀer saline
(PBS), then stored at -20oC in an antifreeze buﬀer (buﬀer F in a mix of glycerol, ethylene glycol).
Tissue was ﬁrst rinsed in PBS for at least 5 hours, then permeabilized and saturated with a
solution of PBS, 3% triton-X-100 (PBST) and 3% goat and donkey serum (Sigma-Aldrich, St
Quentin Fallavier, France) for 2 hours. Brain sections were incubated overnight at 4oC with
a rabbit monoclonal antibody directed against the GFAP protein (diluted at 1:500, AB5804,
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Millipore, Molsheim, France), and a mouse monoclonal antibody directed against the CD11b
protein (diluted at 1:500, CBL1512Z, Millipore, Molsheim, France), in a solution of PBST and
3% goat and donkey serum.
After 3 washes with PBST for 10 min each, the sections were incubated overnight at 4oC with
a donkey anti rabbit IgG antibody coupled to Alexa ﬂuorR© 488 (diluted at 1:1500, A21206,
Molecular Probes), and a goat anti mouse IgG antibody coupled to Alexa ﬂuorR© 633 (diluted
at 1:1500, A21052, Molecular Probes), in a solution of PBST and 3% goat and donkey serum.
Sections were washed for 10 min in PBST, and for 10 min in PBS. Then immobilized on
pre-cleaned microscope slides (Ground Edges 90oC, Menzel-glaser R©, Braunschweig, Germany)
using tap water. Finally slides were mounted using Fluoroshield TM with DAPI (Sigma-Aldrich,
Saint-Quentin Fallavier, France) and stored at 4oC C in the dark until confocal analysis.
2.1.4 Whole slide images
Imaging of whole brain sections was performed at the Cecil Imaging Facility (Université Claude
Bernard Lyon 1, Lyon, France) using AXIO Scan.Z1 (Zeiss). We used a slide scanner with a
20× objective (NA: 0.8) and an Orca Flash 4.0 camera. Excitation and emission wavelengths
were 353 nm and 465 nm for DAPI, 495 nm and 519 nm for Alexa ﬂuor 488 and 650 nm and
673 nm for alexa ﬂuor 633 respectively.
2.1.5 Confocal microscopy
Three brain regions with signiﬁcant neuronal loss (i.e. temporal cortex, thalamus and CA3)
were imaged with confocal microscopy to address glial morphology and density. Slides were
imaged at the Cecil Imaging Facility using a Leica SP5 confocal laser-scanning microscope
(CLSM) with a 40× objective (NA: 0.7). The images were acquired by a three-step process:
positivity for DAPI was assessed at an excitation wavelength of 405 nm and emission wave-
lengths of 418-473 nm, while the signal for Alexa 488 (GFAP immunoreactivity) was assessed
at an excitation wavelength of 488 nm and emission wavelengths of 510-613 nm, and Alexa 633
(CD11b immunoreactivity) at an excitation wavelength of 650 nm and emission wavelength of
650-750 nm. A z-series consisting of 10-15 optical sections, with a 1 μm interval, were imaged
within each region of interest. Individual images were averaged two times for each ﬂuorescent
molecule.
2.2 Results
Using whole slide images we were able to describe a large overview of glial modiﬁcation that
occurs 7 days after LFPI. Subsequent confocal images give us sharper information about cells
morphology, spatial organization and cell density. The present results are still qualitative
and further analysis regarding glial cells counts and quantitative morphology assessment are
ongoing. Nevertheless glial cells have clearly a diﬀerent phenotype within the area where we
observed neuronal loss, spreading from the thalamus to the temporal cortex (Fig 21).
2.2.1 Astrocyte modiﬁcation
As NeuN ﬂuorescence decreased (publication in chapter 1), GFAP over-expression spread also
from the thalamus to the temporal cortex. However maximal over-expression took place at
boundary layer mainly in the hemisphere under the shock (ipsilateral to the trauma). Indeed
as white matter is mainly located between diﬀerent structures, maximal GFAP expression oc-
curs in the corpus callosum ipsilateral to the trauma, around the lateral ventricle. GFAP also
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Figure 21: Whole tissue section images of LFPI induce glial modiﬁcations: Astrocyte
are labelled in green using the GFAP, and microglia in red using the cd11b antigen
increased in the molecular layer of the CA1 area in the hippocampus, and the cortical grey
matter surrounding the area of maximal neuronal loss. Noteworthy, no GFAP staining was
displayed in the ROI where the neuronal loss was the worst. Conversely, within the temporal
cortex astrocytes are also missing (Fig 22). The normal radial spatial organization that was
observed in the cortex of control animals was completely loss in this area after LFPI (Fig 22).
The closer to the core of the lesion, the more the architecture is altered with astrocyte loss.
However we still need to quantify this astrocyte loss and address more precisely their morphol-
ogy.
The contra-lateral hemisphere also displays smaller GFAP increases in the same areas (i.e.
Temporal cortex, and white matter boundary layers, Fig 21 left image).
2.2.2 Microglia modiﬁcation
It is well established that microglial form and function are inextricably linked. In recent years,
the traditional view that microglial form ranges between “ramiﬁed resting” and “activated
amoeboid” has been emphasized through advancing imaging techniques that point to microglial
form being highly dynamic. Moreover, microglia adopt meaningful intermediate forms between
categories, with considerable crossover in function and varying morphologies as they cycle,
migrate, wave, phagocytose, and extend and retract ﬁne and gross processes [138, 139].
Using confocal imaging we were able to evidence diﬀerent morphological categories of microglia.
In control animals the large majority was “resting” microglia with ramiﬁed ﬁne processes and
little peri-nuclear cytoplasm (Fig 22 left panel). Conversely, after a severe LFPI, the thalamus
and CA3 had “bushy” and hypertrophied microglial cells, some of them unramiﬁed with an
amoeboid shape. The temporal cortex that encompass maximal injury, presented a cluster of
conﬂuent unramiﬁed microglia. Such formation of rod-cells with possible cell fusion can be
observed within necrotic foci of CNS parenchyma [347].
Like for astrocytes, microglial cells that over-express CD11b are not restricted to the area of
neuronal loss. Maximal CD11b staining was present in the temporal cortex, the corpus callosum
around lateral ventricle and in the thalamus ispilateral to the trauma (Fig 21, right image).
Area CA3 also present activated microglia, as well as the medial part of CA1, hilus and the
dentate gyrus.
A fewer amount of cells can be seen in the cotra-lateral hemisphere, namely in the thalamus
and the corpus callosum (Fig 21, right image).
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Figure 22: whole tissue section images of LFPI induce glial modiﬁcations: Merge
images of astrocytes (green) using GFAP, microglia (red) using the cd11b antigen, and nuclei
stained with DAPI (blue). Confocal microscopy images 375×375μm, 40× magniﬁcation, 1 μm
optical section.
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2.3 Conclusion
We described an extensive overview of neuronal loss and glial cell reactions after severe LFPI
in adult rats. The most impacted area seven days after a severe LFPI, regarding neuronal loss,
spread from the thalamus (-62% neurons) to the temporal cortex (-60% neurons) including
the CA3 area of the hippocampus (-36% neurons). White matter seems also to be altered as
describe by activated microglia and astrocytes locations in the corpus callosum. However we do
have to quantify speciﬁcally this kind of injury in an ongoing study. Even if hippocampus did
not present signiﬁcant neuronal loss, it was inﬁltrated with activated microglia. This highlights
that a probable aggression has occurred also in this structure.
The pressure wave generated by a severe LFPI did also reach the contra-lateral cortex. If
neuronal density seems not to be aﬀected, glial cells were activated in diﬀerent part of the
contra-lateral hemisphere. Further analysis are ongoing to precisely quantify astrocytic and
microglial cell densities, and to depict microglial forms in the diﬀerent cortical and sub-cortical
area.
We have identiﬁed the area most impacted by severe LFPI and where the main neuronal loss
occurs 7 days after the injury. However, as shown by Conti et al (1998), neuronal loss is a
dynamic process that start at the temporal cortex within the 24 ﬁrst hours post LFPI and last
more than 2 weeks in other part of the brain [348].
We decided to study CSDs in this area which we consider to mimic the “traumatic penumbra”,
compared to a normal cortex in health animals.
However, we had to characterize biosensors recordings validity in diﬀerent ambient conditions,
especially with regard to oxygen and temperature. This is an essential step to precisely use in
vitro calibration for in vivo measurements interpretation.
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Chapter 1
Micro-electrode biosensors
1.1 Biosensor manufacturing
Biosensors were made using a 25 mm diameter 90% Pt/10% Ir wire (Goodfellow, Huntington,
U.K.) glued to a copper wire using conductive silver paint (Radiospares, Beauvais, France). The
sensor wire was inserted into a pulled glass capillary (Harvard Apparatus, Edenbridge, U.K.),
and the tip of the pipette was cut so the Pt wire extended from the glass approximately 100μm.
The junction between the Pt and the pipette tip was sealed by locally melting the glass. The
junction between the copper wire and the glass was sealed with epoxy resin (Araldite, Bostik,
Paris, France). The electrodes were washed for 30 min in ethanol. A PPD screening layer was
deposited by electropolymerization for 20 min in 100 mM PPD (Sigma-Aldrich) solution in 0.01
M PBS at pH 7.4 under a constant potential of +700 mV versus a Ag/AgCl reference electrode.
The enzyme layer was deposited by dipping the Pt tip of the electrode in the enzyme solution
(Fig 19).
Glucose oxidase (EC 1.4.3.11) from Aspergillus niger was purchased in powder form from
Sigma-Aldrich (100-250 U/mg, Saint Quentin Fallavier, France). The ﬁnal enzyme solution
used for biosensor preparation contained 60 mg/mL glucose oxidase, 30 mg/mL bovine serum
albumin (BSA) (Sigma), 10 mg·mL−1 poly(ethylene-glycol) diglycidyl ether (PEGDE) (Sigma-
Aldrich), and 1% glycerol in PBS (0.01 M, pH 7.4). Immobilization methods involving PEGDE,
was found to preserve the substrate specifcity compared to glutaraldehyde [131].
Lactate oxidase (EC 1.13.12.4) from Pediococcus sp. was purchased in powder form from
Sigma-Aldrich (≥ 20 units·mg−1, Saint Quentin Fallavier, France). The ﬁnal enzyme solu-
tion used for biosensor preparation contained 60 mg·mL−1 lactate oxidase, 60 mg·mL−1 BSA
(Sigma), 20 mg·mL−1 PEGDE, and 1% glycerol in PBS.
L-Glutamate oxidase (EC 1.4.3.11) from Streptomyces sp. X119- 6 was purchased from
Yamasa Corporation (Choshi, Chiba, Japan). The working solution contained 57 mg/mL of the
protein, 81 mg·mL−1 BSA, and 1% glycerol in PBS (0.01 M, pH 7.4). PEGDE (Sigma-Aldrich)
was added to the enzyme aliquot prior to biosensor preparation.
Control sensors were treated using a BSA solution consisting of 400 mg·mL−1 BSA, 10
mg·mL−1 PEGDE, and 1% glycerol in PBS.
Glucose and lactate sensors were covered with an additional polyurethane membrane to increase
their dynamic range and to protect the enzyme layer from biofouling in the brain. The tip of
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the electrode was dipped three times in a 5% solution of polyurethane in THF (Sigma) with 10
min intervals between dips at room temperature to dry the layer.
Finally control, glucose and lactate electrodes were placed 2 h in an oven at 55oC, and glutamate
sensors 1h15 at 47oC. Sensors were then stored at 4oC for short term storage and at -20oC for
long term storage (delayed use).
1.2 Recordings set-up
All recordings were obtained using a VA-10 electrochemistry ampliﬁer (NPI Electronics, Tamm,
Germany) equipped with a two-electrode potentiostat. For in vitro experiments, analogue to
digital conversions and data acquisitions were performed using a 16 bit USB-6221 acquisition
board (National Instruments, Nanterre, France) controlled by home-made software based on
Igor Pro 6.4 procedures (Wavemetrics, Eugene, OR). For in vivo experiments analogue to digital
conversions and data acquisitions were performed using a 16 bit PowerLab 16/35 with Labchart
7 (ADInstrument, Oxford, United Kingdom).
The oxidation current was recorded at 1 kHz and averaged over 1000 data points, yielding a
signal sampling frequency of 1 Hz. In vitro calibrations were performed in standard PBS (0.01
M, pH 7.4, at room temperature) solutions. The reference electrode was a chloride-treated
silver wire (Ag/AgCl) placed directly in the recording chamber. Recordings were obtained
using constant potential amperometry at +500 mV versus the Ag/AgCl reference electrode.
Holding potentials between +500 and +700 mV are optimal for H2O2 detection [128].
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Biosensor reliability in changing
conditions
Since biosensors are made using an oxidase, the signal relies on an oxygen dependent enzymatic
reaction, with a subsequent H2O2 that is oxidized on the platinum surface (Fig 19). Therefore
the oxidative current is the result of (1) the enzymatic oxidation and (2) the chemical H2O2
oxidation. As any chemical reaction, both oxidations should be dependent on the temperature
in the medium. Furthermore, the enzymatic reaction rate (by the oxidase) will also depend on
its substrates concentrations: That is to say oxygen and the molecule we want to detect.
Prior to each in vivo experiment, biosensors were calibrated in vitro to compute the relationship
between oxidative current and substrate’s concentration (glucose, lactate or glutamate) in the
medium. However, both temperature and oxygen concentrations were diﬀerent in PBS (used
during the calibrations) and in the animal’s brain (during experimentation). Therefore, we
assessed how changes in temperature or oxygen concentrations modiﬁed constant potential
amperometric measurements.
Biosensors were placed with a temperature and O2 sensitive probe (OxyLab pO2TM , Oxford
Optronix, UK) in an airtight glass chamber ﬁlled with the enzyme substrate in PBS (i.e. 10μM
glutamate, 500μM glucose or lactate; Fig 23). After signal stabilization, in the ﬁrst part of the
experiment the chamber’s temperature rose from 5oC to 40oC during 1-2 hours (Fig 24A.). In
a second part, at a constant temperature of 37oC, N2 was then bubbled to remove oxygen from
the solution thus dropping 02 from ambient partial pressure (i.e. 21% atm ≡ 159.6 mmHg)
down to < 5 mmHg, Fig 24B.).
Figure 23: Airtight glass chamber
ﬁlled with the enzyme substrate
in PBS.
A temperature and O2 sensitive probe
was inserted on the left, a ground elec-
trode and a tube for gas bubbling on
the top, and a biosensor on the right.
The device was immersed in a con-
trolled temperature bath.
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Figure 24: raw data example of a lactate sensitive sensor during temperature and O2
calibration. The top black curve represent the oxidative current recorded from the biosensor.
Beware of diﬀerent scale between A. (1.5-4nA) and B. (2.8-3.6nA) chart. The red curve is
either A. temperature (oC) or B. oxygen partial pressure in the medium (mmHg) recorded
by the Oxylab probe. Note how the oxidative current from the biosensor is increasing with
temperature (indicating an increasing enzymatic reaction), and then decreasing with oxygen
concentration. The gray boxes represent the values (i.e. oxidative current at To = 40 oC
and PO2 = 159.6 mmHg) that were used as references to compute oxygen or temperature
dependency (equation (12)).
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2.1 Eﬀect of temperature variations on biosensors ox-
idative currents
Biosensors currents were recorded as the temperature rose slowly from ≈ 5oC to 40oC for 1-2
hours in a controlled temperature bath, at a given PO2 (159.6 mmHg). Oxidative current was
then related to the signal at 40oC (Fig 24A, gray boxes), to compute in “R” a “normalized”
percentage of variation (equation (12)).
Δ Current(%)temp/O2 =
(Currenttemp/O2 − Current40oC/159.6mmHg) × 100
Current40oC/159.6mmHg
(12)
Based on the shape of the relationship between ΔCurrent and temperature (Fig 25, left column),
we ﬁrst used a linear model to ﬁt our data (i.e. Δ Current(%)temp = Slope × Temperature +
Intercept). The lm() function (package stats) compute a linear least squares regression to
estimate the best parameters of the linear model (i.e. intercept and slope). This linear model
gives us good R2 over 0.9 for glucose and glutamate sensors. Lactate sensor had a more hetero-
geneous reaction against temperature so that the model had worse goodness of ﬁt (R2=0.74).
We tried to improve our models using a non-linear four parameters logistic model (equation (13))
meaning that ΔCurrent was less inﬂuenced by temperature at low and high temperature:
Δ Current(%)temp = A +
(B − A)
1 + exp((xmid − Temperature)/scal) (13)
Where A is the horizontal asymptote on the left side (low of temperature), B the horizontal
asymptote on the right side (high temperature), xmind the temperature value at the inﬂection
point of the curve, and scal a scale parameter on the temperature axis (The smaller one makes
scal, the steeper the curve is at the inﬂection point). These parameters were estimated using
the nls() function with a self-starting equation (SSfpl, package stat) that compute a non-linear
least-squares regression.
The non-linear model validity was compared to the linear model by:
• An approximated R2 as 1 minus the fraction of the residual sum of squares by the total
sum of squares:
R2 = 1 −
∑
residuals2∑(current − current mean)2 (14)
However, it’s not possible to calculate a valid R2 for non-linear regressions. Unlike for
linear regressions, the total sum of square is not equal to the regression sum of squares
+ the residual sum of square. Therefore R2 can exceed 1 and do not always increase for
better non-linear models. Thus we used 2 diﬀerent methods to maximize the validity of the
model: the Akaike’s Information Criterion (AIC) and residuals graphical interpretation.
• AIC is a parameter that seeks a model that has a good ﬁt to the truth (maximizing the
log(Likelihood)) but few parameters: AIC = −2(log(Likelihood)) + 2 × K, where K is
the number of free parameters in the model. The lower the AIC the better the model ﬁts
the data [349].
• Finally, the best way to appreciate a model’s goodness of ﬁt is to visualize the residuals.
We computed 2 residuals plots with the nlsResiduals() function (nlstools package): (1) the
standardized residuals plot against the ﬁtted values of ΔCurrent gives information about
how the residuals behave. A random distribution that is expected will give a vertical
homogeneous repartition of the residuals on both sides of the x-axis. (2) Minimizing the
sum of the squared errors makes the assumption that residuals are normally distributed,
which can be checked on the Q-Q plot (expected to have a linear shape).
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Parameters Glutamate oxidase Glucose oxidase Parameters Lactate oxidase
A -104.2 -92.2 Intercept -76
B 52.6 57.5 Slope 1.9
Xmind 29.8 34.9
scal 13 10.5
R2, linear model 0.93 0.91 0.74
AIC, linear model 92 525.21 190 599.2 225 335.5
R2, logistic model 0.94 0.96
AIC, logistic model 90 902.52 171 053.2
Table 11: Parameters of temperature dependency model according to a logistic (13) or
linear equation, for each enzyme. The model validity is evaluated as the R2 (equation (14)),
and the AIC: Akaike’s Information Criterion.
The “R” scripts used to model ΔCurrent modiﬁcations against temperature and test models
validities are as follow:
1 f i t . ml<−lm( DeltaCurrent~temperature , data=DeltaCurrent . temp)
2 summary( f i t . lm)
3 f i t <− n l s ( DeltaCurrent~SSfp l ( temperature , A, B, xmid , s c a l ) , data=
DeltaCurrent . temp)
4 RSS <− sum( r e s i d u a l s ( f i t ) ^2) # Res idual sum of squares
5 TSS <− sum( ( DeltaCurrent − mean( DeltaCurrent ) ) ^2) # Total sum of squares
6 r . squared <− 1 − (RSS/TSS)
7 AIC( f i t , f i t . lm) # Akaike ’ s In format ion Cr i t e r i on
8 Resuduals <− n l sRe s i dua l s ( f i t )
9 p lo t ( Resuduals , which = 0) # 4 graphs o f r e s i d u a l s
Glucose and glutamate biosensors had homogeneous reactions against temperature so that the
R2 were over 0.9 in both models. The four parameters logistic equation improved the model as
shown by the decrease in the AIC as well as an increased R2. Lactate oxidase covered biosensors
had more heterogeneous reactions against temperature so that we were not able to evaluate a
logistic equation. Residuals behave randomly with an even vertical distribution (Standardized
residuals plot, Fig 25), and looks normally distributed on the Q-Q plot.
Estimated parameters values for each enzymatic layer (i.e. glucose oxidase, lactate oxidase or
glutamate oxidase) are summarized in table 11, as well as the R2 and the AIC of each model.
Fig 25 displays the ΔCurrent modiﬁcations plotted against temperature (one color for each
sensor, n=6), with the modeled data as a dashed black line.
2.2 Eﬀect of oxygen concentration variations on biosen-
sor oxidative current
The airtight chamber was then maintained at a constant temperature of 37oC by the controlled
temperature bath, and N2 bubbling starts until PO2 drop below 5 mmHg after around 20 min
(Fig 24). Like for the temperature calibration, the percentage of current variation was compared
to the one at 159.6 mmHg (ambient oxygen partial pressure: 1Atm × 0.21 ≡ 760.001mmHg ×
0.21 ≡ 159.6mmHg) using the same equation (12).
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Parameters Glutamate oxidase Glucose oxidase Lactate oxidase
Asym = 0
R0 -72.2 -43.9 -21.8
Lrc -2.9 -2.6 -3.17
R2 0.93 0.72 0.82
AIC 47115.56 67488.09 47138.90
free Asym parameter
Asym -2.3 -2.7 -1.1
R0 -73.1 -46.2 -22.7
Lrc -2.8 -2.42 -3.0
R2 0.94 0.72 0.82
AIC 46953.77 67353.06 46956.33
Table 12: Parameters of oxygen sensitivity model according to the asymptotic equa-
tion (15) for each enzyme. The horizontal asymptote on the right side (Asym) was ﬁxed to a
null value
Based on the shape of the relationship between ΔCurrent and temperature (Fig 26), we chose
an asymptotic equation to ﬁt our data:
Δ Current(%) = Asym + (R0 − Asym) × exp(− exp(lrc) × PO2) (15)
Where Asym is the horizontal asymptote on the right side (high values of PO2), R0 the re-
sponse when PO2 is zero, lrc the natural logarithm of the rate constant. Since the value at
159.6 mmHg correspond to a ΔCurrent of 0%, Asym was set to 0%.
The nls() function was used to compute a non-linear least-squares regression to estimate these
parameters. The starting values of R0 and lrc were respectively -50% and -3. We also tested the
eﬀect of leaving Asym as a free parameter and compared the two models with an approximated
R2, and the AIC. The “R” scripts used to model our data and test the goodness of ﬁt were as
follow:
1 f i t 1<−n l s ( DeltaCurrent ~ 0+(R0−0)∗exp(−exp ( l r c ) ∗PO2) , s t a r t=l i s t (R0=−50,
l r c=−3) , data = DeltaCurrent .PO2)
2 f i t 1<−n l s ( DeltaCurrent ~ A+(R0−A) ∗exp(−exp ( l r c ) ∗PO2) , s t a r t=l i s t (R0=−50,
l r c =−3, A=0) , data = DeltaCurrent .PO2)
3 RSS <− sum( r e s i d u a l s ( f i t ) ^2) # Res idual sum of squares
4 TSS <− sum( ( DeltaCurrent − mean( DeltaCurrent ) ) ^2) # Total sum of squares
5 r . squared <− 1 − (RSS/TSS)
6 AIC( f i t 1 , f i t 2 ) # Akaike ’ s In format ion Cr i t e r i on
7 Resuduals <− n l sRe s i dua l s ( f i t 1 )
8 p lo t ( Resuduals , which = 0) # 4 graphs o f r e s i d u a l s
Leaving the Asym parameter free did not improve the R2 and had a little eﬀect on the AIC.
Therefore we chose to keep the model with Asym set at 0%. Indeed an asymptote to 0%
modiﬁcation under high PO2 is meaningful in order to use this model for in vivo currents
correction.
Model’s parameters were evaluated separately for each enzymatic layer (i.e. glucose oxidase,
Lactate oxidase or glutamate oxidase) and are reported in table 12. The ΔCurrent modiﬁcations
were plotted against PO2 (one color for each sensor, n=6), with the modeled data (using
133
V 2.2. Eﬀect of oxygen concentration variations on biosensor oxidative
current
Asym=0) as a dashed black line (Fig 26, left column). Like for the temperature calibrations,
model’s validities were also evaluated using 2 residuals plots with the nlsResiduals() function
(nlstools package, Fig 26 right column).
Every sensors had an asymptotic relation to PO2, but they did not behave evenly as PO2 goes
down. Therefore glucose and lactate residuals were not as randomly distributed as those of
temperature models. Conversely they were more widely distributed at low PO2 (Fig 26 A and
B).
Glutamate oxidase covered sensors had a more homogeneous reaction, so that residuals behave
randomly across diﬀerent PO2 (Fig 26 C). However when we began bubbling of N2 gas, it
induced artifact that spread data at high PO2. Consequently the residuals distribution was
larger, but remains symmetric around the x-axis (Fig 26, C). These artifact were also present
when we used glucose and lactate oxidase covered sensors, however their baseline signal was
higher improving signal to noise ratio for the same artefact amplitude (Fig 24).
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Figure 25: Sensors temperature calibrations: Left column: each panel plots the delta of
currents (%, see equation (12)) against temperature, for a sensor type (A: Glucose oxidase, B:
lactate oxidase and C: glutamate oxidase). 6 sensors were recorded for each sensor type and
are plotted in diﬀerent colors. Modeled data are represented as a dashed black line. Right
column: 2 plots of model’s residuals (i.e. standardized residuals against ﬁtted values and
normal Q-Q plot) are represented leftward from each corresponding sensor plot.
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Figure 26: Sensors PO2 calibrations: Left column: each panel plots the delta of currents
(%, see equation (12)) against PO2, for a sensor type (A: Glucose oxidase, B: lactate oxidase
and C: glutamate oxidase). 6 sensors were recorded for each sensor type and are plotted in
diﬀerent colors. Modeled data are represented as a dashed black line. Right column: 2 plots
of models residuals (i.e. standardized residuals against ﬁtted values and normal Q-Q plot) are
represented leftward from each corresponding sensor plot.
Box plots above each graphs represent the PbtO2 recorded in anesthetized rats (KCl) or after
sever LFPI (TBI). The box plot on the top of each graph represent the percentage of decrease
at these PbtO2.
136
Chapter 3
Implication for in vivo experiments
During in vivo experiments, animal’s temperature was kept at 37oC with a homeothermic blan-
ket using a rectal temperature probe (Harvard apparatusR©). Animals breathed a mixture of
30% oxygen in air, with 0.8-1.5% Isoﬂurane. The PbtO2 recorded in adult anaesthetized Wistar
rats was similar in animals subjected to a severe LFPI (27.5 [18.2;36.6]) and in control animals
(28.1 [26;31.8], W=134 p= 0.96). The overall PbtO2 in all animals was 27.08 [23;35.5]
We expected that oxygen would not limit the oxidase reaction, and that changes in PO2 from
159.6 mmHg (in vitro calibration) to around 27 mmHg (physiological in vivo PbtO2) would not
interfere with our measurements. Conversely, we observed that all oxidase start to depend on
oxygen at physiological ranges of in vivo PbtO2 (i.e. 27.08 [23;35.5]). Indeed in this interval
of PbtO2, sensors covered with glucose oxidase displayed a -9.1% [-11.7;-6.3] decrease, those
with lactate oxidase -7.3% [-7.6;-7], and those with glutamate oxidase -18.4% [-19.7;-15.2], when
compared to measures made at PO2 = 159.6 mmHg (as during in vitro calibration).
The measurements made with the chamber in a controlled temperature bath, revealed that at
25oC (i.e. room temperature) glucose sensors lost -41.7% [-46.1;-39] compared to the oxidative
current at 37oC (i.e. animals central temperature), glutamate sensors lost -47.5% [-49.9;-43.5]
and lactate sensors -25.9% [-31.6;-15.2].
In order to extrapolate the closest substrate concentrations from oxidative currents, we need to
consider calibration data as well as experimental conditions. The “R” package written includes
functions to compute biosensors calibrations and corrections for diﬀerent temperature and oxy-
gen conditions between in vitro and in vivo set-ups (see documentation in Appendix VIII).
The functions called correction.Temp() and correction.TPO2() returns a corrected signal based
on calibration and experimental temperature or PbtO2, using parameters and equations de-
scribed above. The functions are encrypted in “R” as follow:
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1 c o r r e c t i o n .Temp<−f unc t i on (x , enz , temp . c a l i b =25,temp . exp=37) {
2 i f ( enz==" glutamate " ) {
3 A<− −104.2 ; B<− 52 .6 ; xmid<− 29 .8 ; s c a l<− 13
4 de l t a . exp<−A+(B−A)/(1+exp ( ( xmid−temp . exp ) / s c a l ) )
5 de l t a . c a l i b<−A+(B−A)/(1+exp ( ( xmid−temp . c a l i b ) / s c a l ) )
6 }
7 i f ( enz==" g luco s e " ) {
8 A<− −92.2 ; B<− 57 .5 ; xmid<− 34 .9 ; s c a l<− 10 .5
9 de l t a . exp<−A+(B−A)/(1+exp ( ( xmid−temp . exp ) / s c a l ) )
10 de l t a . c a l i b<−A+(B−A)/(1+exp ( ( xmid−temp . c a l i b ) / s c a l ) )
11 }
12 i f ( enz==" l a c t a t e " ) {
13 i n t e r<− −76 ; s l ope<− 1 .9
14 de l t a . exp <− s l ope ∗temp . exp + i n t e r
15 de l t a . c a l i b <− s l ope ∗temp . c a l i b + i n t e r
16 }
17 i f ( enz==" daao " ) {
18 A<−1 ; B<−1 ; xmid<−1 ; s c a l<−1
19 de l t a . exp<−A+(B−A)/(1+exp ( ( xmid−temp . exp ) / s c a l ) )
20 de l t a . c a l i b<−A+(B−A)/(1+exp ( ( xmid−temp . c a l i b ) / s c a l ) )
21 }
22
23 re turn ( vo l t . temp . cor<−x∗ (1+( de l t a . c a l i b / 100) ) /(1+( de l t a . exp/ 100) ) )
24 }
25
26 c o r r e c t i o n .TPO2<−f unc t i on (x , enz ,TPO2=28) {
27 i f ( enz==" glutamate " ) {
28 Asymp<− −0 ; R0<− −74.2 ; l r c<− −2.9
29 }
30 i f ( enz==" g luco s e " ) {
31 Asymp<−0 ;R0<− −43.9 ; l r c<− −2.6
32 }
33 i f ( enz==" l a c t a t e " ) {
34 Asymp<−0 ;R0<−−21.8 ; l r c<− −3.17
35 }
36
37 de l t a<− Asymp + (R0−Asymp) ∗ exp(−exp ( l r c ) ∗TPO2)
38 re turn ( vo l t .O2 . cor<−x/(1+( de l t a / 100) ) )
39 }
Furthermore it is possible that when dynamic process challenge brain tissue metabolism
with large PbtO2 modiﬁcations, such as during CSD or ischemic events, biosensors signals
must be corrected on-line with the results obtained from a PbtO2 probe implanted at the same
time. Due to the lack of space in a rat brain we were not able to record PbtO2, LFPot, LDF,
and several biosensors simultaneously. Instead, we proceeded to an “oﬀ-line” correction of the
raw data obtained from biosensor’s oxidative currents. To compute this correction, we used the
median PbtO2 values recorded in other animals obtained in the same conditions: either after
CSDs triggered by KCl apposition in healthy animals or spontaneous CSDs after LFPI.
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Metabolic and micro-vascular
consequences of cortical spreading
depolarizations, in a normal or injured
brain.
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Introduction
CSDs have been observed in the human brain since the mid-90s [223, 224]. There are growing
evidence to consider CSDs as an important bio-marker for prognosis evaluation in several acute
brain injury (i.e. TBI, ischemic stroke or sub-arachnoid hemorrhage) [225, 227].
Their implication as local “secondary brain aggressions” have been discussed in diﬀerent animal
models. It appears that CSDs have diﬀerent consequences depending on the state of brain tis-
sue (e.g. healthy, injured or ischemic). Local brain micro-vascularization has been extensively
studied in the normal brain and in ischemic models where CBF rated between normal and is-
chemic levels. To date CBF modiﬁcations following spreading depolarizations are considered to
range between a hyperemic response to a terminal ischemic response with intermediate bipha-
sic patterns. These intermediate patterns triggered by CSDs encompassed spreading oligemic
and/or reduced hyperemic responses [252, 253]. Nevertheless, very few studies have presented
these results after TBI where miscellaneous CBF modiﬁcations take place [254].
Carbohydrate and oxygen metabolism have not received such extensive descriptions, with het-
erogeneous published results. Only a few recent experimental studies has reported PbtO2 modi-
ﬁcations that seemed to encompassed either an initial dip or biphasic patterns, with subsequent
decrease in PbtO2 [111, 258, 82]. However further descriptions under diﬀerent experimental con-
ditions are needed to deﬁne a clear pattern for PbtO2 during CSDs.
Glucose and lactate metabolisms are even harder to study because of the temporal resolution
required to observe dynamic processes such as CSDs. So far, the team led by MG Boutelle
in London is the only one that reached a temporal resolution in the order of the minute with
rapid sampling cMD [320]. They described, in anaesthetized animals, a brain glucose decrease
associated with an increase in lactate extracellular concentrations following CSDs [239, 261].
Unfortunately the rapid sampling cMD did not provide real brain concentrations, but only
relative values. More-over when looking at pathological brain either in human or animals, the
results are much more heterogeneous [264, 263] and require further descriptions to understand
how CSDs challenge brain tissue after brain injuries.
In this study we aimed to describe micro-vascular, oxygen and carbohydrate metabolisms (i.e.
glucose and lactate) variations that accompanied CSDs in the normal brain and after a severe
TBI. Therefore we had several objectives that were: (1) To describe the micro-vascular and
metabolic (glucose, lactate, PbtO2) responses observed during and after CSDs in a healthy
cortical tissue; (2) To report how these patterns are altered during spontaneous isolated CSDs
after severe TBI; (3) To determine if clusters of CSDs are generating a worse reponse after
LFPI, compared to isolated ones.
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Methods
2.1 Animals
Experiments were conducted in adult male Wistar rats of 250-400g from Elevage Janvier(Le
Genest Saint Isle, France). All experimental protocols were approved by the local committee on
animals in research at the University Claude Bernard Lyon I (approval number: DR2014-31-V2
MESRverif), and were performed in accordance with European directive 2010/63/EU. There
was no signiﬁcant diﬀerence in body weight between control animals and those subjected to
severe LFPI.
2.2 Experimental design
We used a 3.8 ATA LFPI as model of severe TBI as previously described. Animals were in-
tubated and artiﬁcially ventilated prior LFPI. After LFPI animals were placed again in the
stereotaxic frame under light anesthesia (0.8-1.5 % isoﬂurane in 30% oxygen with air) for 5
hours and were then euthanized. Animal’s temperature was kept at 37oC with a homeothermic
blanket using a rectal temperature probe (Harvard apparatusR©). SpO2 was monitored with
foot clip connected to a MouseOxPlus system (Starr Life Sciences, Oakmont, USA), and ar-
terial blood pressure through an arterial line with a pressure sensor connected to a Bioamp
(ADInstrument). Signals acquisitions and analogue-digital conversions were made with a 16
bit PowerLab 16/35 with Labchart 7 (ADInstrument)
Between 30min and 1h after LFPI, we performed arterial blood gas in 9 animals under me-
chanical ventilation (Harvard apparatusR©, Ispra MA1 55-7058, Vt = 6ml· kg−1, breath rate
= 60·min−1, Peep = 5cm H20). The samples (200-400μL) were analyzed with a GEM 300
device (Instrumentation Laboratory, Bedford, USA): pH=7.35 [7.34-7.38], PaO2=144 mmHg
[136-149], PaCO2=47 mmHg [44-51], HCO−3 =25.5 mmol/L [24.7-26.8], Ht=38 % [34-41] and
Hb=11.8 g/dl [11.2-12.7].
Non-traumatized animals remain in the stereotaxic frame, breathing spontaneously under light
anesthesia (0.8-1.5 % isoﬂurane in 30% oxygen with air) for the duration of the experiment,
with the same monitoring.
In diﬀerent experiments we compared PbtO2, local CBF using LDF and biosensors signals
modiﬁcations during CSDs, which were triggered by diﬀerent stimuli:
• KCl experimental condition: CSDs were triggered by a transient increase in potassium
concentration of the saline solution that was infusing the cortical surface, by stirring a
drop of 1M KCl. This increase in KCl concentration was rinsed with a continuous ﬂow of
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saline solution (5ml/min during 1min). Two CSDs were triggered at least 30 min apart,
in each animals.
• TBIISOLATED experimental condition: Spontaneous CSDs occurred after a severe LFPI,
during the recording period (i.e. 20min-5h post trauma). Neuro-chemical recordings were
made in the temporal cortex (i.e. the “traumatic penumbra”, as deﬁned in the part IV).
We observed only occasional clusters of CSDs in some animals. Due to the lack of frequent
spontaneous clusters, we triggered additional ones after LFPI in other experiments.
• TBICLUSTER experimental condition: After a severe LFPI as in the TBIISOLATED condi-
tion, CSDs were triggered by 1M KCl apposition on the cranial window (without rinsing),
and occurred every 3-5 min. Neuro-chemical recordings were made remotely, also in the
temporal cortex. KCl apposition was made 30-45 min after the LFPI and we recorded at
least 10 successive CSDs during 40-50 min.
Due to the small size of a rat head we were not able to perform all recording at once because
of spatial overload. LFPot electrodes and LDF probes were always implanted to detect CSDs
occurrence. In diﬀerent sets of experiments we recorded PbtO2 (n=6 in each condition), glucose
and lactate (n=6 in each condition).
In the KCl condition, a surgical parietal cranial window was performed on the parietal bone,
and the dura was carefully removed to avoid bleeding and expose the parietal cortex. A 0.9%
saline solution was infused on the cranial window (4ml/hour). The LDF probe was placed
on the exposed cortex away from big vessels, without pressure on the cortical matter. Other
monitoring electrodes (i.e. PbtO2 or biosensors) and LFPot electrodes were inserted between
500 and 1000μm deep inside the cortex, under the LDF probe.
In the TBI conditions, we intended to record neuro-chemical modiﬁcations in the temporal
cortex that we found to be a “traumatic penumbra” area after sever LFPI (see part IV).
Therefore, the temporal bone facing the temporal cortex was drilled until we see the dura and
the LDF probe was placed on this thinned bone, under microscopic vision, not to apply any
pressure on the dura matter. Other electrodes (i.e. PbtO2 or biosensors, and LFPot) were
inserted through the cranial window made for the LFPI with a 25o angle, 2 mm deep to the
temporal cortex.
2.3 Recordings set-up
2.3.1 CSDs detection
LFPot electrodes were made with an Ag/AgCl wire inserted into a pulled 3-5 μm tip glass
capillary (Harvard Apparatus, Edenbridge, U.K.), ﬁlled with a mix 2M NaCl, 1M Na citrate
solution (1:1 ratio). A subcutaneous silver chloride reference was placed in the neck of the
animal. The signal acquisition was made by a near-DC octal bioAmp ampliﬁer (ADInstrument,
Oxford, United Kingdom) with an analogue build-in 0.02 Hz high-pass ﬁlter and a 100Hz low-
pass ﬁlter.
As discussed in the Methods part, our ampliﬁer allowed us to detect CSDs but not to determine
their essential features such as amplitude or duration, because we did not have real DC recording
(see part methods, section 3.1.1).
CSDs were deﬁned by a large slow depolarization, with a subsequent vascular response. A
depression of ongoing cortical activity was currently observed in healthy animals (KCl group).
In the TBIISOLATED and TBICLUSTER groups, CSDs were also charaterized by a large slow
depolarization with a subsequent vascular response. A depression of the ongoing brain electrical
activity can also be observed if not already depressed by the injury or previous depolarizations.
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2.3.2 Neuro-chemical and Micro-vascular recordings
2.3.2.1 Microvascular recording
Micro-vascular response was recorded with a pencil LDF probe connected to a blood Flow
meter (1mm diameter tip, MNP100XP, ADInstrument, Oxford, United Kingdom). Analogue-
digital conversion and data acquisition were made by a 16 bit PowerLab 16/35 with Labchart
7 (ADInstrument). Median BPU measured during the ﬁrst 5min of each experiment was con-
sidered as 100% and after animals were euthanized as 0%. The LDF probe signal will thus be
expressed as a percentage of the BPU measured during the 5 min starting the experiments.
2.3.2.2 PbtO2 recordings
PbtO2 recordings were made with an electrochemical (Clark-type) micro-sensor connected to an
ampliﬁer with a constant potential of -800mV (OX-10, Unisense, Aarhus, Denmark). Analogue-
digital conversion and data acquisition were also made with the same PowerLab 16/35 with
Labchart 7 (ADInstrument)
2.3.2.3 Biosensors for glucose and lactate recordings
Extracellular glucose or lactate concentrations were made using oxidase-based biosensors, con-
nected to a VA-10 ampliﬁer (NPI electronics) with a constant potential of +500mV. All sensors
were tested before and after each in vivo experiments to ensure that the sensitivity and speci-
ﬁcity remained stable all along the experiment.
Indeed, unwanted oxidation of endogenous electroactive molecules like serotonin has to be con-
sidered to ensure biosensors speciﬁcity. To prevent such interference, a screening PPD layer
was present on the surface of the platinum electrode. An additional layer was applied on the
surface of each biosensor prior each in vivo experiment.
Biosensors calibrations encompass several steps that include selectivity assessment with sero-
tonin (20 μM) detection. Then the relationship between the oxidative current and the enzyme
substrate concentration, was tested with a range of concentrations in PBS (i.e. 200 → 15000μM
glucose or lactate), at room temperature and ambient oxygen concentration.
Only those electrodes sensitive enough (i.e. ≥ 50 pA·100μM−1 of glucose or lactate) with an
eﬀective PPD screening layer (<1.2 pA·mM−1 response to serotonin) were used.
Assuming high extracellular concentrations of glucose and lactate in the brain, the signal to
noise ratio from glucose and lactate sensors allow us to avoid control sensor implantation thus
limiting spatial set-up overload.
In the next chapters I will describe our results about neurochemical monitoring of CSDs after
a severe LFPI, in comparison to those observed in a non-injured cortex. The ﬁrst chapter will
give an overview of LFPI eﬀect on systemic and local brain parameters. Then I will report
in diﬀerent chapters vascular, PbtO2, glucose and lactate modiﬁcation that occurred in our
diﬀerent experimental conditions.
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Eﬀect of severe LFPI on systemic and
brain hemodynamic and metabolic
parameters
3.1 Vascular modiﬁcations
All recordings (brain or systemic) begun 20 min after LFPI (time to implant our diﬀerent
sensors) and ended 4 hours later. During this 4 hours time window, 79% of the animals
displayed CSDs. Among them, we were able to record 2 [1.75;4] isolated CSDs per animal.
CSDs did not induce changes in systemic hemodynamic parameters (blood pressure or heart
rate), in both groups (KCl of TBI). Systolic arterial blood pressure remained stable at a mean
of 111 mmHg [105;121]. Despite baseline LDF was impossible to compare between groups due
to its relative value, we observed that cerebral perfusion, measured by the LDF, decreased over
the experiment ending at 67% [44;101] (100% being the LDF signal at the beginning of the
experiment). This trend was not observed in control non-injured animals (KCl). Moreover,
this decreases in the LDF signal tended to be more important in TBI animals that sustained
CSDs (57 % [30;101]) than in those without CSDs (99 % [68;112], W=77, p=0.076).
3.2 Metabolic modiﬁcations
3.2.1 Systemic blood concentrations
Baseline arterial blood glucose concentrations were higher (8.64 mmol/L [7.98;8.9]) in the
TBI groups compared to control animals in the KCl group (7.3 mmol/L [6.4;9.3]; W=24.5,
p=0.46). Beside lactate blood concentrations were not diﬀerent in the TBI groups (1.7 mmol/L
[1.68;1.99]) and in the KCl group (1.7 mmol/L [1.4;2.3]; W=31.4, p=0.96).
LFPI had no impact in PbtO2 that were similar in the KCl (28.1 mmHg [26;31.8]) and the
TBIs groups (27.5 mmHg [18.2; 36.6], W=134 p=0.96).
3.2.2 Brain concentrations
On the other hand, carbohydrate metabolism was impacted in the “traumatic penumbra” after
the severe LFPI. Indeed brain glucose concentration was decreased in the TBI groups (0.42
mmol/L [0.32;0.59]) compared to the KCl group (1.55 mmol/L [1.18;1.89], W=33, p=0.015).
Conversely extracellular lactate concentrations were very close in the TBI groups (0.49 mmol/L
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[0.20;0.79]) compared to the KCl group (0.33 mmol/L [0.11;1.69], W=17, p=0.93).
The PbtO2 recorded in animals subjected to a severe LFPI (27.5 [18.2;36.6]) was not diﬀerent
than those in control animals (28.1 [26;31.8], W=134 p= 0.96) before subsequent CSDs.
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Cortical spreading depolarizations
consequences in a normal or injured
brain.
4.1 Micro-vascular changes
4.1.1 LDF recordings during isolated CSDs
Since the LDF probe was present during each experiment and helped us to detect CSDs occur-
rence (large depolarization with an associated micro-vascular hyperemic response), 18 animals
(PbtO2: n=6, glucose and lactate: n=6, glutamate: n=6) were analyzed in each groups (KCl,
TBIISOLATED and TBICLUSTER).
As the CBF decreased slowly after LFPI the pre-CSD LDF level was lower in the TBIISOLATED
group (n=18, 68 % [54.3;81.9]) compared to the KCl group (n=18, 98.2 [92.39;118.4], W=276,
p<0.001, Fig 27 A). CSDs induced a similar hyperemic response in both groups (Fig 27). How-
ever the area under the curve (AUC) of the hyperemic response was lower in the TBIISOLATED
group (6120 %.sec [3455;8873]) compared to the KCl group (23220 %.sec [13620;30640], W=279
p«0.001). We then separated the LDF signal after the depolarization into 2 min epochs. In
this analysis the pre-CSD percentage was subtracted to the LDF value to compare relative
data over time. Indeed a repeated measure ANOVA including both “time” and “groups” as
factors evidenced diﬀerent responses between the KCl and the TBIISOLATED group (df=20,
F=4.2, p«0.001, Fig 27 A). Post-hoc analysis did not reach signiﬁcance because of multiple
comparisons.
20 min after the CSD, CBF remained lower in the TBIISOLATED group (52.1 % [33.6;66.0]) com-
pared to the KCl group (100.8 % [86.5;116.0], W=289 p«0.001). Moreover in the TBIISOLATED
group, these ﬁnal LDF levels were lower than the pre-CSD values (v=30 p=0.014). Conversely
in the KCl group, CBF had recovered its baseline levels and ﬁnal values were not diﬀerent from
the pre-CSD levels (V=44 p=0.07).
4.1.2 LDF recordings during clusters of CSDs
When we triggered clusters of CSDs after LFPI (TBICLUSTER group) we observed repeated
episodes of hyperemia after each depolarization (Fig 28), with a tendency for the pre-CSD
level of CBF to increase with CSDs repetition (Fig 28 pre-CSD LDF panel, repeated measure
ANOVA df=9 F=3.9 p«0.001). However, the amplitude of the hyperemic response (measured
by the AUCs) decreased with CSDs repetition in a cluster (Fig 28 Hyperemic LDF AUC panel,
repeated measure ANOVA df=9 F=2.9 p=0.003).
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Figure 27: Laser Doppler Flowmetry
(LDF), PbtO2 and CMRO2 modiﬁca-
tions during the ﬁrst 20 min following
a CSD.
A LDF modiﬁcations after a CSD: 100% cor-
respond to the signal at the beginning of the
experiment and 0% after the animal was eu-
thanized.
B: PbtO2 modiﬁcations after a CSD: PbtO2
values are reported in mmHg, as the diﬀer-
ences from the pre-CSD level.
C: CMRO2 modiﬁcations after a CSD:
CMRO2 was calculated from the LDF and
PbtO2 values and is expressed in μmol ·
100g−1 · min−1, as the diﬀerence from the
pre-CSD level.
The panel under all graphics is an example
of LFPot recordings during CSDs. The gray
curve represents the AC signal (0.5-50Hz)
and the black curve the DC signal (0.02-
0.5Hz) in mV.
The red curves represent data observed af-
ter a severe LFPI (TBIISOLATED group).
Whereas the blue curves represent those in
control animals (KCl group). For statisti-
cal analysis, data (post-CSD value - pre-CSD
value) were separated into 2 min epochs and
compared by a repeated measured ANOVA.
** p<0.05: Diﬀerence between the KCl and
the TBIISOLATED group.
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Figure 28: Laser Doppler Flowmetry
(LDF) response during a cluster of
CSDs.
Local Field Potentials: The upper black
curve is an example of the LFPot recorded
during a cluster of CSDs with the subsequent
vascular response represented below in brow
(Laser Doppler Flowmetry).
Hyperemic LDF AUC: the area under the
curve (AUC) of the hyperemic response is
plotted against the CSD index within the
cluster.
pre-CSD LDF: Boxplots of the LDF val-
ues before each depolarization are plotted
against the CSD index within the cluster in
the lower panel.
** p«0.001 repeated measured ANOVA
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4.2 Oxygen concentration (PbtO2) and consumption (CMRO2)
modiﬁcations
4.2.1 PbtO2 recordings during isolated CSDs
There was no diﬀerence on PbtO2 induced by LFPI in comparison to control animals (see
above section 3.2.2). In control animals (KCl), CSDs induced an hyperemic reaction that was
accompanied by a 9 mmHg [5;11.7] transient increase in PbtO2 (Fig 27 B), that return to pre-
CSD values afterwards. Conversely, in the TBIISOLATED group, PbtO2 displayed a ﬁrst dip of
-16.4 mmHg [-21.2;-12.3] preceding the hyperemic response. This dip was signiﬁcantly lower
after TBI than in the KCl group in which it was usually absent (W=42, p=0.02). However
the AUC of the increase in PbtO2 was not diﬀerent between the two groups (W=21, p=0.75).
We then separated the PbtO2 in 2 min epoch to compare the two groups responses over time,
using a repeated measures ANOVA with “groups” and “time” as factors. Using this analysis, we
were able to show that the TBIISOLATED group had a diﬀerent time decay compared to the KCl
group (df=20, F=4.29, p«0.001). We also evidenced that the PbtO2 decreased during the 20 min
following the depolarization in the TBIISOLATED group, unlike in healthy animals. Moreover
if the PbtO2 were similar before the CSD in the two groups, 20 min after the depolarization
the PbtO2 was signiﬁcantly lower in the TBIISOLATED group (19.8 mmHg [12.75]) compared
to the KCl group (28.1 mmHg [26.3;32], W=43 p=0.012).
As described in the Method part (section 3.5), we computed CMRO2 from the LDF and the
PbtO2 values. As expected during the energetic challenge represented by CSDs, the CMRO2 was
increased in the KCL group (111.3 μmol · 100g−1 · min−1 [96.5;124.9]) like in the TBIISOLATED
group (139.2 μmol ·100g−1 ·min−1 [93.8;177], W=17 p=0.413). However the CMRO2 responses
were diﬀerent between the two groups when we used the repeated measures ANOVA performed
on 2 min epochs following CSDs (df=20 F=6.6 p«0.001). However, after 20 min post-CSD the
CMRO2 regain its initial value in both groups.
4.2.2 PbtO2 recordings during clusters of CSDs
In the TBICLUSTER group, the hyperemic responses following each CSD were accompanied
by biphasic PbtO2 modiﬁcations (initial dip and subsequent increase like after isolated CSDs,
Fig 29). As compared with a repeated measures ANOVA, both the dip and the increase re-
sponses were not diﬀerent from one depolarization to another (respectively df=9 F=1.1 p=0.405
and df=9 F=0.56 p=0.497). Likewise the pre-CSD PbtO2 value remained constant over CSDs
repetition in clusters (df=9 F=1.4 p=0.207).
The CMRO2 displayed transient increases during each depolarization that were similar over
the clusters (df=9 F=1.4 p=0.24). Nevertheless the pre-CSD CMRO2 was increasing as CSD
repeated in clusters (Fig 29 pre-CSD CMRO2, df=9 F=4 p«0.001).
4.3 Glucose, Lactate and CMRglucose modiﬁcations
4.3.1 Biosensors recordings during isolated CSDs
In control animals (KCl), isolated depolarizations led to a decrease in extracellular glucose
from 1.55 mmol/L [1.18;1.89] to 0.63 mmol/L [0.43;1.52]. This dip in glucose lasted 16.5 min
[11.7;30.7] and was followed by a overshoot peaking to 1.89 [1.61;2.95]. Finally brain extracel-
lular glucose concentrations returned to their initial values 20-30 min after the CSD (Fig 30
A). The CMRglucose calculated from extracellular glucose values (see part Methods section 3.5)
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Figure 29: Laser Doppler Flowmetry
(LDF), PbtO2 and CMRO2 modiﬁca-
tions during a cluster of CSDs.
Local Field Potentials: The upper black
curve is an example of the LFPot recorded
during a cluster of CSDs with the subsequent
examples of (1) the micro-vascular response
represented below in brow (Laser Doppler
Flowmetry), (2) the PbtO2 in pink and (3)
the CMRO2 in purple.
pre-CSD CMRO2: Boxplots of CMRO2
values in μmol · 100g−1 · min−1 before each
depolarization are plotted against the CSD
index within the cluster.
** p«0.001 repeated measured ANOVA
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displayed a 17.8 μmol · 100g−1 · min−1 [17;21.9] transient increase. 20 min after the depolar-
ization the CMRglucose displayed a -5.6 μmol · 100g−1 · min−1 [-11.7; -2.9] decrease compare to
pre-CSD value (V=21 p=0.031, Fig 30 B).
After LFPI (TBIISOLATED), initial brain extracellular glucose concentrations were lower (0.41
mmol/L [0.32;0.59]) than those of control animals. These values also dropped down to 0.2
mmol/L [0.167;0.242] during 15.6 min [8.2;25.1]. 20 min after the depolarizations, brain glu-
cose also return to concentrations close to the pre-CSDs one (0.40 mmol/L [0.32;0.55], V=7
p=0.56).
This repeated measures ANOVA with “group” and “time” as factors performed on 2 min epochs
of relative glucose concentrations (post-CSD - pre-CSD), showed that the two groups had dif-
ferent time decay (df=20 F=2.4 p«0.001): The amplitude of the glucose decrease was lower
and no overshoot was observed in the TBIISOLATED group.
Lactate modiﬁcations were more heterogeneous in the KCl group but always exhibited a de-
layed large increase from 0.33 mmol/L [0.11;1.69] to 1.93 mmol/L [0.28;3.63], that returned to
concentrations close to the initial value after 20min (0.37 mmol/L [0.13;4.18], V=19 p=0.09,
Fig 30 C). In the TBIISOLATED group lactate concentrations had a diﬀerent pattern. However
it did not reach a signiﬁcant diﬀerence from the control group, because of the KCl responses
heterogeneity (repeated measures ANOVA with “group” and “time” as factors on 2 min epochs
of relative concentrations (post-CSD - pre-CSD), df=20 F=1.4 p=0.096). Brain lactate con-
centrations changes started with an initial dip from 0.49 mmol/L [0.2;0.78] to 0.13 mmol/L
[0.11;0.14] that was not observed in the KCl group (W=31 p=0.041). This dip was followed by
a transient increase peaking to 0.53 mmol/L [0.41;0.88] almost time locked with the vascular
response: its peak occurred 31.5 sec [16.3;43] after the hyperemic acme. Unlike in the KCl
group, extracellular lactate concentrations did not display such large increase. Finally, the
lactate concentrations during the 20 min following CSDs in the TBIISOLATED group tended to
be lower than the pre-CSD levels (0.11 [0.08;0.14], W=6 p=0.06).
The lactate/glucose ratio had similar changes in the KCl and TBIISOLATED groups: As glu-
cose was decreasing the lactate/glucose ratio increased from 0.23 [0.07;0.94] to 1.96 [0.76;3.25]
in the KCL group, and from 0.79 [0.58;1.21] to 2.52 [2.00;2.69] after LFPI (W=15 p=0.69).
Both groups recovered initial lactate/glucose values 20 min after the depolarizations (i.e. 0.24
[0.06;0.92] in the KCl group and 0.58 [0.43;0.99] after LFPI).
4.3.2 Biosensors recordings during clusters of CSDs
When we triggered cluster of CSDs in animals with concomitant glucose and lactate record-
ings we observed more heterogeneous patterns. On the one hand brain glucose concentrations
always decreased during the cluster, thus the median concentrations remains lower than the
pre-cluster values (repeated measures ANOVA, df=10 F=3.8 p«0.001, Fig 31). Subsequently
the CMRglucose was increasing during the cluster compared to the pre-cluster value (repeated
measures ANOVA, df=10 F=4.2 p«0.001).
On the other hand lactate exhibited biphasic patterns with an initial dip and subsequent in-
crease, like the early modiﬁcations induced by isolated CSDs (TBIISOLATED). Both the dip and
the increase were constant over CSDs repetition in clusters (respectively df=9 F=0.7 p=0.68
and df=9 F=1.4 p=0.23). In some animals extracellular lactate tended to increase whereas
no clear trend can be observed in other animals (Fig 31 Lactate modiﬁcations). Therefore no
median brain lactate modiﬁcations were evidenced during clusters compared to the pre-cluster
lactate levels (df=10 F=0.7 p=0.73). The lactate/glucose ratio increased to 1.87 [1.30;5.33]
during the ﬁrst depolarization and was not signiﬁcantly impacted by CSDs repetition (df=10
F=1.28 p=0.26).
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Figure 30: Glucose, lactate and
CMRglucose modiﬁcations during the
ﬁrst 20 min following a CSD. A Ex-
tracellular brain glucose concentrations
modiﬁcations in mmol/L. The horizontal
dashed black lines point out the basal levels
either in the KCl or in the TBIISOLATED
group.
B: Relative values of CMRglucose from the
pre-CSD levels, in μmol · 100g−1 · min−1.
C: Extracellular lactate modiﬁcations in
mmol/L. The horizontal dashed black lines
point out the basal levels either in the KCl
or in the TBIISOLATED group.
The red curves represent values observed
after a severe LFPI (TBIISOLATED group).
Whereas the blue curves represent the
signals in control animals (KCl group).
The panel under all graphics is an example
of LFPot recordings during CSDs. The gray
curve represents the AC signal (0.5-50Hz)
and the black curve the DC signal (0.02-
0.5Hz) in mV.
For statistical analysis, signals were sep-
arated into 2 min epochs versus pre-CSD
levels (post-CSD signal - pre-CSD value).
** p<0.05, *p<0.1: Diﬀerence between the
KCl and the TBIISOLATED group using a
repeated measured ANOVA.
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Figure 31: Glucose and lactate modiﬁ-
cations during a cluster of CSDs.
Local Field Potentials: Example of the
LFPot recored during a cluster of CSDs, with
the subsequent:
(1) boxplots of median glucose concen-
tration modiﬁcation during each CSD, and
(2) boxplots of median CMRglucose modiﬁ-
cations during each CSD.
The last two panels display simultaneous glu-
cose and lactate recordings during clusters of
CSDs. Each color correspond to the record-
ing in one animal (n=6). Glucose and lac-
tate concentrations are plotted in two sep-
arate panels with the same time and color
scales.
** p«0.001 repeated measured ANOVA
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Chapter 5
Discussion
In this part we have described the neuro-chemical and micro-vascular consequences of severe
LFPI and the eﬀects of CSDs occurring either in a “traumatic penumbra” cortex or in a normal
brain tissue.
Our data provide a clear metabolic signature of CSDs in the healthy brain, with a decrease in
brain glucose concentrations and a subsequent delayed increase in brain lactate concentrations.
The PbtO2 displayed a transient increase following the hyperemia and was associated with an
increase in CMRO2. Brain metabolism recovered pre-CSD levels after 20-30 min.
In the “traumatic penumbra” following a severe LFPI, the basal brain glucose concentrations
were lower than in healthy tissue and nonetheless decreased when a CSD was passing through.
Unlike in healthy brain tissue, lactate exhibited an initial biphasic pattern. No delayed increase
was observed but rather a decrease in extracellular brain lactate concentrations that might sign
an intracellular lactate consumption. PbtO2 had a similar response than that of lactate, with
an initial biphasic pattern during the depolarization and a subsequent prolonged decrease.
20-30min after the depolarization onset in the traumatized cortex, lactate concentrations and
PbtO2 remained lower compared to pre-CSD levels.
5.1 How severe LFPI aﬀected brain tissue
Animals subjected to a severe LFPI with mechanical ventilation support, underwent no sys-
temic secondary brain aggression: their systolic blood pressure was over 90 mmHg and they
had a normal blood oxygenation (PaO2>100mmHg). Nevertheless, our respiratory assistance
lead to a light respiratory acidosis (pH=7.35, PaCO2=47mmHg), that might inﬂuence CBF
with a small vasodilation.
This experimental procedure did not produce signiﬁcant other organ dysfunction as blood lac-
tate levels remained below 2 mmol/L in both control (KCl) and traumatized (TBI) animals.
Under Isoﬂurane anesthesia control or traumatized animals did not present any hypoglycemia.
Conversely severe TBI animals had around 1 mmol/L increase in blood glucose concentrations
compared to control animals, suggesting a stress response to the brain trauma. A similar in-
crease has been described in patients after moderate or severe TBI, levels above 11 mmol/L
being observed among patients with the worse outcome [61].
79% of traumatized animals displayed at least one CSD during the ﬁrst 4 hours following the
LFPI. In human pathology, the rate of CSD is lower (58% after severe TBI [225]), however
recordings are made later in the clinical course and usually began after neuro-surgical proce-
dures (i.e. at least 5-10 hours after the trauma). Therefore, it is possible that more CSDs
occurred within the ﬁrst hours, which can match the time window we studied. Similarly, other
authors showed that every animal had one heterogeneous DC potential shift immediately after
LFPI, with a subsequent low rate of CSDs 0.38 CSD/h like in our experiments [295].
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Finally, we observed that animals with CSDs had a progressive decrease in CBF in the “trau-
matic penumbra” dropping to -43% 4-5 hours after the trauma. Our observations are close to
the values reported by Hayward et al. (54% decrease in CBF 6 hours after the LFPI) in a similar
temporal cortex, using the arterial spin labelling-MRI technique [318]. The fact that animals
without CSDs tended to have a higher CBF suggest that CSD repetition during the ﬁrst hours
after the injury played a role in the decrease of regional CBF. Moreover, it is possible that the
CBF decline observed in some animals without CSDs, was the result of early depolarizations
that occurred before we implanted the LFPot electrode. Indeed vascular responses like CSDs
induced hyperemia, were sometimes recorded while we were implanting LFPot electrodes.
5.2 Micro-vascular modiﬁcations
In our experiments CSDs induced hyperemic responses in both conditions (KCl or TBI), even
though these responses were less important after LFPI. Unlike in ischemic stroke models, we did
not evidence inverse vascular response with a terminal ischemia [252]. The “traumatic penum-
bra” might diﬀer from the “ischemic penumbra” in several ways namely due to diﬀerent CBF
supply from pial arteries. Hayward et al. reported CBF values in the “traumatic penumbra” (-
54% ≡ 60 ml ·100g−1 ·min−1) which were well above either ischemic (15ml· 100g−1·min−1 [116])
or oligemic thresholds (33-35ml· 100g−1·min−1 [118, 119]).
In our experiments we used low doses of Isoﬂurane (0.8-1.5%) as anesthetic agent. Like other
halogenated drugs, low doses of Isoﬂurane are known to increase CBF compared to other anes-
thetic agent [326, 331, 319]. CBF has been reported at least 2 fold higher during Isoﬂurane
anesthesia [326] compared to either α-cholarlose [319] or Ketamine [330]. Together with a light
increase in PaCO2, our set-up could have led to a “luxury” perfusion compared to experiments
conducted under α-cholarlose anesthesia. This is a possible reason why we did not evidenced
transient or prolonged ischemia.
As evidenced by several authors, in ischemic models, the CBF levels before CSD onset will
drives the following micro-vascular response features. Prolonged ischemia can be observe in the
ischemic core following the depolarizations. While the CBF increases in remote areas, transient
ischemia and hyperemic responses may appear in the cortex [252, 253]. In TBI models like
LFPI, heterogeneous CBF modiﬁcations occurs corresponding to diﬀerent vascular responses.
The hyperemic response we observed in the TBIISOLATED group, were not that of healthy tis-
sue and matched more the microvascular response observed in a remote area of the ischemic
core [252, 253].
During clusters of CSDs we still observed episodes of hyperemia, but their amplitude was
reduced with the repetition of CSDs. Somme author described a similar decrease in the hyper-
emic response during repeated peri-infarct depolarization [252]. However, instead of ischemic
processes, basal CBF was increasing during clusters of CSDs. Such pattern is closer to those
described during vasogenic edema formation observed with MRI after severe TBI [350] or is-
chemic stroke [351]. In fact, repeated CSDs are known to generate both cytotoxic edema with
cell swelling [236], and BBB disruption with vasogenic edema [352, 353, 354].
5.3 PbtO2 modiﬁcations
In our experiments, CSDs led to an increase in PbtO2 that followed the micro-vascular hy-
peremia, before returning to its initial values in control animals (KCl). This pattern is quite
diﬀerent from those described by both Piilgaard et al. in rats and Takano et al. in mice.
They rather described either a monophonic decrease when animals breath air [111] or an initial
biphasic pattern with a subsequent prolonged decrease when animals breath an oxygen-enriched
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gas mixture [258] (Fig 11, Introduction part section 4). Nevertheless monophasic increase in
PbtO2 like those we reported in our experiments, has also been reported in the human brain
during CSDs [259].
One explanation might be again the diﬀerence in the anesthetic agent employed (i.e. Isoﬂurane
in 30% O2) which generate higher baseline CBF values than those during experiments con-
ducted under α-cholarlose anesthesia. These experimental conditions led us to record higher
PbtO2 (28.1 [26;31.8]) compared to those reported by Piilgaard et al. (18±1.9). This higher
blood and oxygen supply could have prevented the drop in PbtO2 induced by the increase in
CMRO2.
Surprisingly the initial biphasic pattern, described by these authors, is closer to the signals we
have recorded in animals subjected to a severe TBI. This rise the question about the monitoring
probes location inside the cortex.
In control animals we implanted our electrodes (PbtO2, LFPot and biosensors) deeper than
500 μm, because we usually found very low values of glucose or PbtO2 in upper cortical layers.
We hypothesized that these superﬁcial layers have been impacted by the surgery and the dura
removal, and therefore resemble an injured cortex. Then we decided to avoid the ﬁrst 500μm of
the cortex for neuro-chemical brain assessment. This could explain why other authors reported
patterns closer to those we recorded in traumatized animals since they implanted their probes
between 300 and 600μm [258].
CMRO2 calculated from PbtO2 and CBF displayed a similar increase than the one described
by Piilgaard et al. using the same algorithm (i.e. 100-150 μmol · 100g−1 · min−1) [258]. The
CMRO2 has then recovered its initial values 20-30 min following the depolarization, faster in a
healthy cortex than after TBI.
It seems that PbtO2 variations during CSDs encompass a range of modiﬁcations depending
on CBF and oxygen supplies: (1) Under high CBF and oxygen concentration, CSD triggers
a transient monophasic PbtO2 increase subsequently returning to baseline values. (2) When
CBF decreases under high oxygen concentrations, the PbtO2 will display an initial biphasic
pattern (short dip followed by a transient increase), with a subsequent prolonged decrease for
at least 20 min. In this situation the the CMRO2 increase starts to exceed oxygen supply. (3)
If oxygen supply is also missing (e.g. breathing either air or lower oxygen gas mixture) then
PbtO2 undergoes a monophasic decrease which duration rise as the oxygen supply goes down.
During clusters of CSDs after LFPI, PbtO2 went through repeated biphasic modiﬁcations like
during isolated depolarizations. The pattern was not signiﬁcantly altered over the clusters.
Conversely, CSD repetition induced a progressive increase in CMRO2 that might be deleterious
in already injured areas. . However, this can also be the signature of the cortical ability to
extract O2 from the blood compartment, in reaction to an aggression.
5.4 Glucose and lactate metabolism
As glucose is the main energetic substrate in the brain, it is expected that CSDs induce a
decrease in its cortical concentration to produce ATP. Prior studies had already showed such
eﬀects with rapid sampling cMD [239, 261]. The present results are, to our knowledge, the
ﬁrst to provide real brain glucose and lactate concentrations with a high temporal resolution
in the order of a second. In the normal brain submitted to KCl induced CSD, we recorded a
decrease of brain glucose concentrations from normal values (1.55 mmol/L) to 0.63 mmol/L
lasting around 16 min. This large dip was followed by a small overshoot to 1.89 mmol/L before
recovering normal values 20-30 min after the depolarization.
In the “traumatic penumbra”, baseline cerebral glucose concentrations were already lower
(<1mmol/L) than those in control animals. Such values below 1mmol/L have been associ-
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ated with a bad outcome in patients with acute brain injury [203, 62]. Moreover, CSDs still
induced a decrease in cerebral glucose reaching a critical value of 0.2mmol/L. This threshold
(0.2mmol/L) was used by Vespa et al. to deﬁne metabolic crisis with cMD [202]. This deep
drop in brain glucose concentrations may be associated either to a lack of blood glucose sup-
ply or to an excess in glucose fuelling by cells. As calculated by a reversible Michaelis-Menten
model from brain glucose, CMRglucose increased in both groups (KCl and TBI). This increase in
glucose consumption can be related to several metabolic states usually described in the human
brain with cMD [203, 202]:
• Aerobic hyperglycolysis characterized by a Lactate increase, a low L/P ratio, and low
glucose concentrations.
• Anaerobic hyperglycolysis, also called metabolic crisis, characterized by a hight L/P ratio
and low glucose. This altered patterns has been divided in two diﬀerent entities:
1. A type 1 ischemic pattern with a lactate increase, a high L/P ratio, a low glucose,
and low PbtO2 levels.
2. A type 2 “low pyruvate” pattern where glucose is low, PbtO2 is normal, and L/P is
high because of low pyruvate brain concentrations. Lactate concentrations remain
normal or low.
Even if pyruvate sensitive biosensors are not yet available, brain lactate concentrations had clear
diﬀerent responses in the normal and injured brain. As previously described with cMD [239,
261], CSDs induced in a non-injured brain a large and delayed increase in extracellular lactate
concentrations to almost 2 mmol/L, which was returning to normal values 20-30 min after the
depolarization. The lactate/glucose ratio was also transiently increased but remained in the
range of normal values indicating that most glucose molecules are metabolized in the oxidative
pathway [355, 356]. This patterns of glucose decrease and lactate release was associated with
an increase in CMRO2, and resembled the “aerobic hyperglycolysis” state. This metabolic state
is considered a normal reaction of brain tissue to an aggression, and has been associated with
a better outcome in human pathology [208, 209].
Other authors studied lactate dynamics in the brain, for example after electrical stimulation,
and described similar results with a large delayed increase in lactate during 15-20 min [357,
104, 358, 359]. The results from Hu and Wilson in 1997 are usually taken as a model of phys-
iological brain activations. However they needed to repeat electrical stimulation (1-ms pulse
width, 40 Hz at 250μA) for at least 5 seconds to see any modiﬁcation in brain lactate or glu-
cose concentrations. Shorter duration caused no observable change [104]. Likewise Kuhr et
al. as well as Kruger et al. used electroconvulsive shock to model brain aggression or seizure,
and found similar brain lactate concentrations changes [359, 358]. Like in 1944 when Leão
discovered CSDs trying to study epileptic activity with 1-5 sec “tetanizing” current [219], these
stimulations probably triggered CSDs rather than seizures or normal brain signaling!
Therefore the model published in 2007 by Simpson et al. based on Hu and Wilson results could
explain brain metabolism during CSDs in a normal brain tissue. Under such circumstances
it seems that glucose catabolism and lactate production are supported by both neurons and
astrocytes [90].
Takano et al. described, with 2-photon imaging, NADH spatial and temporal modiﬁcations
during CSD in the normal brain. Unlike during physiological brain activity where a redox-
coupling has been described between astrocyte and neurons [108], changes in NADH ﬂuores-
cence was a function of the distance to the vasculature: (1) tissues located closer than 8–10
μm from a capillary vessel wall showed NADH dips (indicating oxidative metabolism), whereas
(2) those located further away showed NADH overshoots, consistent with a shift in the NAD-
H/NAD+ ratio toward NADH because of inadequate oxygenation to support increased aerobic
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metabolism [111].
These results are in accordance with a glucose uptake by both neurons and astrocytes with
diﬀerent cellular cooperation.
After TBI, CSD induced a lactate initial dip from 0.49 mmol/L to 0.13mmol/L followed by a
transient and small increase to 0.53mmol/L. Then lactate concentrations either remained at its
initial value or even decreased. Unlike after CSDs in a non-injured brain, prolonged increase
in lactate concentrations was never observed in traumatized animals. Similar modiﬁcations
has been described with cMD in some animals or patients who displayed no lactate modiﬁca-
tions after CSDs [264, 263]. One possible explanation could be that oxidative pathway already
worked at its full capacity after LFPI, and therefore all glucose molecules consumed during
glycolysis goes to the mitochondria in the tricarboxylic acid cycle. Indeed the lactate/glucose
ratio remains in a normal range of values after LFPI (2.7 [1.5;4.9] [356]) indicating a preserved
oxidative pathway [355, 356]. Then we would expect that pyruvate molecules are not converted
into lactate as during type 1 anaerobic glycolysis, but rather into acetyl-Coa to enter the tri-
carboxylic acid cycle.
It is possible that extracellular lactate and pyruvate were transferred to the intracellular com-
partment resulting in a decrease in their extracellular brain concentrations that are accessible
to biosensors or cMD. Even if we did not have pyruvate concentrations recordings, we hypothe-
sized that CSDs could underpin the type 2 “low pyruvate” state described with cMD, whereby
glucose, lactate and pyruvate extracellular concentrations are low.
Two patterns emerge from our data: (1) a “normal” hyperglycolylis in healthy brain tissue,
whereby glucose will decrease with a subsequent increase in lactate, and recover after 20-30min.
The L/P ratio is expected to remain normal. (2) An impaired response in the “traumatic
penumbra”, with a decrease in brain glucose and a lactate concentrations, reﬂecting their in-
tracellular consumption. These modiﬁcations will eventually recover after 20-30 min. However,
in some animals glucose and lactate concentrations remained at low levels after the CSD.
Finally clusters of CSDs led to a sustain decrease in glucose with a subsequent increase in
CMRglucose. Brain lactate had more heterogeneous responses with alternating release and con-
sumption during each CSD. The overall lactate concentrations sometimes increased or remained
stable in other animals. These diﬀerences might reﬂect a range of metabolic patterns depend-
ing on cellular capacity to use glucose in the tricarboxylic acid cycle (oxidative pathway). In
animals where the brain glucose was the lowest (Fig 31, dark green and blue curves) lactate
tended to increase, indicating that mitochondrial oxidative pathway was overwhelm and needed
additional anaerobic glycolysis for ATP production. This would be a mechanism leading to type
1 “metabolic crisis” with low glucose, high lactate and expected high L/P ratio. On the other
hand animals with higher levels of glucose (Fig 31, turquoise and red curves), lactate concen-
trations remained stable indicating that all glucose is consumed in the oxidative pathway as
during isolated CSDs (type 2 “metabolic crisis”).
158
Chapter 6
Conclusion
These experiments described the metabolic and micro-vascular consequences of CSDs depending
on pre-CSD brain state, either a normal or a traumatized brain tissue. We also gave an overview
of the modiﬁcations generated by clusters of depolarizations after brain trauma, which are
supposed to be associated with the worst outcome in human pathology [225].
The view whereby micro-vascular response is inﬂuenced by pre-CSD CBF levels also applies to
carbohydrate and oxygen metabolism:
• In a cortex with high energetic supply (CBF, oxygen and glucose), a single depolarization
will trigger transient modiﬁcations characterized by (1) an increase in CBF, (2) an increase
in CMRO2 that does not exceed oxygen supply. Therefore PbtO2 variations will mimic
those of CBF. (3) A physiologic aerobic hyper-glycolysis with a brain glucose decrease
and a delayed prolonged lactate increase. Brain tissue will then recover from this huge
metabolic challenge approximately 20-30 min after the depolarization.
• When energetic supplies are inadequate, then (1) a paradoxical decreased micro-vascular
response can take a variety of forms depending on CBF level. (2) CMRO2 starts to
exceed oxygen supply. Then PbtO2 variations will range between a biphasic pattern with
a subsequent decrease, to a monophasic decrease, depending on pre-CSD PbtO2 levels.
(3) Hyper-glycolysis still occurs, however energetic needs seems to drive every glucose
molecule to the mitochondria. This pathological reaction could be related to the type
2 “low pyruvate” state observed with cMD in humans, where brain glucose, lactate and
pyruvate are low and the L/P is high. To conﬁrm this, we will need to study the conditions
with pyruvate biosensors.
• Finally when energetic supplies are missing like in the ischemic core, then terminal depo-
larization with terminal ischemia will occur. PbtO2 is also very low, and at these oxygen
concentrations oxidase-based biosensors will not be reliable. Maybe cMD will provide
such informations in the future.
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Chapter 1
General conclusion
At the beginning of my thesis we made the hypothesis that CSDs have diﬀerent neuro-chemical
consequences in healthy tissue compared to a “traumatic penumbra” where neuronal death
is expected to occur. Our second hypothesis was that clusters of CSDs would have worse
consequences after TBI than isolated CSDs.
Then, our objectives were to:
1. Describe the metabolic (glucose, lactate, PbtO2) and micro-vascular patterns observed
during and after CSDs in a healthy cortical tissue.
2. Report how these patterns are altered during spontaneous isolated CSDs after severe TBI.
3. Determine if cluster of CSDs would have worse consequences.
4. Study CSDs direct toxicity through glutamate release or ROS.
So far we achieved the description on isolated and clusters of CSDs in regard to metabolic and
micro-vascular changes, and the results can be summarized as follow.
A fundamental step was the analysis of severe LFPI consequences on brain parenchymal to
deﬁne the “traumatic penumbra” where to study CSDs. We found the most aﬀected areas after
LFPI to be in the thalamus, the CA3 area and the temporal cortex ipsi-lateral to the injury.
These regions exhibited, 7days after the trauma, 40-60% neuronal loss and an inﬁltration with
activated microglia. We then chose to study CSDs in the temporal cortex, located lateral to the
impact, which mimic a cortical “traumatic penumbra”. Moreover we found that the metabolic
state of this “traumatic penumbra” resemble those of patients with bad outcomefollowing brain
injury with low brain glucose concentrations, and low regional CBF.
However, before in vivo experiments analysis, we questioned the validity of oxidase-based
biosensors as experimental conditions were supposed to be diﬀerent between the in vitro calibra-
tion and the in vivo implantation. It was expected that temperature, and oxygen concentration
available, would impact the oxidase responses, despite it was previously admitted that in vivo
oxygen concentrations were not limiting the enzymatic reactions. Surprisingly, we found that
all oxidase-based biosensors were signiﬁcantly impacted by oxygen concentrations as well as
temperature. Therefore we developed algorithms to compute real brain concentrations of glu-
cose or lactate from oxidative currents, depending on oxygen and temperature.
Once we were conﬁdent about both our TBI model and the monitoring techniques reliability, we
then described CSDs neuro-chemical and micro-vascular consequences in diﬀerent conditions:
(1) Isolated CSDs in a normal brain, (2) isolated CSDs after a severe LFPI or (3) repeated
CSDs in clusters after a severe LFPI.
Our data provide a clear metabolic signature of CSDs in the healthy brain close to an aerobic
hyper-glycolysis. We observed a decrease in brain glucose concentrations and a subsequent
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delayed increase in brain lactate concentrations. The PbtO2 displayed a transient increase
following the hyperemia and was associated with an increase in CMRO2. Brain metabolism
recovered pre-CSD levels after 20-30 min.
In the “traumatic penumbra” following a severe LFPI, the basal brain glucose concentrations
were lower than in healthy tissue and nonetheless decreased when a CSD was passing through.
Unlike in healthy brain tissue, brain lactate concentrations exhibited an initial biphasic pat-
tern. No delayed increase was observed but rather a decrease in extracellular brain lactate
concentrations that might sign an intracellular consumption. PbtO2 had a similar response
than that of lactate, with an initial biphasic pattern during the depolarization and a subse-
quent prolonged decrease. 20-30min after the depolarization onset in the traumatized cortex,
lactate concentrations and PbtO2 remained lower compared to pre-CSD levels. We made the
hypothesis that such pattern could underpin “low pyruvate” states observed in some patients
with cMD and that are currently poorly understood.
Finally clusters of CSDs after TBI led to a progressive increase in CBF, CMRO2 and CMRglucose.
However brain lactate concentrations had miscellaneous variations, depending on how brain
parenchyma can sustain such energetic expenditure.
Our data conﬁrm that CSDs have diﬀerent consequences on brain tissue depending on the pre-
CSD state, with an altered metabolic response in the “traumatic penumbra”. Clusters of CSDs
led to a prolonged metabolism alteration, which can eventually turn into a pattern looking like
a metabolic crisis.
These results rose several questions about CSDs toxicity and therapeutic actions to consider:
• Does CSDs lead to additional neuronal damage in an injured brain tissue?
• Are these damages due to a direct toxicity of CSDs through glutamate and/or ROS? Or
is it only due to an excessive energetic expenditure?
• Is there a way to help brain tissue to recover from CSDs? Should we block CSDs occur-
rence?
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Chapter 2
Perspectives
2.1 Does CSD lead to neuronal damage?
The question whether spontaneous CSDs occurring after brain injury would lead to additional
secondary neuronal damage is hard to answer. It seems complicated to trigger speciﬁcally such
interlinked phenomena triggered by primary injuries and/or spreading depolarizations. In fact
therapeutic agent like NMDAR antagonists, usually used to block CSDs [267, 268, 269] may
act on several mechanisms independent from the depolarization.
Therefore, instead of decreasing the CSD rate, we will try to address the consequences of
increasing CSDs rate after LFPI on neuronal density and glial cells behavior.
2.2 What about glutamate and ROS during CSDs?
2.2.1 Introduction
The ﬁrst evidence of glutamate release in the extracellular space after CSDs were made on
the retina by Van Harreveld and Fifková in 1970 [265]. A transient increase in extracellular
glutamate concentrations during CSDs was conﬁrmed later with rapid sampling cMD in vivo in
rats [266]. Hypothesis about glutamate implications during CSDs have been mainly based on
indirect observations, using NMDAR blockers to stop glutamate transmission [267, 268, 269].
More recently a few studies described glutamate dynamics with a high temporal resolution
during CSD in healthy animals or after middle cerebral artery occlusion. A glutamate tran-
sient release (11.6 ± 1.3μM) was described by Hinzman et al. in 2015 with enzyme based
biosensors, in healthy rats that was able to triggered neuronal lesions if glutamate uptake was
inhibited [240]. They also reported a glutamate release during anoxic or peri-infarct depolariza-
tion which duration was related to the depolarization length [240]. Based on these observations,
the authors suggested that CSDs can mediate excitotoxicity after brain aggression.
The term ROS is a collective one that includes not only oxygen-centered radicals such as su-
peroxide ion (O.−2 ), NO. and OH. but also some non-radical derivatives, such as H2O2, singlet
oxygen, and hypochlorous acid. O.−2 can be converted to H2O2 spontaneously or via superoxide
dismutase (SOD) [360], and may also react with NO. to give peroxynitrite [361]. ROS, such
as O.−2 , NO and H2O2, are involved in physiological phenomena such as apoptosis [362], cell
growth [363], modulation of long term potentiation [364, 365], and signal transmission [366, 367]
or neuro-vascular coupling [73]. However, the excess of ROS production has damaging eﬀects
such as membrane lipid peroxidation, protein oxidation and DNA degradation [368, 369].
Only a few studies described H2O2 or NO increase after CSD using ﬂuorescent probes usually
without any time resolution [255, 370].
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In preliminary experiments we aimed to describe real time glutamate and ROS modiﬁcations
triggered by CSDs in the normal brain or after a severe TBI.
2.2.2 Methods
During these analysis, we followed the same experimental design as described in the previous
part VI. We studied brain glutamate concentration in the same 3 experimental groups:
• KCl experimental condition: CSDs were triggered by a transient increase in potassium
concentration of the saline solution that was infusing the cortical surface, by stirring a
drop of 1M KCl.
• TBIISOLATED experimental condition: Spontaneous CSDs occurred after a severe LFPI.
• TBICLUSTER experimental condition: Clusters of CSDs were triggered by 1M KCl appo-
sition on the cranial window.
H2O2 measurements have been performed only in the KCl and the TBIISOLATED groups,
whereas only a few preliminary experiments of NO recordings were made in the KCl group.
Extracellular H2O2 measurements were made using the comparison of oxidative currents ob-
tained by two diﬀerent biosensors: (1) A control biosensors (covered only with albumin),
since the oxidative current is based on ambient H2O2 oxidation on the platinum surface,
and (2) a catalase covered biosensor, where catalase decomposed H2O2 in water and oxygen
(2 · H2O2 → 2 · H2O + O2). These sensors are only sensitive to all other non-speciﬁc current
modiﬁcations, and had a lower increase in oxidative current during CSDs (Fig 32 A, red curve).
Comparing their signals gave us the current coming from extracellular H2O2.
NO detection was made with carbon ﬁbre sensors (100 μm length, 7 μm diameter). The active
part of the electrode undergoes various treatments, including a porphyrines-nickel layer and
Methyltrimethoxysilane screening layer [371].
Extracellular brain glutamate concentrations were obtained using oxidase-based biosensors,
which were tested before and after each in vivo experiments to ensure that the sensitivity
and speciﬁcity remained stable all along the experiment. Due to the very low extracellular
concentrations of glutamate in the cortex, glutamate biosensors were implanted in vivo close
to a control biosensor (i.e. covered only with BSA). Signals from control sensors were then
subtracted from those of the glutamate biosensor, to remove non-speciﬁc current modiﬁcations.
2.2.3 Reactive oxygen species release
We were able to record a 1.12 μmol/L [0.37;2.48] H2O2 transient release during 22.5 sec [7.5;36]
in the KCl group. In the TBIISOLATED group a similar release was also recorded of 1.78 μmol/L
[0.51;2.24] (W=21, p=1), during 33 sec [16.5;43] (W=15.5 p=0.8). These values are close to
those reported by Viggiano et al. in 2011 with cMD after repeated CSD (i.e. 10-20% increase
from a baseline of 9.1 μmol/L ≡ 0.9−1.8μmol/L) [370]. They also reported that this increase
in H2O2 was associated with an increase in SOD activity and a subsequent decrease in O−2
concentrations [370].
In a few preliminary experiments we used carbon micro-electrodes to record extracellular NO
modiﬁcations during CSD after KCl cortical apposition (like in the KCl group). 30-40 min
after the ﬁrst depolarization we perfused the neuronal NO-synthase inhibitor (L-NNA) during
45 min and triggered a second CSD with KCl.
The ﬁrst depolarization triggered a transient increase in extracellular NO (Fig 32 B, black
curve) that was suppressed during the second CSD by L-NNA cortical infusion (Fig 32 B, red
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Figure 32: Hydrogen peroxide and nitric
oxide sensors signals during a CSD.
A. Hydrogen peroxide: The DC (0-0.5
Hz) of a micro-electrode biosensor covered
only with albumin (no enzymatic layer) is
represented in black. This signal represent
the oxidative current generated by extracel-
lular H2O2 oxidation on the platinum sur-
face. The AC (0.5-30Hz) LFPot is also
recorded by the electrode and the gray curve
point out the depression part of the CSD. To
control for non-speciﬁc modiﬁcations a sec-
ond sensor covered with catalase (not sensi-
tive to H2O2) was placed close to the other
biosensor. DC signal is represented in red.
B. nitric oxide: the AC signal (0.5-30 Hz)
of the NO sensitive sensor is represented in
gray whereas the DC signal (0-0.5 Hz) is in
black. Note the increase in oxidative current
during the depression of LFPot that repre-
sent NO release in the extracellular space.
A second CSD was triggered after an NO
synthase inhibitor (L-NNA) cortical infusion.
The signal recorded from the same NO sen-
sitive sensor, during the second depolariza-
tion, is represented in red. The increase in
oxidative current is abolished after L-NNA
infusion.
curve). These results are in agreement with an NO release produced by the neuronal NO-
synthase during CSDs. NO release during CSDs has been evidenced with ﬂuorescent [255]. If
NO release is blocked by L-NNA or scavenged by hemoglobin, then the high K+ concentration
would lead to a vaso-constriction through SMCs depolarization [80, 83].
2.2.4 Glutamate release
Every isolated depolarization (KCL or TBI) triggered a transient extracellular glutamate con-
centration increase. Extracellular glutamate peaked to 7.7 μmol/L [7.1;15.9] in control animals
from a baseline concentration of 2.49 μmol/L [0.8;5.6] (KCl). Baseline brain glutamate con-
centrations following the LFPI tended to be higher than in KCL group (5.2 μmol/L [3.7;8.9],
W=108 p=0.09). Glutamate release during spontaneous depolarization after LFPI was also
larger: 32.4 μmol/L [26.8;39.9] (W=16 p=0.046, Fig 33). Similar concentrations have recently
been observed by Hinzman et al. with larger biosensors (i.e. 11.6 μmol/L ± 3) [240]. Using
a diﬀerent ischemic model, these authors did not ﬁnd that the amplitude of the glutamate
release was enhanced during peri-infact depolarizations [240]. However they did not measure
the PbtO2 in the cortex where they implanted their biosensors. As presented in the previous
part V, oxidase based biosensors are dependent on oxygen concentrations. Thus, as previously
mentioned, the lower the oxygen the lower the oxidative current. Therefore it is possible that
they had underestimated the glutamate release in the ischemic core as well as in the penumbra
area where PbtO2 was expected to be lower compared to normal brain tissue [372].
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Overall, the glutamate released peak occurred 12 sec [2;36.5] before the hyperemic acme and
11.5 sec [2;26] after the depolarization nadir. The duration of the glutamate release was not
diﬀerent in the KCl (118.5 sec [54.1;218.9]) and in the TBIISOLATED group (125.5 sec [87;147],
W=35 p=0.765).
During repeated CSDs in clusters (TBICLUSTER), the glutamate release decreased from 18.3
μmol/L [2.9;32.3] to 3.1 [1.56.7] (repeated measures ANOVA, df=9 F=5.2 p«0.001), without
increase in basal glutamate concentrations. Similar processes have also been suggested during
repeated peri-infact depolarization [240].
High levels of extracellular glutamate was expected to mediate neuronal death through NM-
DAR over activation [127, 125]. However NMDAR inward current can be modulated by several
extracellular co-factors such as D-Serine, which binds the glycine binding site on the NR1 sub-
unit (Fig 6). The lower the extracellular D-Serine concentration, the lower the NMDAR inward
current [125]. Therefore further investigations on NMDAR co-agonist levels during CSDs may
provide more information about their toxicity.
Figure 33: Glutamate release following
isolated CSDs.
The red curves represent values observed
after a severe LFPI (TBIISOLATED group),
whereas the blue curves represent the signals
in control animals (KCl group). The black
curve point out the micro-vascular response
after TBI as recorded by the LDF probe.
The graphic represent a 400 seconds record-
ing surrounding the depolarization.
The lower panel is an example of LFPot
recordings during CSDs. The gray curve
represents the AC signal (0.5-50Hz) and the
black curve the DC signal (0.02-0.5Hz) in
mV.
2.3 Fuelling the injured brain?
Based on our preliminary results, it is unclear if CSDs have a direct toxicity on injured brain
tissue via glutamate or ROS. However the metabolic modiﬁcations described in the part VI
argue in favor of an indirect toxicity through excessive energetic expenditure. Therefore we
chose to pool our eﬀorts on a way to improve altered brain metabolism.
The objective of a ﬁrst set of experiments will be to determine how diﬀerent oxygen supply (15%
to 100% oxygen gas mixture) impact brain carbohydrate concentrations. Indeed several oxygen
conditions are interchangeably used during in vivo or ex vivo (e.g. brain slice) experiments,
that could underpin some results discrepancies. Moreover the inﬂuence of hypoxia will give
further insight on brain adaptations to high altitude in healthy subjects or after TBI.
Recent studies observed that during a systemic stress induced by a severe TBI, the large
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Figure 34: Glutamate release modiﬁca-
tions during a cluster of CSDs.
Local Field Potentials: Example of the
LFPot recorded during a cluster of 10 CSDs,
with the subsequent glutamate concentra-
tion modiﬁcations during each CSD.
glutamate release: boxplots of maximum
glutamate release during each CSD in a clus-
ter of 10 depolarizations.
** p«0.001 repeated measures ANOVA
majority of brain carbohydrate consumption derives from systemic lactate [373, 115]. The
monocarboxylate transporters are responsible for the transport of ketones, pyruvate and lactate
across the BBB and cell membranes. As MCT brain expressions can increase after TBI [97], it
has been suggested that lactate act as a metabolic shuttle between stressed organs (e.g. brain)
and those where glycogen is stored (e.g. liver or muscles). Even if systemic lactate infusion
seems to improve cMD parameters after TBI [374], the impact of such therapeutic intervention
and their way of actions at the cellular and tissue levels may be clariﬁed.
Therefore subsequent experiments will focus on the eﬀect of diﬀerent systemic carbohydrate
infusion on basal brain metabolism in a normal or injured brain. Moreover, we will intend to
study these therapeutic intervention on brain metabolism parameters during CSDs.
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Package ‘BrainMetabolism’
August 23, 2015
Type Package
Title calculate brain metabolism rates from extracellular
conentrations
Version 1.0
Date 2015-03-03
Author baptiste balanca
Maintainer baptiste balanca <baptiste.balanca@gmail.com>
Depends R (>= 3.1.0), ggplot2, stats
Imports ggplot2
Description calculate CMRO2, CMRgluc, mitochondrialPO2 ... provide functions to pro-
cess data from biosensors
License MIT
NeedsCompilation no
R topics documented:
BrainMetabolism-package . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
auc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
calibration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
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polyval . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
roll.funct . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
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2 BrainMetabolism-package
BrainMetabolism-package
calculate brain metabolism rate from extracellular conentrations
Description
calculate CMRO2, CMRgluc, mitochondrialPO2 ...
provide functions to process data from biosensors
Details
Package: BrainMetabolism
Type: Package
Version: 1.0
Date: 2015-03-03
License: MIT
Author(s)
Baptiste Balanca
Lyon Neuroscience Research Center
Team TIGER
Maintainer: baptiste balanca <baptiste.balanca@gmail.com>
References
Piilgaard Lauritzen JCBFM (2009) 29, 1517
Gjedde et al JCBFM (2005) 25(9), 1183
Gjedde et al JCBFM (2000) 20(4), 747
Du et al JCBFM 2012 32(9)
Gruetter et al J Neurochem 1998 70(1)
balanca et al (2016) in preparation
Examples
MyTPO2<-23 #mmHg
MyLDF<-95 #percent
MyL<-L.calc(CMR=219, TPO2=MyTPO2, P50=36, h=2.7, Ca=8, cbf=53 )
MyCMRO2<-CMRO2.calc(LDF=MyLDF, MyTPO2, P50=36, h=2.7, Ca=8, L=MyL,cbfbase=53)
MyGlucBrain<-1 #mM
MyGlucPlasma<-6 #mM
MyCRMgluc<-CMRGluc.calc(MyGlucbrain, Vd=0.77, Kt=13.4, Tmax=1.35, Gplasma=MyGlucPlasma)
auc 3
auc area under the curve
Description
take a numeric vector and return the area under the curve (AUC)
Usage
auc(data, pos = TRUE)
Arguments
data : a numeric vector
pos : a logical value. if TRUE (default) AUC is calculated on positive values, if
FALSE on negative values.
Value
auc : area under the curve
max/min : maxiaml value (or minimal if pos=FALSE)
calibration Sensor calibration
Description
Fit an nth degree polynom
(y = CnX
n + Cn−1Xn−1 + . . .+ C1X + C0)
to vectors x=volt and y=concentration
Usage
calibration(volt, mol, order = 1)
Arguments
volt : a numeric vector of the biosensor voltage
mol : a numeric vector of the molecule conentration in the medium (x and y must
have the same length)
order : a numeric value for the polynomial degree. default is one.
Value
Coef : coeﬁcients in ascending order (i.e. C0, C1, C2, . . . , Cn )
R2 : goodness of ﬁt
4 CMRGluc.calc
CMRGluc.calc CMRGluc calculation
Description
take extracellular glucose concentration and return brain metabolic rate of glucose, using a re-
versible Michaelis-Menten model equation:
Usage
CMRGluc.calc(Gbrain, Vd = 0.77, Kt = 1.4, Tmax = 1.27, Gplasma = 7.3)
Arguments
Gbrain : a vector/numeric value of extracellular glucose concentration in mmol/L, time
decay
Vd : glucose brain space diffusion (default is 0.77 ml/g)
Kt : glucose apparent maximal transport rate (default is 1.4 mmol/L)
Tmax : the apparent maximal transport rate (default is 1.27 micormol/g/min)
Gplasma : plasma glucose concentration (default=6mmol/L)
Details
Gbrain = Vd
(
Tmax
CMRgluc
− 1
)
×Gplasma −Kt
Tmax
CMRgluc
+ 1
Value
CMRGlucose : numeric value of Cerebral metabolic rate of glucose in micromol/g/min
References
Morgenthaler et al. Neurochem Int 2006, 48
Ori et al. Anesthesiology 1986, 65(2)
Duarte et al. Front in Neuroenrgetics 2009, 1
Gruetter et al J Neurochem 1998, 70(1)
CMRO2.calc 5
CMRO2.calc CMRO2 calculation
Description
take tissue oxygen pressure (tPO2) and cerebral blood ﬂow (relative value, e.g. laser doopler lowme-
try BPU)
Usage
CMRO2.calc(LDF, TPO2, P50 = 36, h = 2.7, Ca = 8, L = 4.03,
cbfbase = 53)
Arguments
LDF : a vector/numeric value of LDF (percentage of baseline, i.e: basal value is 100
% )
TPO2 : a vector/numeric value of brain oxygnen pressure (mmHg)
P50 : half-saturation tension of hemoglobine (default is 36 mmHg)
h : hill’s coeﬁcient
Ca : oxygen arterial concentration (default is 8 micromol/ml)
L : effective diffusion coefﬁcient of oxygen in brain tissue, default is 4.03 mi-
comol/100g/mmHg, but one should use the L.calc function to calculate it from
their data.
cbfbase : basal expected value of CBF (default is 53 ml/100g/min wich was used to
calculate L)
LBF and TPO2 must be the same length
Details
PbtO2 = P50· h
√
2·Ca·CBF
CMRO2
− 1− CMRO2
2·L
Value
CMRO2 : vector/numeric value of Cerebral Metabolic Rate of Oxygen in micromol/100g/min
References
Gjedde et al JCBFM (2005) 25(9), 1183
Piilgaard et al JCBFM (2009) 29, 1517
6 correction.TPO2
correction.Temp Temperature correction
Description
Biosensor enzymatic reaction, that underpin amperometric measures, has a sigmoid relation to tem-
perature :
m(x, P ) =
P1 + (P2 − P1)
(1 + exp((P3 − x)/P4))
parameters are different for each enzyme and has been measured in vitro.
This function correct biosensor signal depending on temperature conditions during calibration and
experimentation
Usage
correction.Temp(x, enz, temp.calib = 25, temp.exp = 37)
Arguments
x : a numeric vector of the biosensor voltage
enz : enzyme on the biosensor i.e. "glucose", "lactate", "glutamate, "daao"
temp.calib : temperature of the medium where sensor has been calibrated the default is
25oC (i.e. room temperature).
temp.exp : temperature of the medium during experiment the default is 37oC (i.e. animal
central temperature)
Value
volt.temp.cor : a vector of corected x values for temperature
References
balanca et al 2015
correction.TPO2 Oxygen Tension correction
Description
Biosensor enzymatic reaction, that underpin amperometric measures, has an asymptotic relation to
oxygen tention in the medium :
m(PO2, P ) = P1 + (P2 − P1)× exp(− exp(P3)PO2)
parameters are different for each enzyme and has been measured in vitro
This function correct biosensor signal depending on PO2 conditions during calibration and experi-
mentation
IO2.calc 7
Usage
correction.TPO2(x, enz, TPO2 = 28)
Arguments
x : a numeric vector of the biosensor voltage
enz : enzyme on the biosensor i.e. "glucose", "lactate", "glutamate, "daao"
TPO2 : oxygene tension in the medium during the experiment. the default is 30mmHg
measured in anesthetized rat brain.
Value
volt.O2.cor : a vector of corected x values for TPO2
References
balanca et al 2015
IO2.calc Oxidative index calculation
Description
take CMRO2 and LDF to give an oxidative index
Usage
IO2.calc(CMRO2, LDF, cbfbasal = 53)
Arguments
CMRO2 : vector/numeric value of Cerebral metabolic rate of oxygen in micromol/100g/min
LDF : a vector/numeric value of LDF (percentage from baseline, baseline is 100 %)
cbfbasal : basale expected value of CBF from the litterature (default is 53 ml/100g/min
wich was used to calculate L)
Details
IO2 = CMRO2/(cbfbasal ∗ LDF )
Value
IO2 : oxidative index, reﬂect the degree of ﬂow metabolism coupling
References
Gjedde et al JCBFM (2000) 20(4), 747
8 L.calc
L.calc Calculate the effective diffusion coefﬁcient of oxygen in brain tissue,
L.
Description
take CMRO2 and cerebral blood ﬂow (CBF) to calculate the effective diffusion coefﬁcient of oxygen
in brain tissue (L)
Usage
L.calc(CMR = 219, TPO2, P50 = 36, h = 2.7, Ca = 8, cbf = 53)
Arguments
CMR : Cerebral Metabolic Rate of Oxygen, default is 219 micro mol/100
TPO2 : numeric value of brain oxygnen pressure (mmHg)
P50 : half-saturation tension of hemoglobine (default is 36 mmHg)
h : hill’s coeﬁcient
Ca : oxygen arterial concentration (default is 8 micromol/ml)
cbf : expected value of CBF (default is 53 ml/100g/min wich was used to calculate
L
Details
PbtO2 = P50· h
√
2·Ca·CBF
CMRO2
− 1− CMRO2
2·L
Value
L : numeric value of the effective diffusion coefﬁcient of oxygen in brain tissue micomol/100g/mmHg
References
Gjedde et al JCBFM (2005) 25(9), 1183
Piilgaard et al JCBFM (2009) 29, 1517
noise.na 9
noise.na Remove artifacts from biosensor signal, based on data’s standar devi-
ation
Description
Remove artifacts from biosensor signal, based on data’s standar deviation
Usage
noise.na(data, z = 20, width = 30)
Arguments
data : a numeric vector
z : a numeric value. Number of SD over which values should be exculded
width : size of the window used to roll SD over data (see roll.funct)
Value
a vector with NA remplacing exculded values
OGI.calc Oxygene Glucose index (OGI)
Description
take CMRO2 and CMRGlucose to give an OGI
Usage
OGI.calc(CMRO2, CMRGluc)
Arguments
CMRO2 : vector (numeric value) of Cerebral metabolic rate of oxygen in micromol/100g/min
CMRGluc : a vector (numeric value) of CMRGlucose in micromol/100g/min
Details
OGI = CMRO2/CMRGlucose
Value
OGI
10 polyval
polyfit polynomial ﬁt
Description
Fit a nth degree polynom
(y = CnX
n + Cn−1Xn−1 + . . .+ C1X + C0)
to vectors x and y
Usage
polyfit(x, y, order = 1)
Arguments
x : a numeric vector
y : a numeric vector (x and y must have the same length)
order : a numeric value for the polynomial degree. default is one.
Value
model formula
Coef: coeﬁcients in ascending order (i.e. C0, C1, C2, . . . , Cn )
R2: Rsquare
polyval polynomial evaluation
Description
evaluation a nth degree polynom
(y = CnX
n + Cn−1Xn−1 + . . .+ C1X + C0)
at given values of x
Usage
polyval(x, coef)
Arguments
x : a numeric vector
coef : a n dimention vector corresponding to the polynom coefﬁcient (ascending or-
der, i.e. C0, C1, C2, ... , Cn )
roll.funct 11
Value
y
roll.funct apply a function FUN on a rooling windows of a vector
Description
apply a function FUN on a rooling windows of a vector
Usage
roll.funct(data, width, FUN, size = T, ...)
Arguments
data : a numeric vector
width : the size of the rolling window
FUN : the function to apply
size : a logical value indicating if the returned vector have the same length as original
data. default is TRUE.
... : additional argument to pass to the FUN
Value
a vector with FUN result
Index
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IX
This work has been the subject of one publication in an international journal:
• Neuronal loss as evidenced by automated quantiﬁcation of neuronal density following
moderate and severe traumatic brain injury in rats. Balança B, Bapteste L, Lieutaud T,
Ressnikoﬀ D, Guy R, Bezin L, Marinesco S.J Neuroscience Research, 2016 Jan;94(1):39-
49.
And several communications in national or international congress:
• SFAR 2013 (R207): Exploration électrocorticographique et microvasculaire des courants
corticaux lents de dépolarisation (CSD) après un traumatisme crânien sévère chez le rat.
B. BALANCA, C. MAUCLER, A. MEILLER, T. LIEUTAUD, S. MARINESCO
• SFAR 2014 (R037): Couplage neuro-vasculaire et production d’ H2O2 lié aux «cortical
spreading depolarization» après un traumatisme crânien expérimental sévère chez le rat.
B BALANCA, S MARINESCO, A MEILLER, T LIEUTAUD
• SFAR 2015 (R150): Modiﬁcations métaboliques lié aux dépolarisations corticales en-
vahissantes après un traumatisme crânien sévère chez le rat: une origine des crises
métaboliques? B BALANCA, S MARINESCO, A MEILLER, T LIEUTAUD
• FENS 2014: Cortical spreading depolarization consequences on cerebral blood ﬂow and
metabolism. B. BALANCA, T. LIEUTAUD, A. MEILLER, S. MARINESCO
• COSBID 2014: Cortical spreading depolarization consequences on cerebral blood ﬂow,
cortical oxygenation and metabolism: comparison of healthy and traumatized brain. B
BALANCA, T LIEUTAUD, A MEILLER, S MARINESCO.
• COSBID 2015: Real time glutamate dynamics during cortical spreading depolariza-
tions. B. BALANCA, T. LIEUTAUD, A. MEILLER, S. MARINESCO
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